

# CANWARD 2012 Study

**George G. Zhanel<sup>1</sup>, Melanie Baxter<sup>1</sup>, Heather Adam<sup>1,2</sup>, Nancy Laing<sup>1</sup>, Barb Weshnoweski<sup>2</sup>, Ravi Vashisht<sup>1</sup>, Kim Nichol<sup>2</sup>, Andrew Denisuik<sup>1</sup>, Philippe Lagacé-Wiens<sup>1,2</sup>, Melissa McCracken<sup>3</sup>, Michael Mulvey<sup>3</sup>, Jack Johnson<sup>4</sup>, the Canadian Antimicrobial Resistance Alliance (CARA), and Daryl J. Hoban<sup>1,2</sup>**

University of Manitoba<sup>1</sup>, Diagnostic Services of Manitoba<sup>2</sup>, National Microbiology Lab<sup>3</sup>, Winnipeg, Canada and International Health Management Associates (IHMA)<sup>4</sup>, Chicago, USA

# CANWARD 2012

## Participating Centres/Investigators

|    |                         |  |
|----|-------------------------|--|
| 1  | Dr. D. Roscoe           | Vancouver Hospital, Vancouver                  |
| 2  | Dr. J. Fuller           | University of Alberta Hospital, Edmonton       |
| 3  | Dr. J. Blondeau         | Royal University Hospital, Saskatoon           |
| 4  | Drs. D. Hoban/G. Zhanel | Health Sciences Centre, Winnipeg               |
| 5  | Dr. M. John             | London Health Sciences Centre, London          |
| 6  | Dr. S. Poutanen         | Mount Sinai Hospital, Toronto                  |
| 7  | Dr. L. Matukas          | St. Michael's Hospital, Toronto                |
| 8  | Dr. F. Chan             | Children's Hospital of Eastern Ontario, Ottawa |
| 9  | Dr. M. Laverdière       | Hopital Maisonneuve-Rosemont, Montreal         |
| 10 | Dr. M. Goyette          | CHRTTR Pavilion Ste. Marie, Trois-Rivières     |
| 11 | Dr. M. Kuhn             | South East Regional Health Authority, Moncton  |
| 12 | Dr. R. Davidson         | Queen Elizabeth II HSC, Halifax                |

# CANWARD 2012

## CANWARD 2012 – Methods

- 12 sentinel Canadian hospitals (8/10 provinces) participating
  - Regions: West (BC, AB, SK, MB), Ontario, Quebec, Maritimes
- Isolates from patients attending:
  - hospital clinics, ER, wards (medical, surgical) and ICUs
- Isolates per infection site:
  - blood (100), respiratory (100), urine (25), wound (25)

# CANWARD 2012 Study

## CANWARD 2012 – Isolate Selection

- Isolates from respiratory tract, blood, urinary tract, wounds/IV sites
- Isolates deemed “clinically significant” by local site criteria
- Consecutive pathogens
- One pathogen per patient per infection site
- Exclusions: eye/ear/nose swabs, genital tract specimens, surveillance swabs, anaerobes, fungi

# CANWARD 2012

## Ward Specimen Source

**N (%)**

|                  | Clinic     | ER         | ICU        | Med        | Surg      | Total          |
|------------------|------------|------------|------------|------------|-----------|----------------|
| <b>National</b>  | 484 (17.2) | 716 (25.5) | 621 (22.1) | 819 (29.2) | 168 (6.0) | 2808           |
| <b>West</b>      | 182 (18.4) | 270 (27.2) | 225 (22.7) | 246 (24.8) | 68 (6.9)  | 991<br>(35.3%) |
| <b>Ontario</b>   | 90 (9.4)   | 200 (20.9) | 268 (28.0) | 340 (35.6) | 58 (6.1)  | 956<br>(34.1%) |
| <b>Quebec</b>    | 113 (31.1) | 144 (39.7) | 25 (6.9)   | 67 (18.5)  | 14 (3.9)  | 363<br>(12.9%) |
| <b>Maritimes</b> | 99 (19.9)  | 102 (20.5) | 103 (20.7) | 166 (33.3) | 28 (5.6)  | 498<br>(17.7%) |

# CANWARD 2012 Specimen Source

|              | Clinic     |      | ER         |      | ICU        |      | Med        |      | Surg       |      | Total       |      |
|--------------|------------|------|------------|------|------------|------|------------|------|------------|------|-------------|------|
|              | N          | %    | N          | %    | N          | %    | N          | %    | N          | %    | N           | %    |
| Blood        | 79         | 16.3 | 471        | 65.8 | 185        | 29.8 | 382        | 46.6 | 51         | 30.4 | 1168        | 41.6 |
| Resp         | 226        | 46.7 | 67         | 9.4  | 406        | 65.4 | 301        | 36.8 | 67         | 39.9 | 1067        | 38.0 |
| Urine        | 91         | 18.8 | 112        | 15.6 | 10         | 1.6  | 65         | 7.9  | 20         | 11.9 | 298         | 10.6 |
| Wound        | 88         | 18.2 | 66         | 9.2  | 20         | 3.2  | 71         | 8.7  | 30         | 17.9 | 275         | 9.8  |
| <b>Total</b> | <b>484</b> |      | <b>716</b> |      | <b>621</b> |      | <b>819</b> |      | <b>168</b> |      | <b>2808</b> |      |

# CANWARD 2012

## Specimen (isolates) / Infection Site

**N (%)**

|           | Blood       | Respiratory | Urine      | Wound      | Total |
|-----------|-------------|-------------|------------|------------|-------|
| National  | 1168 (41.6) | 1067 (38.0) | 298 (10.6) | 275 (9.8)  | 2808  |
| West      | 398 (40.2)  | 393 (39.7)  | 100 (10.1) | 100 (10.1) | 991   |
| Ontario   | 373 (39.0)  | 385 (40.3)  | 98 (10.3)  | 100 (10.5) | 956   |
| Quebec    | 198 (54.5)  | 90 (24.8)   | 50 (13.8)  | 25 (6.9)   | 363   |
| Maritimes | 199 (40.0)  | 199 (40.0)  | 50 (10.0)  | 50 (10.0)  | 498   |

# CANWARD 2012

## Patient Age Demographics

**N (%)**

|                  | ≤17        | 18-64       | ≥65         | Total |
|------------------|------------|-------------|-------------|-------|
| <b>National</b>  | 451 (16.1) | 1204 (42.9) | 1153 (41.1) | 2808  |
| <b>West</b>      | 162 (16.3) | 464 (46.8)  | 365 (36.8)  | 991   |
| <b>Ontario</b>   | 265 (27.7) | 379 (39.6)  | 312 (32.6)  | 956   |
| <b>Quebec</b>    | 7 (1.9)    | 133 (36.6)  | 223 (61.4)  | 363   |
| <b>Maritimes</b> | 17 (3.4)   | 228 (45.8)  | 253 (50.8)  | 498   |



# CANWARD 2012

## Gender of Patient Isolates

**N (%)**

|           | Female      | Male        | Total |
|-----------|-------------|-------------|-------|
| National  | 1251 (44.6) | 1557 (55.4) | 2808  |
| West      | 430 (43.4)  | 561 (56.6)  | 991   |
| Ontario   | 417 (43.6)  | 539 (56.4)  | 956   |
| Quebec    | 173 (47.7)  | 190 (52.3)  | 363   |
| Maritimes | 231 (46.4)  | 267 (53.6)  | 498   |

# CANWARD 2012

## Bacteriology of Top 20 Organisms n=3557

### National - Overall

| Rank | Organism                                | n           | % of Total |
|------|---|-------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 564         | 20.1       |
| 2    | <i>Escherichia coli</i>                 | 500         | 17.8       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 264         | 9.4        |
| 4    | <i>Klebsiella pneumoniae</i>            | 169         | 6.0        |
| 5    | <i>Haemophilus influenzae</i>           | 150         | 5.3        |
| 6    | <i>Streptococcus pneumoniae</i>         | 143         | 5.1        |
| 7    | <i>Staphylococcus aureus, MRSA</i>      | 125         | 4.5        |
| 8    | <i>Enterococcus faecalis</i>            | 93          | 3.3        |
| 9    | CNS / <i>Staphylococcus epidermidis</i> | 85          | 3.0        |
| 10   | <i>Enterobacter cloacae</i>             | 69          | 2.5        |
| 11   | <i>Klebsiella oxytoca</i>               | 50          | 1.8        |
| 12   | <i>Streptococcus agalactiae</i>         | 44          | 1.6        |
| 13   | <i>Stenotrophomonas maltophilia</i>     | 43          | 1.5        |
| 14   | <i>Serratia marcescens</i>              | 41          | 1.5        |
| 15   | <i>Proteus mirabilis</i>                | 39          | 1.4        |
| 16   | <i>Moraxella catarrhalis</i>            | 36          | 1.3        |
| 17   | <i>Streptococcus pyogenes</i>           | 36          | 1.3        |
| 18   | <i>Enterococcus faecium</i>             | 35          | 1.2        |
| 19   | <i>Haemophilus parainfluenzae</i>       | 30          | 1.1        |
| 20   | <i>Staphylococcus hominis</i>           | 26          | 0.9        |
|      | Other                                   | 266         | 9.5        |
|      |   | <b>2808</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms n=3557

West

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 190        | 19.2       |
| 2    | <i>Escherichia coli</i>                 | 163        | 16.4       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 69         | 7.0        |
| 4    | <i>Haemophilus influenzae</i>           | 65         | 6.6        |
| 5    | <i>Staphylococcus aureus, MRSA</i>      | 64         | 6.5        |
| 6    | <i>Streptococcus pneumoniae</i>         | 58         | 5.9        |
| 7    | <i>Klebsiella pneumoniae</i>            | 47         | 4.7        |
| 8    | <i>Enterococcus faecalis</i>            | 35         | 3.5        |
| 9    | <i>Enterobacter cloacae</i>             | 33         | 3.3        |
| 10   | CNS / <i>Staphylococcus epidermidis</i> | 30         | 3.0        |
| 11   | <i>Klebsiella oxytoca</i>               | 25         | 2.5        |
| 12   | <i>Stenotrophomonas maltophilia</i>     | 21         | 2.1        |
| 13   | <i>Streptococcus agalactiae</i>         | 17         | 1.7        |
| 14   | <i>Haemophilus parainfluenzae</i>       | 17         | 1.7        |
| 15   | <i>Streptococcus pyogenes</i>           | 16         | 1.6        |
| 16   | <i>Enterobacter aerogenes</i>           | 11         | 1.1        |
| 17   | <i>Proteus mirabilis</i>                | 11         | 1.1        |
| 18   | <i>Enterococcus faecium</i>             | 11         | 1.1        |
| 19   | <i>Serratia marcescens</i>              | 11         | 1.1        |
| 20   | <i>Candida albicans</i>                 | 9          | 0.9        |
|      | Other                                   | 88         | 8.9        |
|      |   | <b>991</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms n=3557

### Ontario

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 212        | 22.2       |
| 2    | <i>Escherichia coli</i>                 | 172        | 18.0       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 116        | 12.1       |
| 4    | <i>Klebsiella pneumoniae</i>            | 60         | 6.3        |
| 5    | <i>Streptococcus pneumoniae</i>         | 47         | 4.9        |
| 6    | <i>Staphylococcus aureus, MRSA</i>      | 39         | 4.1        |
| 7    | <i>Haemophilus influenzae</i>           | 37         | 3.9        |
| 8    | <i>Enterococcus faecalis</i>            | 30         | 3.1        |
| 9    | CNS / <i>Staphylococcus epidermidis</i> | 26         | 2.7        |
| 10   | <i>Enterobacter cloacae</i>             | 23         | 2.4        |
| 11   | <i>Enterococcus faecium</i>             | 17         | 1.8        |
| 12   | <i>Moraxella catarrhalis</i>            | 17         | 1.8        |
| 13   | <i>Serratia marcescens</i>              | 15         | 1.6        |
| 14   | <i>Proteus mirabilis</i>                | 14         | 1.5        |
| 15   | <i>Enterobacter aerogenes</i>           | 12         | 1.3        |
| 16   | <i>Streptococcus pyogenes</i>           | 12         | 1.3        |
| 17   | <i>Klebsiella oxytoca</i>               | 12         | 1.3        |
| 18   | <i>Staphylococcus hominis</i>           | 9          | 0.9        |
| 19   | <i>Stenotrophomonas maltophilia</i>     | 9          | 0.9        |
| 20   | <i>Candida albicans</i>                 | 6          | 0.6        |
|      | Other                                   | 71         | 7.4        |
|      |   | <b>956</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms n=3557

Quebec

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 75         | 20.7       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 54         | 14.9       |
| 3    | <i>Klebsiella pneumoniae</i>            | 32         | 8.8        |
| 4    | <i>Pseudomonas aeruginosa</i>           | 29         | 8.0        |
| 5    | CNS / <i>Staphylococcus epidermidis</i> | 19         | 5.2        |
| 6    | <i>Streptococcus pneumoniae</i>         | 16         | 4.4        |
| 7    | <i>Haemophilus influenzae</i>           | 14         | 3.9        |
| 8    | <i>Enterococcus faecalis</i>            | 13         | 3.6        |
| 9    | <i>Haemophilus parainfluenzae</i>       | 11         | 3.0        |
| 10   | <i>Streptococcus agalactiae</i>         | 11         | 3.0        |
| 11   | <i>Staphylococcus hominis</i>           | 10         | 2.8        |
| 12   | <i>Staphylococcus aureus, MRSA</i>      | 7          | 1.9        |
| 13   | <i>Staphylococcus capitis</i>           | 5          | 1.4        |
| 14   | <i>Proteus mirabilis</i>                | 5          | 1.4        |
| 15   | <i>Enterobacter cloacae</i>             | 5          | 1.4        |
| 16   | <i>Klebsiella oxytoca</i>               | 5          | 1.4        |
| 17   | <i>Moraxella catarrhalis</i>            | 5          | 1.4        |
| 18   | <i>Streptococcus pyogenes</i>           | 4          | 1.1        |
| 19   | <i>Streptococcus viridans</i>           | 4          | 1.1        |
| 20   | <i>Stenotrophomonas maltophilia</i>     | 4          | 1.1        |
|      | Other                                   | 35         | 9.6        |
|      |   | <b>363</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms n=3557

### Maritimes

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 108        | 21.7       |
| 2    | <i>Escherichia coli</i>                 | 90         | 18.1       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 50         | 10.0       |
| 4    | <i>Haemophilus influenzae</i>           | 34         | 6.8        |
| 5    | <i>Klebsiella pneumoniae</i>            | 30         | 6.0        |
| 6    | <i>Streptococcus pneumoniae</i>         | 22         | 4.4        |
| 7    | <i>Staphylococcus aureus, MRSA</i>      | 15         | 3.0        |
| 8    | <i>Enterococcus faecalis</i>            | 15         | 3.0        |
| 9    | <i>Serratia marcescens</i>              | 14         | 2.8        |
| 10   | <i>Streptococcus agalactiae</i>         | 11         | 2.2        |
| 11   | CNS / <i>Staphylococcus epidermidis</i> | 10         | 2.0        |
| 12   | <i>Stenotrophomonas maltophilia</i>     | 9          | 1.8        |
| 13   | <i>Proteus mirabilis</i>                | 9          | 1.8        |
| 14   | <i>Moraxella catarrhalis</i>            | 8          | 1.6        |
| 15   | <i>Enterobacter cloacae</i>             | 8          | 1.6        |
| 16   | <i>Klebsiella oxytoca</i>               | 8          | 1.6        |
| 17   | <i>Enterococcus faecium</i>             | 5          | 1.0        |
| 18   | <i>Streptococcus, Beta-H, Grp G</i>     | 5          | 1.0        |
| 19   | <i>Streptococcus pyogenes</i>           | 4          | 0.8        |
| 20   | <i>Streptococcus, Beta-H, Grp C</i>     | 4          | 0.8        |
|      | Other                                   | 39         | 7.8        |
|      |   | <b>498</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Blood/Sterile Sites

| National |   |             |            |
|----------|---|-------------|------------|
| Rank     | Organism                                | n           | % of Total |
| 1        | <i>Escherichia coli</i>                 | 275         | 23.5       |
| 2        | <i>Staphylococcus aureus, MSSA</i>      | 189         | 16.2       |
| 3        | <i>Klebsiella pneumoniae</i>            | 90          | 7.7        |
| 4        | CNS / <i>Staphylococcus epidermidis</i> | 71          | 6.1        |
| 5        | <i>Pseudomonas aeruginosa</i>           | 50          | 4.3        |
| 6        | <i>Streptococcus pneumoniae</i>         | 49          | 4.2        |
| 7        | <i>Enterococcus faecalis</i>            | 42          | 3.6        |
| 8        | <i>Staphylococcus aureus, MRSA</i>      | 37          | 3.2        |
| 9        | <i>Streptococcus agalactiae</i>         | 30          | 2.6        |
| 10       | <i>Enterobacter cloacae</i>             | 29          | 2.5        |
| 11       | <i>Enterococcus faecium</i>             | 28          | 2.4        |
| 12       | <i>Staphylococcus hominis</i>           | 26          | 2.2        |
| 13       | <i>Streptococcus pyogenes</i>           | 21          | 1.8        |
| 14       | <i>Klebsiella oxytoca</i>               | 17          | 1.5        |
| 15       | <i>Proteus mirabilis</i>                | 15          | 1.3        |
| 16       | <i>Serratia marcescens</i>              | 14          | 1.2        |
| 17       | <i>Candida albicans</i>                 | 14          | 1.2        |
| 18       | <i>Staphylococcus capitis</i>           | 10          | 0.9        |
| 19       | <i>Streptococcus viridans</i>           | 10          | 0.9        |
| 20       | <i>Streptococcus, Beta-H, Grp G</i>     | 8           | 0.7        |
|          | Other                                   | 143         | 12.2       |
|          |   | <b>1168</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Blood/Sterile Sites

West

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 89         | 22.4       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 72         | 18.1       |
| 3    | <i>Klebsiella pneumoniae</i>            | 23         | 5.8        |
| 4    | <i>CNS / Staphylococcus epidermidis</i> | 20         | 5.0        |
| 5    | <i>Streptococcus pneumoniae</i>         | 20         | 5.0        |
| 6    | <i>Enterococcus faecalis</i>            | 16         | 4.0        |
| 7    | <i>Staphylococcus aureus, MRSA</i>      | 16         | 4.0        |
| 8    | <i>Streptococcus agalactiae</i>         | 14         | 3.5        |
| 9    | <i>Pseudomonas aeruginosa</i>           | 13         | 3.3        |
| 10   | <i>Enterobacter cloacae</i>             | 12         | 3.0        |
| 11   | <i>Streptococcus pyogenes</i>           | 11         | 2.8        |
| 12   | <i>Candida albicans</i>                 | 9          | 2.3        |
| 13   | <i>Enterococcus faecium</i>             | 8          | 2.0        |
| 14   | <i>Klebsiella oxytoca</i>               | 7          | 1.8        |
| 15   | <i>Serratia marcescens</i>              | 6          | 1.5        |
| 16   | <i>Staphylococcus hominis</i>           | 5          | 1.3        |
| 17   | <i>Acinetobacter baumannii</i>          | 4          | 1.0        |
| 18   | <i>Proteus mirabilis</i>                | 4          | 1.0        |
| 19   | <i>Candida glabrata</i>                 | 3          | 0.8        |
| 20   | <i>Streptococcus viridans</i>           | 3          | 0.8        |
|      | Other                                   | 43         | 10.8       |
|      |   | <b>398</b> |            |



# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Blood/Sterile Sites

Ontario

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 90         | 24.1       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 53         | 14.2       |
| 3    | <i>Klebsiella pneumoniae</i>            | 32         | 8.6        |
| 4    | <i>Pseudomonas aeruginosa</i>           | 23         | 6.2        |
| 5    | CNS / <i>Staphylococcus epidermidis</i> | 23         | 6.2        |
| 6    | <i>Enterococcus faecalis</i>            | 17         | 4.6        |
| 7    | <i>Streptococcus pneumoniae</i>         | 15         | 4.0        |
| 8    | <i>Enterococcus faecium</i>             | 13         | 3.5        |
| 9    | <i>Enterobacter cloacae</i>             | 12         | 3.2        |
| 10   | <i>Staphylococcus aureus, MRSA</i>      | 10         | 2.7        |
| 11   | <i>Staphylococcus hominis</i>           | 9          | 2.4        |
| 12   | <i>Streptococcus agalactiae</i>         | 5          | 1.3        |
| 13   | <i>Candida albicans</i>                 | 4          | 1.1        |
| 14   | <i>Streptococcus pyogenes</i>           | 4          | 1.1        |
| 15   | <i>Bacillus, non-speciated</i>          | 4          | 1.1        |
| 16   | <i>Staphylococcus capitis</i>           | 4          | 1.1        |
| 17   | <i>Klebsiella oxytoca</i>               | 4          | 1.1        |
| 18   | <i>Serratia marcescens</i>              | 4          | 1.1        |
| 19   | <i>Citrobacter freundii</i>             | 3          | 0.8        |
| 20   | <i>Proteus mirabilis</i>                | 3          | 0.8        |
|      | Other                                   | 41         | 11.0       |
|      |   | <b>373</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Blood/Sterile Sites

### Quebec

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 50         | 25.3       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 25         | 12.6       |
| 3    | <i>CNS / Staphylococcus epidermidis</i> | 19         | 9.6        |
| 4    | <i>Klebsiella pneumoniae</i>            | 16         | 8.1        |
| 5    | <i>Streptococcus pneumoniae</i>         | 12         | 6.1        |
| 6    | <i>Staphylococcus hominis</i>           | 10         | 5.1        |
| 7    | <i>Pseudomonas aeruginosa</i>           | 6          | 3.0        |
| 8    | <i>Staphylococcus capitis</i>           | 5          | 2.5        |
| 9    | <i>Streptococcus agalactiae</i>         | 4          | 2.0        |
| 10   | <i>Streptococcus viridans</i>           | 4          | 2.0        |
| 11   | <i>Klebsiella oxytoca</i>               | 4          | 2.0        |
| 12   | <i>Streptococcus pyogenes</i>           | 4          | 2.0        |
| 13   | <i>Proteus mirabilis</i>                | 4          | 2.0        |
| 14   | <i>Enterobacter cloacae</i>             | 3          | 1.5        |
| 15   | <i>Haemophilus influenzae</i>           | 3          | 1.5        |
| 16   | <i>Staphylococcus aureus, MRSA</i>      | 3          | 1.5        |
| 17   | <i>Streptococcus mitis</i>              | 2          | 1.0        |
| 18   | <i>Micrococcus, non-speciated</i>       | 2          | 1.0        |
| 19   | <i>Streptococcus, Beta-H, Grp C</i>     | 2          | 1.0        |
| 20   | <i>Streptococcus, Beta-H, Grp G</i>     | 2          | 1.0        |
|      | Other                                   | 18         | 9.1        |
|      |   | <b>198</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Blood/Sterile Sites

### Maritimes

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 46         | 23.1       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 39         | 19.6       |
| 3    | <i>Klebsiella pneumoniae</i>            | 19         | 9.5        |
| 4    | <i>Enterococcus faecalis</i>            | 9          | 4.5        |
| 5    | CNS / <i>Staphylococcus epidermidis</i> | 9          | 4.5        |
| 6    | <i>Pseudomonas aeruginosa</i>           | 8          | 4.0        |
| 7    | <i>Staphylococcus aureus, MRSA</i>      | 8          | 4.0        |
| 8    | <i>Streptococcus agalactiae</i>         | 7          | 3.5        |
| 9    | <i>Enterococcus faecium</i>             | 5          | 2.5        |
| 10   | <i>Serratia marcescens</i>              | 4          | 2.0        |
| 11   | <i>Proteus mirabilis</i>                | 4          | 2.0        |
| 12   | <i>Streptococcus, Beta-H, Grp G</i>     | 4          | 2.0        |
| 13   | <i>Stenotrophomonas maltophilia</i>     | 2          | 1.0        |
| 14   | <i>Staphylococcus hominis</i>           | 2          | 1.0        |
| 15   | <i>Streptococcus pyogenes</i>           | 2          | 1.0        |
| 16   | <i>Enterobacter cloacae</i>             | 2          | 1.0        |
| 17   | <i>Staphylococcus warneri</i>           | 2          | 1.0        |
| 18   | <i>Streptococcus pneumoniae</i>         | 2          | 1.0        |
| 19   | <i>Streptococcus, Beta-H, Grp C</i>     | 2          | 1.0        |
| 20   | <i>Klebsiella oxytoca</i>               | 2          | 1.0        |
|      | Other                                   | 21         | 10.6       |
|      |   | <b>199</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Respiratory

| National |   |             |            |
|----------|---|-------------|------------|
| Rank     | Organism                                    | n           | % of Total |
| 1        | <i>Staphylococcus aureus, MSSA</i>          | 242         | 22.7       |
| 2        | <i>Pseudomonas aeruginosa</i>               | 185         | 17.3       |
| 3        | <i>Haemophilus influenzae</i>               | 142         | 13.3       |
| 4        | <i>Streptococcus pneumoniae</i>             | 94          | 8.8        |
| 5        | <i>Staphylococcus aureus, MRSA</i>          | 58          | 5.4        |
| 6        | <i>Escherichia coli</i>                     | 56          | 5.2        |
| 7        | <i>Klebsiella pneumoniae</i>                | 48          | 4.5        |
| 8        | <i>Moraxella catarrhalis</i>                | 36          | 3.4        |
| 9        | <i>Stenotrophomonas maltophilia</i>         | 35          | 3.3        |
| 10       | <i>Enterobacter cloacae</i>                 | 29          | 2.7        |
| 11       | <i>Haemophilus parainfluenzae</i>           | 27          | 2.5        |
| 12       | <i>Serratia marcescens</i>                  | 24          | 2.2        |
| 13       | <i>Klebsiella oxytoca</i>                   | 18          | 1.7        |
| 14       | <i>Enterobacter aerogenes</i>               | 10          | 0.9        |
| 15       | <i>Streptococcus agalactiae</i>             | 9           | 0.8        |
| 16       | <i>Acinetobacter baumannii</i>              | 7           | 0.7        |
| 17       | <i>Proteus mirabilis</i>                    | 6           | 0.6        |
| 18       | <i>Streptococcus pyogenes</i>               | 4           | 0.4        |
| 19       | <i>Corynebacterium pseudodiphtheriticum</i> | 3           | 0.3        |
| 20       | <i>Pseudomonas putida</i>                   | 3           | 0.3        |
|          | Other                                       | 31          | 2.9        |
|          |   | <b>1067</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Respiratory

West

| Rank | Organism                                    | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>          | 76         | 19.3       |
| 2    | <i>Haemophilus influenzae</i>               | 61         | 15.5       |
| 3    | <i>Pseudomonas aeruginosa</i>               | 51         | 13.0       |
| 4    | <i>Streptococcus pneumoniae</i>             | 38         | 9.7        |
| 5    | <i>Staphylococcus aureus, MRSA</i>          | 28         | 7.1        |
| 6    | <i>Escherichia coli</i>                     | 23         | 5.9        |
| 7    | <i>Stenotrophomonas maltophilia</i>         | 19         | 4.8        |
| 8    | <i>Klebsiella pneumoniae</i>                | 16         | 4.1        |
| 9    | <i>Enterobacter cloacae</i>                 | 15         | 3.8        |
| 10   | <i>Haemophilus parainfluenzae</i>           | 15         | 3.8        |
| 11   | <i>Klebsiella oxytoca</i>                   | 11         | 2.8        |
| 12   | <i>Moraxella catarrhalis</i>                | 6          | 1.5        |
| 13   | <i>Enterobacter aerogenes</i>               | 6          | 1.5        |
| 14   | <i>Serratia marcescens</i>                  | 4          | 1.0        |
| 15   | <i>Acinetobacter baumannii</i>              | 4          | 1.0        |
| 16   | <i>Streptococcus agalactiae</i>             | 3          | 0.8        |
| 17   | <i>Corynebacterium pseudodiphtheriticum</i> | 2          | 0.5        |
| 18   | <i>Enterococcus faecalis</i>                | 2          | 0.5        |
| 19   | <i>Burkholderia cepacia</i>                 | 2          | 0.5        |
| 20   | <i>Acinetobacter, non-speciated</i>         | 1          | 0.3        |
|      | Other                                       | 10         | 2.5        |
|      |   | <b>393</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Respiratory

Ontario

| Rank | Organism                            | n          | % of Total |
|------|-------------------------------------|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>  | 114        | 29.6       |
| 2    | <i>Pseudomonas aeruginosa</i>       | 84         | 21.8       |
| 3    | <i>Haemophilus influenzae</i>       | 37         | 9.6        |
| 4    | <i>Streptococcus pneumoniae</i>     | 32         | 8.3        |
| 5    | <i>Staphylococcus aureus, MRSA</i>  | 19         | 4.9        |
| 6    | <i>Klebsiella pneumoniae</i>        | 19         | 4.9        |
| 7    | <i>Moraxella catarrhalis</i>        | 17         | 4.4        |
| 8    | <i>Escherichia coli</i>             | 16         | 4.2        |
| 9    | <i>Serratia marcescens</i>          | 10         | 2.6        |
| 10   | <i>Stenotrophomonas maltophilia</i> | 7          | 1.8        |
| 11   | <i>Enterobacter cloacae</i>         | 7          | 1.8        |
| 12   | <i>Enterobacter aerogenes</i>       | 4          | 1.0        |
| 13   | <i>Proteus mirabilis</i>            | 3          | 0.8        |
| 14   | <i>Klebsiella oxytoca</i>           | 3          | 0.8        |
| 15   | <i>Candida albicans</i>             | 2          | 0.5        |
| 16   | <i>Alcaligenes xylosoxidans</i>     | 2          | 0.5        |
| 17   | <i>Streptococcus pyogenes</i>       | 2          | 0.5        |
| 18   | <i>Acinetobacter baumannii</i>      | 1          | 0.3        |
| 19   | <i>Pasteurella multocida</i>        | 1          | 0.3        |
| 20   | <i>Achromobacter, non-specified</i> | 1          | 0.3        |
|      | Other                               | 4          | 1.0        |
|      |                                     | <b>385</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Respiratory

### Quebec

| Rank | Organism                            | n         | % of Total |
|------|-------------------------------------|-----------|------------|
| 1    | <i>Pseudomonas aeruginosa</i>       | 17        | 18.9       |
| 2    | <i>Staphylococcus aureus</i> , MSSA | 14        | 15.6       |
| 3    | <i>Haemophilus influenzae</i>       | 11        | 12.2       |
| 4    | <i>Haemophilus parainfluenzae</i>   | 11        | 12.2       |
| 5    | <i>Streptococcus agalactiae</i>     | 5         | 5.6        |
| 6    | <i>Escherichia coli</i>             | 5         | 5.6        |
| 7    | <i>Moraxella catarrhalis</i>        | 5         | 5.6        |
| 8    | <i>Staphylococcus aureus</i> , MRSA | 4         | 4.4        |
| 9    | <i>Klebsiella pneumoniae</i>        | 4         | 4.4        |
| 10   | <i>Streptococcus pneumoniae</i>     | 4         | 4.4        |
| 11   | <i>Stenotrophomonas maltophilia</i> | 3         | 3.3        |
| 12   | <i>Enterobacter cloacae</i>         | 2         | 2.2        |
| 13   | <i>Klebsiella oxytoca</i>           | 1         | 1.1        |
| 14   | <i>Acinetobacter calcoaceticus</i>  | 1         | 1.1        |
| 15   | <i>Chryseobacterium indologenes</i> | 1         | 1.1        |
| 16   | <i>Enterococcus faecalis</i>        | 1         | 1.1        |
| 17   | <i>Alcaligenes xylosoxidans</i>     | 1         | 1.1        |
|      |                                     | <b>90</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Respiratory

### Maritimes

| Rank | Organism                            | n          | % of Total |
|------|-------------------------------------|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>  | 38         | 19.1       |
| 2    | <i>Pseudomonas aeruginosa</i>       | 33         | 16.6       |
| 3    | <i>Haemophilus influenzae</i>       | 33         | 16.6       |
| 4    | <i>Streptococcus pneumoniae</i>     | 20         | 10.1       |
| 5    | <i>Escherichia coli</i>             | 12         | 6.0        |
| 6    | <i>Serratia marcescens</i>          | 10         | 5.0        |
| 7    | <i>Klebsiella pneumoniae</i>        | 9          | 4.5        |
| 8    | <i>Moraxella catarrhalis</i>        | 8          | 4.0        |
| 9    | <i>Staphylococcus aureus, MRSA</i>  | 7          | 3.5        |
| 10   | <i>Stenotrophomonas maltophilia</i> | 6          | 3.0        |
| 11   | <i>Enterobacter cloacae</i>         | 5          | 2.5        |
| 12   | <i>Klebsiella oxytoca</i>           | 3          | 1.5        |
| 13   | <i>Proteus mirabilis</i>            | 2          | 1.0        |
| 14   | <i>Pseudomonas putida</i>           | 2          | 1.0        |
| 15   | <i>Acinetobacter baumannii</i>      | 2          | 1.0        |
| 16   | <i>Raoultella planticola</i>        | 1          | 0.5        |
| 17   | <i>Citrobacter koseri</i>           | 1          | 0.5        |
| 18   | <i>Haemophilus parainfluenzae</i>   | 1          | 0.5        |
| 19   | <i>Moraxella, non-speciated</i>     | 1          | 0.5        |
| 20   | <i>Citrobacter freundii</i>         | 1          | 0.5        |
|      | Other                               | 4          | 2.0        |
|      |                                     | <b>199</b> |            |



# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Urine

| National |   |            |            |
|----------|---|------------|------------|
| Rank     | Organism                                | n          | % of Total |
| 1        | <i>Escherichia coli</i>                 | 154        | 51.7       |
| 2        | <i>Enterococcus faecalis</i>            | 36         | 12.1       |
| 3        | <i>Klebsiella pneumoniae</i>            | 28         | 9.4        |
| 4        | <i>Proteus mirabilis</i>                | 14         | 4.7        |
| 5        | <i>Klebsiella oxytoca</i>               | 11         | 3.7        |
| 6        | CNS / <i>Staphylococcus epidermidis</i> | 8          | 2.7        |
| 7        | <i>Enterobacter aerogenes</i>           | 8          | 2.7        |
| 8        | <i>Staphylococcus aureus</i> , MSSA     | 7          | 2.3        |
| 9        | <i>Pseudomonas aeruginosa</i>           | 7          | 2.3        |
| 10       | <i>Enterobacter cloacae</i>             | 6          | 2.0        |
| 11       | <i>Citrobacter freundii</i>             | 3          | 1.0        |
| 12       | <i>Citrobacter amalonaticus</i>         | 2          | 0.7        |
| 13       | <i>Streptococcus agalactiae</i>         | 2          | 0.7        |
| 14       | <i>Morganella morganii</i>              | 2          | 0.7        |
| 15       | <i>Enterococcus faecium</i>             | 2          | 0.7        |
| 16       | <i>Citrobacter braakii</i>              | 1          | 0.3        |
| 17       | <i>Enterobacter amnigenus</i>           | 1          | 0.3        |
| 18       | <i>Serratia marcescens</i>              | 1          | 0.3        |
| 19       | <i>Citrobacter koseri</i>               | 1          | 0.3        |
| 20       | <i>Staphylococcus saprophyticus</i>     | 1          | 0.3        |
|          | Other                                   | 3          | 1.0        |
|          |   | <b>298</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Urine

West

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 50         | 50.0       |
| 2    | <i>Enterococcus faecalis</i>            | 11         | 11.0       |
| 3    | <i>Klebsiella pneumoniae</i>            | 8          | 8.0        |
| 4    | CNS / <i>Staphylococcus epidermidis</i> | 6          | 6.0        |
| 5    | <i>Klebsiella oxytoca</i>               | 6          | 6.0        |
| 6    | <i>Proteus mirabilis</i>                | 4          | 4.0        |
| 7    | <i>Enterobacter cloacae</i>             | 3          | 3.0        |
| 8    | <i>Enterobacter aerogenes</i>           | 3          | 3.0        |
| 9    | <i>Citrobacter freundii</i>             | 2          | 2.0        |
| 10   | <i>Staphylococcus aureus</i> , MSSA     | 2          | 2.0        |
| 11   | <i>Enterococcus faecium</i>             | 1          | 1.0        |
| 12   | <i>Pseudomonas aeruginosa</i>           | 1          | 1.0        |
| 13   | <i>Citrobacter amalonaticus</i>         | 1          | 1.0        |
| 14   | <i>Enterobacter amnigenus</i>           | 1          | 1.0        |
| 15   | <i>Staphylococcus saprophyticus</i>     | 1          | 1.0        |
|      |   | <b>100</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Urine

Ontario

| Rank | Organism                                | n         | % of Total |
|------|---|-----------|------------|
| 1    | <i>Escherichia coli</i>                 | 55        | 56.1       |
| 2    | <i>Enterococcus faecalis</i>            | 10        | 10.2       |
| 3    | <i>Proteus mirabilis</i>                | 6         | 6.1        |
| 4    | <i>Klebsiella pneumoniae</i>            | 6         | 6.1        |
| 5    | <i>Enterobacter aerogenes</i>           | 5         | 5.1        |
| 6    | <i>Klebsiella oxytoca</i>               | 3         | 3.1        |
| 7    | <i>Enterobacter cloacae</i>             | 3         | 3.1        |
| 8    | <i>Pseudomonas aeruginosa</i>           | 2         | 2.0        |
| 9    | CNS / <i>Staphylococcus epidermidis</i> | 2         | 2.0        |
| 10   | <i>Citrobacter amalonaticus</i>         | 1         | 1.0        |
| 11   | <i>Staphylococcus aureus</i> , MSSA     | 1         | 1.0        |
| 12   | <i>Serratia fonticola</i>               | 1         | 1.0        |
| 13   | <i>Enterococcus faecium</i>             | 1         | 1.0        |
| 14   | <i>Hafnia alvei</i>                     | 1         | 1.0        |
| 15   | <i>Streptococcus pyogenes</i>           | 1         | 1.0        |
|      |   | <b>98</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Urine

Quebec

| Rank | Organism                           | n         | % of Total |
|------|------------------------------------|-----------|------------|
| 1    | <i>Escherichia coli</i>            | 19        | 38.0       |
| 2    | <i>Klebsiella pneumoniae</i>       | 12        | 24.0       |
| 3    | Enterococcus faecalis              | 10        | 20.0       |
| 4    | <i>Staphylococcus aureus, MSSA</i> | 2         | 4.0        |
| 5    | <i>Proteus mirabilis</i>           | 1         | 2.0        |
| 6    | <i>Citrobacter koseri</i>          | 1         | 2.0        |
| 7    | <i>Pseudomonas aeruginosa</i>      | 1         | 2.0        |
| 8    | <i>Serratia marcescens</i>         | 1         | 2.0        |
| 9    | <i>Citrobacter braakii</i>         | 1         | 2.0        |
| 10   | <i>Morganella morganii</i>         | 1         | 2.0        |
| 11   | <i>Streptococcus agalactiae</i>    | 1         | 2.0        |
|      |                                    | <b>50</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Urine

### Maritimes

| Rank | Organism                           | n         | % of Total |
|------|------------------------------------|-----------|------------|
| 1    | <i>Escherichia coli</i>            | 30        | 60.0       |
| 2    | <i>Enterococcus faecalis</i>       | 5         | 10.0       |
| 3    | <i>Proteus mirabilis</i>           | 3         | 6.0        |
| 4    | <i>Pseudomonas aeruginosa</i>      | 3         | 6.0        |
| 5    | <i>Staphylococcus aureus, MSSA</i> | 2         | 4.0        |
| 6    | <i>Klebsiella oxytoca</i>          | 2         | 4.0        |
| 7    | <i>Klebsiella pneumoniae</i>       | 2         | 4.0        |
| 8    | <i>Citrobacter freundii</i>        | 1         | 2.0        |
| 9    | <i>Morganella morganii</i>         | 1         | 2.0        |
| 10   | <i>Streptococcus agalactiae</i>    | 1         | 2.0        |
|      |                                    | <b>50</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Wounds/IV

| National |   |            |            |
|----------|---|------------|------------|
| Rank     | Organism                                | n          | % of Total |
| 1        | <i>Staphylococcus aureus, MSSA</i>      | 126        | 45.8       |
| 2        | <i>Staphylococcus aureus, MRSA</i>      | 30         | 10.9       |
| 3        | <i>Pseudomonas aeruginosa</i>           | 22         | 8.0        |
| 4        | <i>Escherichia coli</i>                 | 15         | 5.5        |
| 5        | <i>Enterococcus faecalis</i>            | 12         | 4.4        |
| 6        | <i>Streptococcus pyogenes</i>           | 10         | 3.6        |
| 7        | CNS / <i>Staphylococcus epidermidis</i> | 6          | 2.2        |
| 8        | <i>Streptococcus, Beta-H, Grp G</i>     | 6          | 2.2        |
| 9        | <i>Enterobacter cloacae</i>             | 5          | 1.8        |
| 10       | <i>Klebsiella oxytoca</i>               | 4          | 1.5        |
| 11       | <i>Proteus mirabilis</i>                | 4          | 1.5        |
| 12       | <i>Enterococcus faecium</i>             | 4          | 1.5        |
| 13       | <i>Streptococcus agalactiae</i>         | 3          | 1.1        |
| 14       | <i>Klebsiella pneumoniae</i>            | 3          | 1.1        |
| 15       | <i>Streptococcus, Beta-H, Grp C</i>     | 3          | 1.1        |
| 16       | <i>Enterobacter aerogenes</i>           | 2          | 0.7        |
| 17       | <i>Staphylococcus lugdunensis</i>       | 2          | 0.7        |
| 18       | <i>Serratia marcescens</i>              | 2          | 0.7        |
| 19       | <i>Haemophilus parainfluenzae</i>       | 1          | 0.4        |
| 20       | <i>Pasteurella multocida</i>            | 1          | 0.4        |
|          | Other                                   | 14         | 5.1        |
|          |   | <b>275</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Wounds/IV

West

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 40         | 40.0       |
| 2    | <i>Staphylococcus aureus, MRSA</i>      | 20         | 20.0       |
| 3    | <i>Enterococcus faecalis</i>            | 6          | 6.0        |
| 4    | <i>Streptococcus pyogenes</i>           | 4          | 4.0        |
| 5    | CNS / <i>Staphylococcus epidermidis</i> | 4          | 4.0        |
| 6    | <i>Pseudomonas aeruginosa</i>           | 4          | 4.0        |
| 7    | <i>Enterobacter cloacae</i>             | 3          | 3.0        |
| 8    | <i>Streptococcus, Beta-H, Grp G</i>     | 3          | 3.0        |
| 9    | <i>Proteus mirabilis</i>                | 2          | 2.0        |
| 10   | <i>Klebsiella oxytoca</i>               | 1          | 1.0        |
| 11   | <i>Serratia marcescens</i>              | 1          | 1.0        |
| 12   | <i>Myroides non-speciated</i>           | 1          | 1.0        |
| 13   | <i>Enterococcus avium</i>               | 1          | 1.0        |
| 14   | <i>Haemophilus parainfluenzae</i>       | 1          | 1.0        |
| 15   | <i>Enterococcus casseliflavus</i>       | 1          | 1.0        |
| 16   | <i>Morganella morganii</i>              | 1          | 1.0        |
| 17   | <i>Enterococcus faecium</i>             | 1          | 1.0        |
| 18   | <i>Citrobacter freundii</i>             | 1          | 1.0        |
| 19   | <i>Pasteurella multocida</i>            | 1          | 1.0        |
| 20   | <i>Escherichia coli</i>                 | 1          | 1.0        |
|      | Other                                   | 3          | 3.0        |
|      |   | <b>100</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Wounds/IV

### Ontario

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 44         | 44.0       |
| 2    | <i>Escherichia coli</i>                 | 11         | 11.0       |
| 3    | <i>Staphylococcus aureus, MRSA</i>      | 10         | 10.0       |
| 4    | <i>Pseudomonas aeruginosa</i>           | 7          | 7.0        |
| 5    | <i>Streptococcus pyogenes</i>           | 5          | 5.0        |
| 6    | <i>Enterococcus faecalis</i>            | 3          | 3.0        |
| 7    | <i>Klebsiella pneumoniae</i>            | 3          | 3.0        |
| 8    | <i>Enterococcus faecium</i>             | 3          | 3.0        |
| 9    | <i>Enterobacter aerogenes</i>           | 2          | 2.0        |
| 10   | <i>Proteus mirabilis</i>                | 2          | 2.0        |
| 11   | <i>Klebsiella oxytoca</i>               | 2          | 2.0        |
| 12   | <i>Serratia marcescens</i>              | 1          | 1.0        |
| 13   | <i>Citrobacter koseri</i>               | 1          | 1.0        |
| 14   | <i>Aeromonas sobria</i>                 | 1          | 1.0        |
| 15   | <i>Enterobacter cloacae</i>             | 1          | 1.0        |
| 16   | <i>CNS / Staphylococcus epidermidis</i> | 1          | 1.0        |
| 17   | <i>Capnocytophaga, non-speciated</i>    | 1          | 1.0        |
| 18   | <i>Streptococcus, Beta-H, Grp C</i>     | 1          | 1.0        |
| 19   | <i>Streptococcus, Beta-H, Grp G</i>     | 1          | 1.0        |
|      |   | <b>100</b> |            |



# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Wounds/IV

### Quebec

| Rank | Organism                            | n         | % of Total |
|------|-------------------------------------|-----------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>  | 13        | 52.0       |
| 2    | <i>Pseudomonas aeruginosa</i>       | 5         | 20.0       |
| 3    | <i>Enterococcus faecalis</i>        | 2         | 8.0        |
| 4    | <i>Citrobacter youngae</i>          | 1         | 4.0        |
| 5    | <i>Acinetobacter calcoaceticus</i>  | 1         | 4.0        |
| 6    | <i>Streptococcus agalactiae</i>     | 1         | 4.0        |
| 7    | <i>Escherichia coli</i>             | 1         | 4.0        |
| 8    | <i>Streptococcus, Beta-H, Grp G</i> | 1         | 4.0        |
|      |                                     | <b>25</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Specimen Source – Wounds/IV

### Maritimes

| Rank | Organism                                | n         | % of Total |
|------|---|-----------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 29        | 58.0       |
| 2    | <i>Pseudomonas aeruginosa</i>           | 6         | 12.0       |
| 3    | <i>Streptococcus agalactiae</i>         | 2         | 4.0        |
| 4    | <i>Escherichia coli</i>                 | 2         | 4.0        |
| 5    | <i>Streptococcus, Beta-H, Grp C</i>     | 1         | 2.0        |
| 6    | <i>Serratia liquefaciens</i>            | 1         | 2.0        |
| 7    | <i>Enterococcus faecalis</i>            | 1         | 2.0        |
| 8    | <i>Staphylococcus lugdunensis</i>       | 1         | 2.0        |
| 9    | <i>CNS / Staphylococcus epidermidis</i> | 1         | 2.0        |
| 10   | <i>Enterobacter cloacae</i>             | 1         | 2.0        |
| 11   | <i>Stenotrophomonas maltophilia</i>     | 1         | 2.0        |
| 12   | <i>Klebsiella oxytoca</i>               | 1         | 2.0        |
| 13   | <i>Streptococcus pyogenes</i>           | 1         | 2.0        |
| 14   | <i>Kocuria kristinae</i>                | 1         | 2.0        |
| 15   | <i>Streptococcus, Beta-H, Grp G</i>     | 1         | 2.0        |
|      |   | <b>50</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age ≤17 years

| National |   |            |            |
|----------|---|------------|------------|
| Rank     | Organism                                | n          | % of Total |
| 1        | <i>Staphylococcus aureus, MSSA</i>      | 84         | 18.6       |
| 2        | <i>Escherichia coli</i>                 | 51         | 11.3       |
| 3        | <i>Haemophilus influenzae</i>           | 47         | 10.4       |
| 4        | <i>Pseudomonas aeruginosa</i>           | 39         | 8.6        |
| 5        | <i>Streptococcus pneumoniae</i>         | 33         | 7.3        |
| 6        | CNS / <i>Staphylococcus epidermidis</i> | 22         | 4.9        |
| 7        | <i>Enterobacter cloacae</i>             | 18         | 4.0        |
| 8        | <i>Staphylococcus aureus, MRSA</i>      | 17         | 3.8        |
| 9        | <i>Klebsiella pneumoniae</i>            | 17         | 3.8        |
| 10       | <i>Streptococcus pyogenes</i>           | 15         | 3.3        |
| 11       | <i>Moraxella catarrhalis</i>            | 15         | 3.3        |
| 12       | <i>Stenotrophomonas maltophilia</i>     | 10         | 2.2        |
| 13       | <i>Enterococcus faecalis</i>            | 10         | 2.2        |
| 14       | <i>Klebsiella oxytoca</i>               | 8          | 1.8        |
| 15       | <i>Proteus mirabilis</i>                | 8          | 1.8        |
| 16       | <i>Serratia marcescens</i>              | 7          | 1.6        |
| 17       | <i>Streptococcus agalactiae</i>         | 7          | 1.6        |
| 18       | <i>Staphylococcus hominis</i>           | 6          | 1.3        |
| 19       | <i>Staphylococcus warneri</i>           | 3          | 0.7        |
| 20       | <i>Staphylococcus capitis</i>           | 3          | 0.7        |
|          | Other                                   | 31         | 6.9        |
|          |   | <b>451</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age ≤17 years

West

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 34         | 21.0       |
| 2    | <i>Haemophilus influenzae</i>           | 20         | 12.3       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 16         | 9.9        |
| 4    | <i>Escherichia coli</i>                 | 11         | 6.8        |
| 5    | <i>Staphylococcus aureus, MRSA</i>      | 9          | 5.6        |
| 6    | <i>Streptococcus pneumoniae</i>         | 9          | 5.6        |
| 7    | CNS / <i>Staphylococcus epidermidis</i> | 8          | 4.9        |
| 8    | <i>Enterobacter cloacae</i>             | 7          | 4.3        |
| 9    | <i>Stenotrophomonas maltophilia</i>     | 6          | 3.7        |
| 10   | <i>Streptococcus agalactiae</i>         | 5          | 3.1        |
| 11   | <i>Enterococcus faecalis</i>            | 5          | 3.1        |
| 12   | <i>Klebsiella oxytoca</i>               | 5          | 3.1        |
| 13   | <i>Klebsiella pneumoniae</i>            | 5          | 3.1        |
| 14   | <i>Streptococcus pyogenes</i>           | 5          | 3.1        |
| 15   | <i>Serratia marcescens</i>              | 4          | 2.5        |
| 16   | <i>Streptococcus mitis</i>              | 1          | 0.6        |
| 17   | <i>Staphylococcus hominis</i>           | 1          | 0.6        |
| 18   | <i>Enterobacter aerogenes</i>           | 1          | 0.6        |
| 19   | <i>Salmonella, non-speciated</i>        | 1          | 0.6        |
| 20   | <i>Staphylococcus warneri</i>           | 1          | 0.6        |
|      | Other                                   | 8          | 4.9        |
|      |   | <b>162</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age ≤17 years

Ontario

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 45         | 17.0       |
| 2    | <i>Escherichia coli</i>                 | 39         | 14.7       |
| 3    | <i>Haemophilus influenzae</i>           | 25         | 9.4        |
| 4    | <i>Streptococcus pneumoniae</i>         | 23         | 8.7        |
| 5    | <i>Pseudomonas aeruginosa</i>           | 21         | 7.9        |
| 6    | <i>Moraxella catarrhalis</i>            | 14         | 5.3        |
| 7    | CNS / <i>Staphylococcus epidermidis</i> | 13         | 4.9        |
| 8    | <i>Streptococcus pyogenes</i>           | 9          | 3.4        |
| 9    | <i>Enterobacter cloacae</i>             | 9          | 3.4        |
| 10   | <i>Klebsiella pneumoniae</i>            | 9          | 3.4        |
| 11   | <i>Staphylococcus aureus, MRSA</i>      | 8          | 3.0        |
| 12   | <i>Proteus mirabilis</i>                | 7          | 2.6        |
| 13   | <i>Staphylococcus hominis</i>           | 5          | 1.9        |
| 14   | <i>Enterococcus faecalis</i>            | 4          | 1.5        |
| 15   | <i>Stenotrophomonas maltophilia</i>     | 4          | 1.5        |
| 16   | <i>Klebsiella oxytoca</i>               | 3          | 1.1        |
| 17   | <i>Staphylococcus capitis</i>           | 3          | 1.1        |
| 18   | <i>Serratia marcescens</i>              | 2          | 0.8        |
| 19   | <i>Enterobacter agglomerans</i>         | 1          | 0.4        |
| 20   | <i>Staphylococcus lugdunensis</i>       | 1          | 0.4        |
|      | Other                                   | 20         | 7.5        |
|      |   | <b>265</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age ≤17 years

### Quebec

| Rank | Organism                           | n        | % of Total |
|------|------------------------------------|----------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i> | 2        | 28.6       |
| 2    | <i>Escherichia coli</i>            | 1        | 14.3       |
| 3    | <i>Klebsiella pneumoniae</i>       | 1        | 14.3       |
| 4    | <i>Citrobacter koseri</i>          | 1        | 14.3       |
| 5    | <i>Enterococcus faecalis</i>       | 1        | 14.3       |
| 6    | <i>Streptococcus pneumoniae</i>    | 1        | 14.3       |
|      |                                    | <b>7</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age ≤17 years

### Maritimes

| Rank | Organism                                | n         | % of Total |
|------|---|-----------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 3         | 17.6       |
| 2    | <i>Haemophilus influenzae</i>           | 2         | 11.8       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 2         | 11.8       |
| 4    | <i>Enterobacter cloacae</i>             | 2         | 11.8       |
| 5    | <i>Klebsiella pneumoniae</i>            | 2         | 11.8       |
| 6    | <i>Serratia marcescens</i>              | 1         | 5.9        |
| 7    | <i>Streptococcus agalactiae</i>         | 1         | 5.9        |
| 8    | <i>Staphylococcus warneri</i>           | 1         |            |
| 9    | CNS / <i>Staphylococcus epidermidis</i> | 1         |            |
| 10   | <i>Pseudomonas putida</i>               | 1         | 5.9        |
| 11   | <i>Streptococcus pyogenes</i>           | 1         | 5.9        |
|      |   | <b>17</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age 18-64 years

| National |   |             |            |
|----------|---|-------------|------------|
| Rank     | Organism                                | n           | % of Total |
| 1        | <i>Staphylococcus aureus, MSSA</i>      | 298         | 24.8       |
| 2        | <i>Escherichia coli</i>                 | 192         | 15.9       |
| 3        | <i>Pseudomonas aeruginosa</i>           | 112         | 9.3        |
| 4        | <i>Streptococcus pneumoniae</i>         | 75          | 6.2        |
| 5        | <i>Klebsiella pneumoniae</i>            | 63          | 5.2        |
| 6        | <i>Staphylococcus aureus, MRSA</i>      | 62          | 5.1        |
| 7        | <i>Haemophilus influenzae</i>           | 59          | 4.9        |
| 8        | <i>Enterococcus faecalis</i>            | 36          | 3.0        |
| 9        | CNS / <i>Staphylococcus epidermidis</i> | 34          | 2.8        |
| 10       | <i>Enterobacter cloacae</i>             | 27          | 2.2        |
| 11       | <i>Streptococcus agalactiae</i>         | 20          | 1.7        |
| 12       | <i>Enterococcus faecium</i>             | 19          | 1.6        |
| 13       | <i>Haemophilus parainfluenzae</i>       | 16          | 1.3        |
| 14       | <i>Serratia marcescens</i>              | 15          | 1.2        |
| 15       | <i>Stenotrophomonas maltophilia</i>     | 15          | 1.2        |
| 16       | <i>Klebsiella oxytoca</i>               | 13          | 1.1        |
| 17       | <i>Streptococcus pyogenes</i>           | 12          | 1.0        |
| 18       | <i>Proteus mirabilis</i>                | 12          | 1.0        |
| 19       | <i>Acinetobacter baumannii</i>          | 10          | 0.8        |
| 20       | <i>Enterobacter aerogenes</i>           | 10          | 0.8        |
|          | Other                                   | 104         | 8.6        |
|          |   | <b>1204</b> |            |



# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age 18-64 years

West

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 117        | 25.2       |
| 2    | <i>Escherichia coli</i>                 | 69         | 14.9       |
| 3    | <i>Staphylococcus aureus, MRSA</i>      | 35         | 7.5        |
| 4    | <i>Streptococcus pneumoniae</i>         | 33         | 7.1        |
| 5    | <i>Pseudomonas aeruginosa</i>           | 30         | 6.5        |
| 6    | <i>Haemophilus influenzae</i>           | 30         | 6.5        |
| 7    | <i>Klebsiella pneumoniae</i>            | 16         | 3.4        |
| 8    | <i>Enterobacter cloacae</i>             | 14         | 3.0        |
| 9    | CNS / <i>Staphylococcus epidermidis</i> | 14         | 3.0        |
| 10   | <i>Enterococcus faecalis</i>            | 14         | 3.0        |
| 11   | <i>Haemophilus parainfluenzae</i>       | 10         | 2.2        |
| 12   | <i>Streptococcus agalactiae</i>         | 7          | 1.5        |
| 13   | <i>Streptococcus pyogenes</i>           | 7          | 1.5        |
| 14   | <i>Klebsiella oxytoca</i>               | 6          | 1.3        |
| 15   | <i>Acinetobacter baumannii</i>          | 6          | 1.3        |
| 16   | <i>Enterobacter aerogenes</i>           | 5          | 1.1        |
| 17   | <i>Enterococcus faecium</i>             | 5          | 1.1        |
| 18   | <i>Proteus mirabilis</i>                | 4          | 0.9        |
| 19   | <i>Stenotrophomonas maltophilia</i>     | 3          | 0.6        |
| 20   | <i>Candida albicans</i>                 | 3          | 0.6        |
|      | Other                                   | 36         | 7.8        |
|      |   | <b>464</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age 18-64 years

Ontario

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 99         | 26.1       |
| 2    | <i>Escherichia coli</i>                 | 63         | 16.6       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 54         | 14.2       |
| 4    | <i>Klebsiella pneumoniae</i>            | 25         | 6.6        |
| 5    | <i>Streptococcus pneumoniae</i>         | 20         | 5.3        |
| 6    | <i>Staphylococcus aureus, MRSA</i>      | 16         | 4.2        |
| 7    | <i>Enterococcus faecalis</i>            | 11         | 2.9        |
| 8    | <i>Enterococcus faecium</i>             | 11         | 2.9        |
| 9    | <i>Serratia marcescens</i>              | 10         | 2.6        |
| 10   | <i>Enterobacter cloacae</i>             | 8          | 2.1        |
| 11   | CNS / <i>Staphylococcus epidermidis</i> | 8          | 2.1        |
| 12   | <i>Haemophilus influenzae</i>           | 6          | 1.6        |
| 13   | <i>Enterobacter aerogenes</i>           | 5          | 1.3        |
| 14   | <i>Klebsiella oxytoca</i>               | 4          | 1.1        |
| 15   | <i>Proteus mirabilis</i>                | 4          | 1.1        |
| 16   | <i>Citrobacter freundii</i>             | 4          | 1.1        |
| 17   | <i>Stenotrophomonas maltophilia</i>     | 3          | 0.8        |
| 18   | <i>Streptococcus pyogenes</i>           | 2          | 0.5        |
| 19   | <i>Streptococcus agalactiae</i>         | 2          | 0.5        |
| 20   | <i>Acinetobacter baumannii</i>          | 2          | 0.5        |
|      | Other                                   | 22         | 5.8        |
|      |   | <b>379</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age 18-64 years

Quebec

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 24         | 18.0       |
| 2    | <i>Escherichia coli</i>                 | 23         | 17.3       |
| 3    | <i>Klebsiella pneumoniae</i>            | 11         | 8.3        |
| 4    | <i>Streptococcus pneumoniae</i>         | 10         | 7.5        |
| 5    | CNS / <i>Staphylococcus epidermidis</i> | 9          | 6.8        |
| 6    | <i>Haemophilus influenzae</i>           | 7          | 5.3        |
| 7    | <i>Streptococcus agalactiae</i>         | 6          | 4.5        |
| 8    | <i>Pseudomonas aeruginosa</i>           | 6          | 4.5        |
| 9    | <i>Haemophilus parainfluenzae</i>       | 5          | 3.8        |
| 10   | <i>Enterococcus faecalis</i>            | 5          | 3.8        |
| 11   | <i>Staphylococcus hominis</i>           | 4          | 3.0        |
| 12   | <i>Stenotrophomonas maltophilia</i>     | 2          | 1.5        |
| 13   | <i>Staphylococcus aureus, MRSA</i>      | 2          | 1.5        |
| 14   | <i>Enterobacter cloacae</i>             | 2          | 1.5        |
| 15   | <i>Streptococcus viridans</i>           | 2          | 1.5        |
| 16   | <i>Moraxella catarrhalis</i>            | 2          | 1.5        |
| 17   | <i>Morganella morganii</i>              | 1          | 0.8        |
| 18   | <i>Streptococcus pyogenes</i>           | 1          | 0.8        |
| 19   | <i>Streptococcus mitis</i>              | 1          | 0.8        |
| 20   | <i>Acinetobacter baumannii</i>          | 1          | 0.8        |
|      | Other                                   | 9          | 6.8        |
|      |   | <b>133</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age 18-64 years

### Maritimes

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 58         | 25.4       |
| 2    | <i>Escherichia coli</i>                 | 37         | 16.2       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 22         | 9.6        |
| 4    | <i>Haemophilus influenzae</i>           | 16         | 7.0        |
| 5    | <i>Streptococcus pneumoniae</i>         | 12         | 5.3        |
| 6    | <i>Klebsiella pneumoniae</i>            | 11         | 4.8        |
| 7    | <i>Staphylococcus aureus, MRSA</i>      | 9          | 3.9        |
| 8    | <i>Stenotrophomonas maltophilia</i>     | 7          | 3.1        |
| 9    | <i>Enterococcus faecalis</i>            | 6          | 2.6        |
| 10   | <i>Streptococcus agalactiae</i>         | 5          | 2.2        |
| 11   | <i>Serratia marcescens</i>              | 5          | 2.2        |
| 12   | <i>Moraxella catarrhalis</i>            | 4          | 1.8        |
| 13   | <i>Proteus mirabilis</i>                | 3          | 1.3        |
| 14   | <i>Enterococcus faecium</i>             | 3          | 1.3        |
| 15   | CNS / <i>Staphylococcus epidermidis</i> | 3          | 1.3        |
| 16   | <i>Enterobacter cloacae</i>             | 3          | 1.3        |
| 17   | <i>Klebsiella oxytoca</i>               | 3          | 1.3        |
| 18   | <i>Streptococcus pyogenes</i>           | 2          | 0.9        |
| 19   | <i>Streptococcus, Beta-H, Grp G</i>     | 2          | 0.9        |
| 20   | <i>Staphylococcus lugdunensis</i>       | 1          | 0.4        |
|      | Other                                   | 16         | 7.0        |
|      |   | <b>228</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age $\geq 65$ years

| National |   |             |            |
|----------|---|-------------|------------|
| Rank     | Organism                                | n           | % of Total |
| 1        | <i>Escherichia coli</i>                 | 257         | 22.3       |
| 2        | <i>Staphylococcus aureus, MSSA</i>      | 182         | 15.8       |
| 3        | <i>Pseudomonas aeruginosa</i>           | 113         | 9.8        |
| 4        | <i>Klebsiella pneumoniae</i>            | 89          | 7.7        |
| 5        | <i>Enterococcus faecalis</i>            | 47          | 4.1        |
| 6        | <i>Staphylococcus aureus, MRSA</i>      | 46          | 4.0        |
| 7        | <i>Haemophilus influenzae</i>           | 44          | 3.8        |
| 8        | <i>Streptococcus pneumoniae</i>         | 35          | 3.0        |
| 9        | CNS / <i>Staphylococcus epidermidis</i> | 29          | 2.5        |
| 10       | <i>Klebsiella oxytoca</i>               | 29          | 2.5        |
| 11       | <i>Enterobacter cloacae</i>             | 24          | 2.1        |
| 12       | <i>Serratia marcescens</i>              | 19          | 1.6        |
| 13       | <i>Proteus mirabilis</i>                | 19          | 1.6        |
| 14       | <i>Stenotrophomonas maltophilia</i>     | 18          | 1.6        |
| 15       | <i>Streptococcus agalactiae</i>         | 17          | 1.5        |
| 16       | <i>Enterococcus faecium</i>             | 16          | 1.4        |
| 17       | <i>Haemophilus parainfluenzae</i>       | 14          | 1.2        |
| 18       | <i>Enterobacter aerogenes</i>           | 12          | 1.0        |
| 19       | <i>Staphylococcus hominis</i>           | 12          | 1.0        |
| 20       | <i>Moraxella catarrhalis</i>            | 12          | 1.0        |
|          | Other                                   | 119         | 10.3       |
|          |   | <b>1153</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age ≥65 years

West

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 83         | 22.7       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 39         | 10.7       |
| 3    | <i>Klebsiella pneumoniae</i>            | 26         | 7.1        |
| 4    | <i>Pseudomonas aeruginosa</i>           | 23         | 6.3        |
| 5    | <i>Staphylococcus aureus, MRSA</i>      | 20         | 5.5        |
| 6    | <i>Enterococcus faecalis</i>            | 16         | 4.4        |
| 7    | <i>Streptococcus pneumoniae</i>         | 16         | 4.4        |
| 8    | <i>Haemophilus influenzae</i>           | 15         | 4.1        |
| 9    | <i>Klebsiella oxytoca</i>               | 14         | 3.8        |
| 10   | <i>Enterobacter cloacae</i>             | 12         | 3.3        |
| 11   | <i>Stenotrophomonas maltophilia</i>     | 12         | 3.3        |
| 12   | <i>CNS / Staphylococcus epidermidis</i> | 8          | 2.2        |
| 13   | <i>Serratia marcescens</i>              | 7          | 1.9        |
| 14   | <i>Haemophilus parainfluenzae</i>       | 7          | 1.9        |
| 15   | <i>Enterococcus faecium</i>             | 6          | 1.6        |
| 16   | <i>Proteus mirabilis</i>                | 6          | 1.6        |
| 17   | <i>Candida albicans</i>                 | 6          | 1.6        |
| 18   | <i>Enterobacter aerogenes</i>           | 5          | 1.4        |
| 19   | <i>Streptococcus agalactiae</i>         | 5          | 1.4        |
| 20   | <i>Streptococcus pyogenes</i>           | 4          | 1.1        |
|      | Other                                   | 35         | 9.6        |
|      |   | <b>365</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age $\geq 65$ years

Ontario

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 70         | 22.4       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 68         | 21.8       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 41         | 13.1       |
| 4    | <i>Klebsiella pneumoniae</i>            | 26         | 8.3        |
| 5    | <i>Staphylococcus aureus, MRSA</i>      | 15         | 4.8        |
| 6    | <i>Enterococcus faecalis</i>            | 15         | 4.8        |
| 7    | <i>Enterobacter aerogenes</i>           | 6          | 1.9        |
| 8    | <i>Enterobacter cloacae</i>             | 6          | 1.9        |
| 9    | <i>Enterococcus faecium</i>             | 6          | 1.9        |
| 10   | <i>Haemophilus influenzae</i>           | 6          | 1.9        |
| 11   | CNS / <i>Staphylococcus epidermidis</i> | 5          | 1.6        |
| 12   | <i>Klebsiella oxytoca</i>               | 5          | 1.6        |
| 13   | <i>Streptococcus pneumoniae</i>         | 4          | 1.3        |
| 14   | <i>Proteus mirabilis</i>                | 3          | 1.0        |
| 15   | <i>Staphylococcus hominis</i>           | 3          | 1.0        |
| 16   | <i>Candida albicans</i>                 | 3          | 1.0        |
| 17   | <i>Serratia marcescens</i>              | 3          | 1.0        |
| 18   | <i>Moraxella catarrhalis</i>            | 3          | 1.0        |
| 19   | <i>Stenotrophomonas maltophilia</i>     | 2          | 0.6        |
| 20   | <i>Bacillus, non-specified</i>          | 2          | 0.6        |
|      | Other                                   | 20         | 6.4        |
|      |   | <b>312</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age $\geq 65$ years

Quebec

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 51         | 22.9       |
| 2    | <i>Staphylococcus aureus</i> , MSSA     | 28         | 12.6       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 23         | 10.3       |
| 4    | <i>Klebsiella pneumoniae</i>            | 20         | 9.0        |
| 5    | CNS / <i>Staphylococcus epidermidis</i> | 10         | 4.5        |
| 6    | <i>Enterococcus faecalis</i>            | 7          | 3.1        |
| 7    | <i>Haemophilus influenzae</i>           | 7          | 3.1        |
| 8    | <i>Staphylococcus hominis</i>           | 6          | 2.7        |
| 9    | <i>Haemophilus parainfluenzae</i>       | 6          | 2.7        |
| 10   | <i>Staphylococcus aureus</i> , MRSA     | 5          | 2.2        |
| 11   | <i>Streptococcus pneumoniae</i>         | 5          | 2.2        |
| 12   | <i>Streptococcus agalactiae</i>         | 5          | 2.2        |
| 13   | <i>Klebsiella oxytoca</i>               | 5          | 2.2        |
| 14   | <i>Staphylococcus capitis</i>           | 4          | 1.8        |
| 15   | <i>Proteus mirabilis</i>                | 4          | 1.8        |
| 16   | <i>Moraxella catarrhalis</i>            | 3          | 1.3        |
| 17   | <i>Streptococcus pyogenes</i>           | 3          | 1.3        |
| 18   | <i>Enterobacter cloacae</i>             | 3          | 1.3        |
| 19   | <i>Stenotrophomonas maltophilia</i>     | 2          | 0.9        |
| 20   | <i>Streptococcus viridans</i>           | 2          | 0.9        |
|      | Other                                   | 24         | 10.8       |
|      |   | <b>223</b> |            |



# CANWARD 2012

## Bacteriology of Top 20 Organisms by Age ≥65 years

### Maritimes

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 53         | 20.9       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 47         | 18.6       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 26         | 10.3       |
| 4    | <i>Klebsiella pneumoniae</i>            | 17         | 6.7        |
| 5    | <i>Haemophilus influenzae</i>           | 16         | 6.3        |
| 6    | <i>Streptococcus pneumoniae</i>         | 10         | 4.0        |
| 7    | <i>Enterococcus faecalis</i>            | 9          | 3.6        |
| 8    | <i>Serratia marcescens</i>              | 8          | 3.2        |
| 9    | <i>Staphylococcus aureus, MRSA</i>      | 6          | 2.4        |
| 10   | <i>Proteus mirabilis</i>                | 6          | 2.4        |
| 11   | CNS / <i>Staphylococcus epidermidis</i> | 6          | 2.4        |
| 12   | <i>Streptococcus agalactiae</i>         | 5          | 2.0        |
| 13   | <i>Klebsiella oxytoca</i>               | 5          | 2.0        |
| 14   | <i>Moraxella catarrhalis</i>            | 4          | 1.6        |
| 15   | <i>Enterobacter cloacae</i>             | 3          | 1.2        |
| 16   | Streptococcus, Beta-H, Grp C            | 3          | 1.2        |
| 17   | Streptococcus, Beta-H, Grp G            | 3          | 1.2        |
| 18   | <i>Acinetobacter baumannii</i>          | 2          | 0.8        |
| 19   | <i>Citrobacter koseri</i>               | 2          | 0.8        |
| 20   | <i>Stenotrophomonas maltophilia</i>     | 2          | 0.8        |
|      | Other                                   | 20         | 7.9        |
|      |   | <b>253</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Clinic

| National |   |            |            |
|----------|---|------------|------------|
| Rank     | Organism                                | n          | % of Total |
| 1        | <i>Staphylococcus aureus, MSSA</i>      | 122        | 25.2       |
| 2        | <i>Escherichia coli</i>                 | 77         | 15.9       |
| 3        | <i>Pseudomonas aeruginosa</i>           | 60         | 12.4       |
| 4        | <i>Haemophilus influenzae</i>           | 32         | 6.6        |
| 5        | <i>Staphylococcus aureus, MRSA</i>      | 22         | 4.5        |
| 6        | <i>Haemophilus parainfluenzae</i>       | 21         | 4.3        |
| 7        | <i>Streptococcus pneumoniae</i>         | 20         | 4.1        |
| 8        | <i>Klebsiella pneumoniae</i>            | 19         | 3.9        |
| 9        | <i>Streptococcus agalactiae</i>         | 13         | 2.7        |
| 10       | <i>Enterococcus faecalis</i>            | 12         | 2.5        |
| 11       | CNS / <i>Staphylococcus epidermidis</i> | 10         | 2.1        |
| 12       | <i>Stenotrophomonas maltophilia</i>     | 8          | 1.7        |
| 13       | <i>Moraxella catarrhalis</i>            | 8          | 1.7        |
| 14       | <i>Serratia marcescens</i>              | 8          | 1.7        |
| 15       | <i>Proteus mirabilis</i>                | 6          | 1.2        |
| 16       | <i>Enterobacter cloacae</i>             | 6          | 1.2        |
| 17       | <i>Klebsiella oxytoca</i>               | 5          | 1.0        |
| 18       | <i>Staphylococcus hominis</i>           | 5          | 1.0        |
| 19       | <i>Citrobacter freundii</i>             | 3          | 0.6        |
| 20       | <i>Streptococcus, Beta-H, Grp G</i>     | 3          | 0.6        |
|          | Other                                   | 24         | 5.0        |
|          |   | <b>484</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Clinic

### West

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 47         | 25.8       |
| 2    | <i>Escherichia coli</i>                 | 23         | 12.6       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 21         | 11.5       |
| 4    | <i>Haemophilus influenzae</i>           | 16         | 8.8        |
| 5    | <i>Staphylococcus aureus, MRSA</i>      | 15         | 8.2        |
| 6    | <i>Streptococcus pneumoniae</i>         | 10         | 5.5        |
| 7    | <i>Haemophilus parainfluenzae</i>       | 10         | 5.5        |
| 8    | CNS / <i>Staphylococcus epidermidis</i> | 6          | 3.3        |
| 9    | <i>Enterococcus faecalis</i>            | 5          | 2.7        |
| 10   | <i>Stenotrophomonas maltophilia</i>     | 4          | 2.2        |
| 11   | <i>Klebsiella oxytoca</i>               | 2          | 1.1        |
| 12   | <i>Staphylococcus hominis</i>           | 2          | 1.1        |
| 13   | <i>Streptococcus agalactiae</i>         | 2          | 1.1        |
| 14   | <i>Enterobacter cloacae</i>             | 2          | 1.1        |
| 15   | <i>Citrobacter freundii</i>             | 2          | 1.1        |
| 16   | <i>Klebsiella pneumoniae</i>            | 2          | 1.1        |
| 17   | <i>Staphylococcus lugdunensis</i>       | 1          | 0.5        |
| 18   | <i>Streptococcus mitis</i>              | 1          | 0.5        |
| 19   | <i>Streptococcus, Beta-H, Grp C</i>     | 1          | 0.5        |
| 20   | <i>Proteus mirabilis</i>                | 1          | 0.5        |
|      | Other                                   | 9          | 4.9        |
|      |   | <b>182</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Clinic

### Ontario

| Rank | Organism                              | n         | % of Total |
|------|---------------------------------------|-----------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>    | 34        | 37.8       |
| 2    | <i>Pseudomonas aeruginosa</i>         | 15        | 16.7       |
| 3    | <i>Escherichia coli</i>               | 7         | 7.8        |
| 4    | <i>Staphylococcus aureus, MRSA</i>    | 6         | 6.7        |
| 5    | <i>Haemophilus influenzae</i>         | 4         | 4.4        |
| 6    | <i>Moraxella catarrhalis</i>          | 3         | 3.3        |
| 7    | <i>Klebsiella pneumoniae</i>          | 3         | 3.3        |
| 8    | <i>Streptococcus pneumoniae</i>       | 3         | 3.3        |
| 9    | <i>Staphylococcus hominis</i>         | 2         | 2.2        |
| 10   | <i>Serratia marcescens</i>            | 2         | 2.2        |
| 11   | <i>Candida albicans</i>               | 1         | 1.1        |
| 12   | <i>Streptococcus agalactiae</i>       | 1         | 1.1        |
| 13   | <i>Enterococcus faecium</i>           | 1         | 1.1        |
| 14   | <i>Corynebacterium, non-specified</i> | 1         | 1.1        |
| 15   | <i>Aeromonas sobria</i>               | 1         | 1.1        |
| 16   | <i>Proteus mirabilis</i>              | 1         | 1.1        |
| 17   | <i>Bacillus, non-specified</i>        | 1         | 1.1        |
| 18   | <i>Enterobacter aerogenes</i>         | 1         | 1.1        |
| 19   | <i>Stenotrophomonas maltophilia</i>   | 1         | 1.1        |
| 20   | <i>Enterobacter cloacae</i>           | 1         | 1.1        |
|      | Other                                 | 1         | 1.1        |
|      |                                       | <b>90</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Clinic

### Quebec

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 24         | 21.2       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 20         | 17.7       |
| 3    | <i>Klebsiella pneumoniae</i>            | 10         | 8.8        |
| 4    | <i>Haemophilus parainfluenzae</i>       | 10         | 8.8        |
| 5    | <i>Pseudomonas aeruginosa</i>           | 9          | 8.0        |
| 6    | <i>Streptococcus agalactiae</i>         | 7          | 6.2        |
| 7    | <i>Haemophilus influenzae</i>           | 6          | 5.3        |
| 8    | <i>Enterococcus faecalis</i>            | 3          | 2.7        |
| 9    | <i>Streptococcus pneumoniae</i>         | 3          | 2.7        |
| 10   | CNS / <i>Staphylococcus epidermidis</i> | 3          | 2.7        |
| 11   | <i>Moraxella catarrhalis</i>            | 2          | 1.8        |
| 12   | <i>Acinetobacter calcoaceticus</i>      | 2          | 1.8        |
| 13   | <i>Proteus mirabilis</i>                | 2          | 1.8        |
| 14   | <i>Klebsiella oxytoca</i>               | 2          | 1.8        |
| 15   | <i>Streptococcus, Beta-H, Grp G</i>     | 2          | 1.8        |
| 16   | <i>Stenotrophomonas maltophilia</i>     | 1          | 0.9        |
| 17   | <i>Staphylococcus aureus, MRSA</i>      | 1          | 0.9        |
| 18   | <i>Serratia marcescens</i>              | 1          | 0.9        |
| 19   | <i>Enterobacter cloacae</i>             | 1          | 0.9        |
| 20   | <i>Staphylococcus hominis</i>           | 1          | 0.9        |
|      | Other                                   | 3          | 2.7        |
|      |   | <b>113</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Clinic

### Maritimes

| Rank | Organism                                | n         | % of Total |
|------|---|-----------|------------|
| 1    | <i>Escherichia coli</i>                 | 23        | 23.2       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 21        | 21.2       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 15        | 15.2       |
| 4    | <i>Haemophilus influenzae</i>           | 6         | 6.1        |
| 5    | <i>Klebsiella pneumoniae</i>            | 4         | 4.0        |
| 6    | <i>Serratia marcescens</i>              | 4         | 4.0        |
| 7    | <i>Enterococcus faecalis</i>            | 4         | 4.0        |
| 8    | <i>Streptococcus pneumoniae</i>         | 4         | 4.0        |
| 9    | <i>Streptococcus agalactiae</i>         | 3         | 3.0        |
| 10   | <i>Moraxella catarrhalis</i>            | 2         | 2.0        |
| 11   | <i>Proteus mirabilis</i>                | 2         | 2.0        |
| 12   | <i>Enterobacter cloacae</i>             | 2         | 2.0        |
| 13   | <i>Stenotrophomonas maltophilia</i>     | 2         | 2.0        |
| 14   | <i>Raoultella planticola</i>            | 1         | 1.0        |
| 15   | <i>Staphylococcus lugdunensis</i>       | 1         | 1.0        |
| 16   | CNS / <i>Staphylococcus epidermidis</i> | 1         | 1.0        |
| 17   | <i>Citrobacter freundii</i>             | 1         | 1.0        |
| 18   | <i>Haemophilus parainfluenzae</i>       | 1         | 1.0        |
| 19   | <i>Klebsiella oxytoca</i>               | 1         | 1.0        |
| 20   | <i>Streptococcus pyogenes</i>           | 1         | 1.0        |
|      |   | <b>99</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Emergency Room

National

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 198        | 27.7       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 132        | 18.4       |
| 3    | <i>Klebsiella pneumoniae</i>            | 52         | 7.3        |
| 4    | <i>Streptococcus pneumoniae</i>         | 51         | 7.1        |
| 5    | <i>Pseudomonas aeruginosa</i>           | 32         | 4.5        |
| 6    | CNS / <i>Staphylococcus epidermidis</i> | 26         | 3.6        |
| 7    | <i>Staphylococcus aureus, MRSA</i>      | 25         | 3.5        |
| 8    | <i>Enterococcus faecalis</i>            | 17         | 2.4        |
| 9    | <i>Haemophilus influenzae</i>           | 16         | 2.2        |
| 10   | <i>Streptococcus pyogenes</i>           | 16         | 2.2        |
| 11   | <i>Proteus mirabilis</i>                | 14         | 2.0        |
| 12   | <i>Streptococcus agalactiae</i>         | 12         | 1.7        |
| 13   | <i>Klebsiella oxytoca</i>               | 11         | 1.5        |
| 14   | <i>Staphylococcus hominis</i>           | 11         | 1.5        |
| 15   | <i>Enterobacter cloacae</i>             | 9          | 1.3        |
| 16   | <i>Streptococcus, Beta-H, Grp G</i>     | 8          | 1.1        |
| 17   | <i>Staphylococcus capitis</i>           | 7          | 1.0        |
| 18   | <i>Enterococcus faecium</i>             | 6          | 0.8        |
| 19   | <i>Streptococcus, Beta-H, Grp C</i>     | 5          | 0.7        |
| 20   | <i>Salmonella, non-specified</i>        | 4          | 0.6        |
|      | Other                                   | 64         | 8.9        |
|      |   | <b>716</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Emergency Room

West

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 74         | 27.4       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 55         | 20.4       |
| 3    | <i>Streptococcus pneumoniae</i>         | 24         | 8.9        |
| 4    | <i>Klebsiella pneumoniae</i>            | 16         | 5.9        |
| 5    | <i>Staphylococcus aureus, MRSA</i>      | 13         | 4.8        |
| 6    | <i>Haemophilus influenzae</i>           | 11         | 4.1        |
| 7    | <i>Streptococcus pyogenes</i>           | 10         | 3.7        |
| 8    | <i>Pseudomonas aeruginosa</i>           | 7          | 2.6        |
| 9    | <i>Proteus mirabilis</i>                | 6          | 2.2        |
| 10   | CNS / <i>Staphylococcus epidermidis</i> | 6          | 2.2        |
| 11   | <i>Klebsiella oxytoca</i>               | 6          | 2.2        |
| 12   | <i>Streptococcus agalactiae</i>         | 5          | 1.9        |
| 13   | <i>Enterococcus faecalis</i>            | 5          | 1.9        |
| 14   | <i>Enterobacter cloacae</i>             | 4          | 1.5        |
| 15   | <i>Enterococcus faecium</i>             | 3          | 1.1        |
| 16   | <i>Streptococcus, Beta-H, Grp G</i>     | 3          | 1.1        |
| 17   | <i>Salmonella, non-speciated</i>        | 2          | 0.7        |
| 18   | <i>Stenotrophomonas maltophilia</i>     | 2          | 0.7        |
| 19   | <i>Haemophilus parainfluenzae</i>       | 2          | 0.7        |
| 20   | <i>Citrobacter farmeri</i>              | 1          | 0.4        |
|      | Other                                   | 15         | 5.6        |
|      |   | <b>270</b> |            |



# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Emergency Room

### Ontario

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 63         | 31.5       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 35         | 17.5       |
| 3    | <i>Klebsiella pneumoniae</i>            | 14         | 7.0        |
| 4    | <i>Streptococcus pneumoniae</i>         | 14         | 7.0        |
| 5    | <i>Pseudomonas aeruginosa</i>           | 10         | 5.0        |
| 6    | CNS / <i>Staphylococcus epidermidis</i> | 8          | 4.0        |
| 7    | <i>Staphylococcus aureus, MRSA</i>      | 7          | 3.5        |
| 8    | <i>Staphylococcus hominis</i>           | 6          | 3.0        |
| 9    | <i>Proteus mirabilis</i>                | 5          | 2.5        |
| 10   | <i>Enterococcus faecalis</i>            | 4          | 2.0        |
| 11   | <i>Streptococcus pyogenes</i>           | 4          | 2.0        |
| 12   | <i>Enterobacter aerogenes</i>           | 2          | 1.0        |
| 13   | <i>Enterobacter cloacae</i>             | 2          | 1.0        |
| 14   | <i>Staphylococcus cohnii</i>            | 1          | 0.5        |
| 15   | <i>Granulicatella adiacens</i>          | 1          | 0.5        |
| 16   | <i>Stenotrophomonas maltophilia</i>     | 1          | 0.5        |
| 17   | <i>Klebsiella oxytoca</i>               | 1          | 0.5        |
| 18   | <i>Staphylococcus auricularis</i>       | 1          | 0.5        |
| 19   | <i>Citrobacter freundii</i>             | 1          | 0.5        |
| 20   | <i>Staphylococcus lugdunensis</i>       | 1          | 0.5        |
|      | Other                                   | 19         | 9.5        |
|      |   | <b>200</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Emergency Room

### Quebec

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 34         | 23.6       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 19         | 13.2       |
| 3    | <i>Klebsiella pneumoniae</i>            | 15         | 10.4       |
| 4    | <i>Streptococcus pneumoniae</i>         | 10         | 6.9        |
| 5    | CNS / <i>Staphylococcus epidermidis</i> | 9          | 6.3        |
| 6    | <i>Pseudomonas aeruginosa</i>           | 8          | 5.6        |
| 7    | <i>Enterococcus faecalis</i>            | 5          | 3.5        |
| 8    | <i>Staphylococcus capitis</i>           | 5          | 3.5        |
| 9    | <i>Staphylococcus hominis</i>           | 4          | 2.8        |
| 10   | <i>Enterobacter cloacae</i>             | 3          | 2.1        |
| 11   | <i>Haemophilus influenzae</i>           | 3          | 2.1        |
| 12   | <i>Proteus mirabilis</i>                | 3          | 2.1        |
| 13   | <i>Staphylococcus caprae</i>            | 2          | 1.4        |
| 14   | <i>Streptococcus pyogenes</i>           | 2          | 1.4        |
| 15   | <i>Streptococcus agalactiae</i>         | 2          | 1.4        |
| 16   | <i>Micrococcus, non-speciated</i>       | 2          | 1.4        |
| 17   | <i>Klebsiella oxytoca</i>               | 2          | 1.4        |
| 18   | <i>Streptococcus, Beta-H, Grp C</i>     | 2          | 1.4        |
| 19   | <i>Streptococcus anginosus</i>          | 1          | 0.7        |
| 20   | <i>Serratia liquefaciens</i>            | 1          | 0.7        |
|      | Other                                   | 12         | 8.3        |
|      |   | <b>144</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Emergency Room

### Maritimes

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 27         | 26.5       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 23         | 22.5       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 7          | 6.9        |
| 4    | <i>Klebsiella pneumoniae</i>            | 7          | 6.9        |
| 5    | <i>Streptococcus agalactiae</i>         | 4          | 3.9        |
| 6    | <i>Staphylococcus aureus, MRSA</i>      | 4          | 3.9        |
| 7    | <i>Streptococcus pneumoniae</i>         | 3          | 2.9        |
| 8    | <i>Enterococcus faecalis</i>            | 3          | 2.9        |
| 9    | CNS / <i>Staphylococcus epidermidis</i> | 3          | 2.9        |
| 10   | <i>Streptococcus, Beta-H, Grp G</i>     | 3          | 2.9        |
| 11   | <i>Haemophilus influenzae</i>           | 2          | 2.0        |
| 12   | <i>Klebsiella oxytoca</i>               | 2          | 2.0        |
| 13   | <i>Streptococcus, Beta-H, Grp C</i>     | 2          | 2.0        |
| 14   | <i>Streptococcus oralis</i>             | 1          | 1.0        |
| 15   | <i>Aerococcus urinae</i>                | 1          | 1.0        |
| 16   | <i>Salmonella paratyphi B</i>           | 1          | 1.0        |
| 17   | <i>Acinetobacter baumannii</i>          | 1          | 1.0        |
| 18   | <i>Staphylococcus warneri</i>           | 1          | 1.0        |
| 19   | <i>Enterococcus faecium</i>             | 1          | 1.0        |
| 20   | <i>Pseudomonas putida</i>               | 1          | 1.0        |
|      | Other                                   | 5          | 4.9        |
|      |   | <b>102</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - ICU

| National |   |            |            |
|----------|---|------------|------------|
| Rank     | Organism                                | n          | % of Total |
| 1        | <i>Staphylococcus aureus, MSSA</i>      | 121        | 19.5       |
| 2        | <i>Pseudomonas aeruginosa</i>           | 69         | 11.1       |
| 3        | <i>Escherichia coli</i>                 | 64         | 10.3       |
| 4        | <i>Haemophilus influenzae</i>           | 47         | 7.6        |
| 5        | <i>Klebsiella pneumoniae</i>            | 36         | 5.8        |
| 6        | <i>Streptococcus pneumoniae</i>         | 33         | 5.3        |
| 7        | <i>Enterobacter cloacae</i>             | 31         | 5.0        |
| 8        | <i>Staphylococcus aureus, MRSA</i>      | 29         | 4.7        |
| 9        | <i>Stenotrophomonas maltophilia</i>     | 18         | 2.9        |
| 10       | CNS / <i>Staphylococcus epidermidis</i> | 16         | 2.6        |
| 11       | <i>Serratia marcescens</i>              | 16         | 2.6        |
| 12       | <i>Klebsiella oxytoca</i>               | 14         | 2.3        |
| 13       | <i>Enterococcus faecalis</i>            | 13         | 2.1        |
| 14       | <i>Enterococcus faecium</i>             | 13         | 2.1        |
| 15       | <i>Moraxella catarrhalis</i>            | 12         | 1.9        |
| 16       | <i>Enterobacter aerogenes</i>           | 10         | 1.6        |
| 17       | <i>Streptococcus agalactiae</i>         | 9          | 1.4        |
| 18       | <i>Streptococcus pyogenes</i>           | 8          | 1.3        |
| 19       | <i>Acinetobacter baumannii</i>          | 6          | 1.0        |
| 20       | <i>Citrobacter koseri</i>               | 5          | 0.8        |
|          | Other                                   | 51         | 8.2        |
|          |   | <b>621</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - ICU

### West

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 46         | 20.4       |
| 2    | <i>Escherichia coli</i>                 | 21         | 9.3        |
| 3    | <i>Haemophilus influenzae</i>           | 17         | 7.6        |
| 4    | <i>Pseudomonas aeruginosa</i>           | 16         | 7.1        |
| 5    | <i>Enterobacter cloacae</i>             | 16         | 7.1        |
| 6    | <i>Klebsiella pneumoniae</i>            | 15         | 6.7        |
| 7    | <i>Streptococcus pneumoniae</i>         | 14         | 6.2        |
| 8    | <i>Staphylococcus aureus, MRSA</i>      | 10         | 4.4        |
| 9    | <i>Klebsiella oxytoca</i>               | 8          | 3.6        |
| 10   | <i>Stenotrophomonas maltophilia</i>     | 7          | 3.1        |
| 11   | CNS / <i>Staphylococcus epidermidis</i> | 7          | 3.1        |
| 12   | <i>Enterobacter aerogenes</i>           | 7          | 3.1        |
| 13   | <i>Streptococcus agalactiae</i>         | 6          | 2.7        |
| 14   | <i>Haemophilus parainfluenzae</i>       | 4          | 1.8        |
| 15   | <i>Serratia marcescens</i>              | 3          | 1.3        |
| 16   | <i>Enterococcus faecalis</i>            | 3          | 1.3        |
| 17   | <i>Burkholderia cepacia</i>             | 2          | 0.9        |
| 18   | <i>Enterococcus faecium</i>             | 2          | 0.9        |
| 19   | <i>Candida dubliniensis</i>             | 2          | 0.9        |
| 20   | <i>Acinetobacter baumannii</i>          | 2          | 0.9        |
|      | Other                                   | 17         | 7.6        |
|      |   | <b>225</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - ICU

### Ontario

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 53         | 19.8       |
| 2    | <i>Pseudomonas aeruginosa</i>           | 42         | 15.7       |
| 3    | <i>Escherichia coli</i>                 | 27         | 10.1       |
| 4    | <i>Klebsiella pneumoniae</i>            | 15         | 5.6        |
| 5    | <i>Staphylococcus aureus, MRSA</i>      | 14         | 5.2        |
| 6    | <i>Haemophilus influenzae</i>           | 14         | 5.2        |
| 7    | <i>Streptococcus pneumoniae</i>         | 11         | 4.1        |
| 8    | <i>Enterobacter cloacae</i>             | 11         | 4.1        |
| 9    | <i>Enterococcus faecium</i>             | 9          | 3.4        |
| 10   | <i>Enterococcus faecalis</i>            | 8          | 3.0        |
| 11   | CNS / <i>Staphylococcus epidermidis</i> | 7          | 2.6        |
| 12   | <i>Serratia marcescens</i>              | 7          | 2.6        |
| 13   | <i>Moraxella catarrhalis</i>            | 7          | 2.6        |
| 14   | <i>Stenotrophomonas maltophilia</i>     | 5          | 1.9        |
| 15   | <i>Klebsiella oxytoca</i>               | 5          | 1.9        |
| 16   | <i>Streptococcus pyogenes</i>           | 4          | 1.5        |
| 17   | <i>Proteus mirabilis</i>                | 4          | 1.5        |
| 18   | <i>Enterobacter aerogenes</i>           | 3          | 1.1        |
| 19   | <i>Candida albicans</i>                 | 3          | 1.1        |
| 20   | <i>Acinetobacter baumannii</i>          | 2          | 0.7        |
|      | Other                                   | 17         | 6.3        |
|      |   | <b>268</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - ICU

### Quebec

| Rank | Organism                                | n         | % of Total |
|------|---|-----------|------------|
| 1    | <i>Pseudomonas aeruginosa</i>           | 5         | 20.0       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 4         | 16.0       |
| 3    | <i>Haemophilus influenzae</i>           | 3         | 12.0       |
| 4    | <i>Escherichia coli</i>                 | 2         | 8.0        |
| 5    | <i>Moraxella catarrhalis</i>            | 2         | 8.0        |
| 6    | <i>Streptococcus pneumoniae</i>         | 2         | 8.0        |
| 7    | CNS / <i>Staphylococcus epidermidis</i> | 1         | 4.0        |
| 8    | <i>Staphylococcus hominis</i>           | 1         | 4.0        |
| 9    | <i>Acinetobacter baumannii</i>          | 1         | 4.0        |
| 10   | <i>Chryseobacterium indologenes</i>     | 1         | 4.0        |
| 11   | <i>Streptococcus agalactiae</i>         | 1         | 4.0        |
| 12   | <i>Citrobacter braakii</i>              | 1         | 4.0        |
| 13   | <i>Streptococcus pyogenes</i>           | 1         | 4.0        |
|      |   | <b>25</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - ICU

### Maritimes

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 18         | 17.5       |
| 2    | <i>Escherichia coli</i>                 | 14         | 13.6       |
| 3    | <i>Haemophilus influenzae</i>           | 13         | 12.6       |
| 4    | <i>Stenotrophomonas maltophilia</i>     | 6          | 5.8        |
| 5    | <i>Serratia marcescens</i>              | 6          | 5.8        |
| 6    | <i>Pseudomonas aeruginosa</i>           | 6          | 5.8        |
| 7    | <i>Klebsiella pneumoniae</i>            | 6          | 5.8        |
| 8    | <i>Streptococcus pneumoniae</i>         | 6          | 5.8        |
| 9    | <i>Staphylococcus aureus, MRSA</i>      | 5          | 4.9        |
| 10   | <i>Enterobacter cloacae</i>             | 4          | 3.9        |
| 11   | <i>Citrobacter koseri</i>               | 2          | 1.9        |
| 12   | <i>Moraxella catarrhalis</i>            | 2          | 1.9        |
| 13   | <i>Enterococcus faecium</i>             | 2          | 1.9        |
| 14   | <i>Enterococcus faecalis</i>            | 2          | 1.9        |
| 15   | <i>Staphylococcus hominis</i>           | 1          | 1.0        |
| 16   | <i>CNS / Staphylococcus epidermidis</i> | 1          | 1.0        |
| 17   | <i>Streptococcus agalactiae</i>         | 1          | 1.0        |
| 18   | <i>Streptococcus bovis</i>              | 1          | 1.0        |
| 19   | <i>Enterobacter agglomerans</i>         | 1          | 1.0        |
| 20   | <i>Candida parapsilosis</i>             | 1          | 1.0        |
|      | Other                                   | 5          | 4.9        |
|      |   | <b>103</b> |            |



# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Medical Ward

| National |   |            |            |
|----------|---|------------|------------|
| Rank     | Organism                                | n          | % of Total |
| 1        | <i>Staphylococcus aureus, MSSA</i>      | 154        | 18.8       |
| 2        | <i>Escherichia coli</i>                 | 141        | 17.2       |
| 3        | <i>Pseudomonas aeruginosa</i>           | 87         | 10.6       |
| 4        | <i>Klebsiella pneumoniae</i>            | 52         | 6.3        |
| 5        | <i>Haemophilus influenzae</i>           | 46         | 5.6        |
| 6        | <i>Enterococcus faecalis</i>            | 40         | 4.9        |
| 7        | <i>Staphylococcus aureus, MRSA</i>      | 39         | 4.8        |
| 8        | <i>Streptococcus pneumoniae</i>         | 33         | 4.0        |
| 9        | <i>CNS / Staphylococcus epidermidis</i> | 30         | 3.7        |
| 10       | <i>Enterobacter cloacae</i>             | 18         | 2.2        |
| 11       | <i>Klebsiella oxytoca</i>               | 16         | 2.0        |
| 12       | <i>Stenotrophomonas maltophilia</i>     | 12         | 1.5        |
| 13       | <i>Enterococcus faecium</i>             | 12         | 1.5        |
| 14       | <i>Proteus mirabilis</i>                | 11         | 1.3        |
| 15       | <i>Moraxella catarrhalis</i>            | 11         | 1.3        |
| 16       | <i>Serratia marcescens</i>              | 9          | 1.1        |
| 17       | <i>Candida albicans</i>                 | 9          | 1.1        |
| 18       | <i>Streptococcus pyogenes</i>           | 8          | 1.0        |
| 19       | <i>Streptococcus agalactiae</i>         | 8          | 1.0        |
| 20       | <i>Enterobacter aerogenes</i>           | 8          | 1.0        |
|          | Other                                   | 75         | 9.2        |
|          |   | <b>819</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Medical Ward

### West

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Escherichia coli</i>                 | 38         | 15.4       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 34         | 13.8       |
| 3    | <i>Staphylococcus aureus, MRSA</i>      | 20         | 8.1        |
| 4    | <i>Haemophilus influenzae</i>           | 19         | 7.7        |
| 5    | <i>Pseudomonas aeruginosa</i>           | 18         | 7.3        |
| 6    | <i>Enterococcus faecalis</i>            | 16         | 6.5        |
| 7    | <i>Klebsiella pneumoniae</i>            | 10         | 4.1        |
| 8    | CNS / <i>Staphylococcus epidermidis</i> | 9          | 3.7        |
| 9    | <i>Enterobacter cloacae</i>             | 8          | 3.3        |
| 10   | <i>Stenotrophomonas maltophilia</i>     | 7          | 2.8        |
| 11   | <i>Candida albicans</i>                 | 7          | 2.8        |
| 12   | <i>Streptococcus pneumoniae</i>         | 7          | 2.8        |
| 13   | <i>Klebsiella oxytoca</i>               | 5          | 2.0        |
| 14   | <i>Serratia marcescens</i>              | 4          | 1.6        |
| 15   | <i>Enterococcus faecium</i>             | 4          | 1.6        |
| 16   | <i>Moraxella catarrhalis</i>            | 4          | 1.6        |
| 17   | <i>Streptococcus agalactiae</i>         | 3          | 1.2        |
| 18   | <i>Acinetobacter baumannii</i>          | 3          | 1.2        |
| 19   | <i>Candida glabrata</i>                 | 3          | 1.2        |
| 20   | <i>Enterobacter aerogenes</i>           | 3          | 1.2        |
|      | Other                                   | 24         | 9.8        |
|      |   | <b>246</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Medical Ward

### Ontario

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 74         | 21.8       |
| 2    | <i>Escherichia coli</i>                 | 66         | 19.4       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 43         | 12.6       |
| 4    | <i>Klebsiella pneumoniae</i>            | 25         | 7.4        |
| 5    | <i>Enterococcus faecalis</i>            | 16         | 4.7        |
| 6    | <i>Streptococcus pneumoniae</i>         | 16         | 4.7        |
| 7    | <i>Haemophilus influenzae</i>           | 15         | 4.4        |
| 8    | CNS / <i>Staphylococcus epidermidis</i> | 11         | 3.2        |
| 9    | <i>Staphylococcus aureus, MRSA</i>      | 9          | 2.6        |
| 10   | <i>Enterobacter cloacae</i>             | 9          | 2.6        |
| 11   | <i>Klebsiella oxytoca</i>               | 6          | 1.8        |
| 12   | <i>Enterococcus faecium</i>             | 5          | 1.5        |
| 13   | <i>Serratia marcescens</i>              | 4          | 1.2        |
| 14   | <i>Enterobacter aerogenes</i>           | 4          | 1.2        |
| 15   | <i>Moraxella catarrhalis</i>            | 4          | 1.2        |
| 16   | <i>Streptococcus pyogenes</i>           | 3          | 0.9        |
| 17   | <i>Staphylococcus capitis</i>           | 2          | 0.6        |
| 18   | <i>Citrobacter freundii</i>             | 2          | 0.6        |
| 19   | <i>Candida albicans</i>                 | 2          | 0.6        |
| 20   | <i>Stenotrophomonas maltophilia</i>     | 2          | 0.6        |
|      | Other                                   | 22         | 6.5        |
|      |   | <b>340</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Medical Ward

Quebec

| Rank | Organism                                | n         | % of Total |
|------|---|-----------|------------|
| 1    | <i>Escherichia coli</i>                 | 12        | 17.9       |
| 2    | <i>Staphylococcus aureus, MSSA</i>      | 7         | 10.4       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 6         | 9.0        |
| 4    | <i>Klebsiella pneumoniae</i>            | 6         | 9.0        |
| 5    | CNS / <i>Staphylococcus epidermidis</i> | 5         | 7.5        |
| 6    | <i>Staphylococcus aureus, MRSA</i>      | 5         | 7.5        |
| 7    | <i>Staphylococcus hominis</i>           | 4         | 6.0        |
| 8    | <i>Enterococcus faecalis</i>            | 3         | 4.5        |
| 9    | <i>Stenotrophomonas maltophilia</i>     | 2         | 3.0        |
| 10   | <i>Haemophilus influenzae</i>           | 2         | 3.0        |
| 11   | <i>Streptococcus mitis</i>              | 2         | 3.0        |
| 12   | <i>Streptococcus viridans</i>           | 2         | 3.0        |
| 13   | <i>Streptococcus pneumoniae</i>         | 1         | 1.5        |
| 14   | <i>Klebsiella oxytoca</i>               | 1         | 1.5        |
| 15   | <i>Alcaligenes xylosoxidans</i>         | 1         | 1.5        |
| 16   | <i>Enterobacter aerogenes</i>           | 1         | 1.5        |
| 17   | <i>Streptococcus pyogenes</i>           | 1         | 1.5        |
| 18   | <i>Enterobacter cloacae</i>             | 1         | 1.5        |
| 19   | <i>Staphylococcus haemolyticus</i>      | 1         | 1.5        |
| 20   | <i>Enterococcus faecium</i>             | 1         | 1.5        |
|      | Other                                   | 3         | 4.5        |
|      |   | <b>67</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Medical Ward

### Maritimes

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 39         | 23.5       |
| 2    | <i>Escherichia coli</i>                 | 25         | 15.1       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 20         | 12.0       |
| 4    | <i>Klebsiella pneumoniae</i>            | 11         | 6.6        |
| 5    | <i>Haemophilus influenzae</i>           | 10         | 6.0        |
| 6    | <i>Streptococcus pneumoniae</i>         | 9          | 5.4        |
| 7    | <i>Proteus mirabilis</i>                | 7          | 4.2        |
| 8    | <i>Enterococcus faecalis</i>            | 5          | 3.0        |
| 9    | <i>Staphylococcus aureus, MRSA</i>      | 5          | 3.0        |
| 10   | CNS / <i>Staphylococcus epidermidis</i> | 5          | 3.0        |
| 11   | <i>Klebsiella oxytoca</i>               | 4          | 2.4        |
| 12   | <i>Streptococcus agalactiae</i>         | 3          | 1.8        |
| 13   | <i>Enterococcus faecium</i>             | 2          | 1.2        |
| 14   | <i>Streptococcus, Beta-H, Grp C</i>     | 2          | 1.2        |
| 15   | <i>Streptococcus pyogenes</i>           | 2          | 1.2        |
| 16   | <i>Moraxella catarrhalis</i>            | 2          | 1.2        |
| 17   | <i>Streptococcus, Beta-H, Grp G</i>     | 2          | 1.2        |
| 18   | <i>Streptococcus viridans</i>           | 1          | 0.6        |
| 19   | <i>Staphylococcus hominis</i>           | 1          | 0.6        |
| 20   | <i>Salmonella enteritidis</i>           | 1          | 0.6        |
|      | Other                                   | 10         | 6.0        |
|      |   | <b>166</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Surgical Ward

National

| Rank | Organism                                | n          | % of Total |
|------|---|------------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 35         | 20.8       |
| 2    | <i>Escherichia coli</i>                 | 20         | 11.9       |
| 3    | <i>Pseudomonas aeruginosa</i>           | 16         | 9.5        |
| 4    | <i>Enterococcus faecalis</i>            | 11         | 6.5        |
| 5    | <i>Staphylococcus aureus, MRSA</i>      | 10         | 6.0        |
| 6    | <i>Klebsiella pneumoniae</i>            | 10         | 6.0        |
| 7    | <i>Haemophilus influenzae</i>           | 9          | 5.4        |
| 8    | <i>Serratia marcescens</i>              | 6          | 3.6        |
| 9    | <i>Streptococcus pneumoniae</i>         | 6          | 3.6        |
| 10   | <i>Moraxella catarrhalis</i>            | 5          | 3.0        |
| 11   | <i>Enterobacter cloacae</i>             | 5          | 3.0        |
| 12   | <i>Klebsiella oxytoca</i>               | 4          | 2.4        |
| 13   | <i>Acinetobacter baumannii</i>          | 4          | 2.4        |
| 14   | <i>Enterococcus faecium</i>             | 3          | 1.8        |
| 15   | <i>Proteus mirabilis</i>                | 3          | 1.8        |
| 16   | CNS / <i>Staphylococcus epidermidis</i> | 3          | 1.8        |
| 17   | <i>Streptococcus pyogenes</i>           | 3          | 1.8        |
| 18   | <i>Enterobacter aerogenes</i>           | 2          | 1.2        |
| 19   | <i>Streptococcus agalactiae</i>         | 2          | 1.2        |
| 20   | <i>Stenotrophomonas maltophilia</i>     | 2          | 1.2        |
|      | Other                                   | 9          | 5.4        |
|      |   | <b>168</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Surgical Ward

### West

| Rank | Organism                                | n         | % of Total |
|------|---|-----------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 8         | 11.8       |
| 2    | <i>Pseudomonas aeruginosa</i>           | 7         | 10.3       |
| 3    | <i>Escherichia coli</i>                 | 7         | 10.3       |
| 4    | <i>Staphylococcus aureus, MRSA</i>      | 6         | 8.8        |
| 5    | <i>Enterococcus faecalis</i>            | 6         | 8.8        |
| 6    | <i>Klebsiella pneumoniae</i>            | 4         | 5.9        |
| 7    | <i>Klebsiella oxytoca</i>               | 4         | 5.9        |
| 8    | <i>Acinetobacter baumannii</i>          | 3         | 4.4        |
| 9    | <i>Enterobacter cloacae</i>             | 3         | 4.4        |
| 10   | <i>Streptococcus pneumoniae</i>         | 3         | 4.4        |
| 11   | <i>Haemophilus influenzae</i>           | 2         | 2.9        |
| 12   | <i>Enterococcus faecium</i>             | 2         | 2.9        |
| 13   | <i>Serratia marcescens</i>              | 2         | 2.9        |
| 14   | CNS / <i>Staphylococcus epidermidis</i> | 2         | 2.9        |
| 15   | <i>Streptococcus pyogenes</i>           | 2         | 2.9        |
| 16   | <i>Candida krusei</i>                   | 1         | 1.5        |
| 17   | <i>Proteus mirabilis</i>                | 1         | 1.5        |
| 18   | <i>Morganella morganii</i>              | 1         | 1.5        |
| 19   | <i>Citrobacter freundii</i>             | 1         | 1.5        |
| 20   | <i>Staphylococcus hominis</i>           | 1         | 1.5        |
|      | Other                                   | 2         | 2.9        |
|      |   | <b>68</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Surgical Ward

### Ontario

| Rank | Organism                           | n         | % of Total |
|------|------------------------------------|-----------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i> | 16        | 27.6       |
| 2    | <i>Escherichia coli</i>            | 9         | 15.5       |
| 3    | <i>Pseudomonas aeruginosa</i>      | 6         | 10.3       |
| 4    | <i>Haemophilus influenzae</i>      | 4         | 6.9        |
| 5    | <i>Staphylococcus aureus, MRSA</i> | 3         | 5.2        |
| 6    | <i>Moraxella catarrhalis</i>       | 3         | 5.2        |
| 7    | <i>Klebsiella pneumoniae</i>       | 3         | 5.2        |
| 8    | <i>Streptococcus pneumoniae</i>    | 3         | 5.2        |
| 9    | <i>Enterococcus faecalis</i>       | 2         | 3.4        |
| 10   | <i>Proteus mirabilis</i>           | 2         | 3.4        |
| 11   | <i>Enterobacter aerogenes</i>      | 2         | 3.4        |
| 12   | <i>Candida glabrata</i>            | 1         | 1.7        |
| 13   | <i>Enterococcus faecium</i>        | 1         | 1.7        |
| 14   | <i>Serratia marcescens</i>         | 1         | 1.7        |
| 15   | <i>Bacillus, non-speciated</i>     | 1         | 1.7        |
| 16   | <i>Streptococcus pyogenes</i>      | 1         | 1.7        |
|      |                                    | <b>58</b> |            |



# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Surgical Ward

Quebec

| Rank | Organism                                | n         | % of Total |
|------|---|-----------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i>      | 4         | 28.6       |
| 2    | <i>Escherichia coli</i>                 | 3         | 21.4       |
| 3    | <i>Enterococcus faecalis</i>            | 2         | 14.3       |
| 4    | <i>CNS / Staphylococcus epidermidis</i> | 1         | 7.1        |
| 5    | <i>Stenotrophomonas maltophilia</i>     | 1         | 7.1        |
| 6    | <i>Streptococcus agalactiae</i>         | 1         | 7.1        |
| 7    | <i>Pseudomonas aeruginosa</i>           | 1         | 7.1        |
| 8    | <i>Klebsiella pneumoniae</i>            | 1         | 7.1        |
|      |   | <b>14</b> |            |

# CANWARD 2012

## Bacteriology of Top 20 Organisms by Location - Surgical Ward

### Maritimes

| Rank | Organism                           | n         | % of Total |
|------|------------------------------------|-----------|------------|
| 1    | <i>Staphylococcus aureus, MSSA</i> | 7         | 25.0       |
| 2    | <i>Serratia marcescens</i>         | 3         | 10.7       |
| 3    | <i>Haemophilus influenzae</i>      | 3         | 10.7       |
| 4    | <i>Moraxella catarrhalis</i>       | 2         | 7.1        |
| 5    | <i>Enterobacter cloacae</i>        | 2         | 7.1        |
| 6    | <i>Pseudomonas aeruginosa</i>      | 2         | 7.1        |
| 7    | <i>Klebsiella pneumoniae</i>       | 2         | 7.1        |
| 8    | <i>Acinetobacter baumannii</i>     | 1         | 3.6        |
| 9    | <i>Pseudomonas putida</i>          | 1         | 3.6        |
| 10   | <i>Enterococcus faecalis</i>       | 1         | 3.6        |
| 11   | <i>Candida albicans</i>            | 1         | 3.6        |
| 12   | <i>Staphylococcus aureus, MRSA</i> | 1         | 3.6        |
| 13   | <i>Citrobacter farmeri</i>         | 1         | 3.6        |
| 14   | <i>Escherichia coli</i>            | 1         | 3.6        |
|      |                                    | <b>28</b> |            |

# CANWARD 2012

## *S. aureus*, MSSA Susceptibility - National

### ***Staphylococcus aureus*, MSSA (563)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max  |
| Amikacin                    | 99.5%                  | 0.2%  | 0.4%  | 4                 | 4                 | ≤ 1    | > 64 |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | 0.5               | 1                 | ≤ 0.06 | 1    |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | 0.5    | > 64 |
| Cefazolin                   | No Breakpoints Defined |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 2    |
| Cefepime                    | No Breakpoints Defined |       |       | 2                 | 4                 | ≤ 0.25 | 4    |
| Cefoxitin                   | 99.6%                  |       | 0.4%  | 4                 | 4                 | 0.25   | 8    |
| Ceftazidime                 | No Breakpoints Defined |       |       | 16                | 16                | 4      | 32   |
| Ceftriaxone                 | No Breakpoints Defined |       |       | 4                 | 4                 | 0.5    | 8    |
| Ciprofloxacin               | 87.6%                  | 2.0%  | 10.5% | 0.5               | 4                 | ≤ 0.06 | > 16 |
| Clarithromycin              | 75.7%                  | 0.2%  | 24.2% | 0.25              | > 32              | ≤ 0.03 | > 32 |
| Clindamycin                 | 94.8%                  | 0.2%  | 5.0%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8  |
| Colistin                    | No Breakpoints Defined |       |       | > 16              | > 16              | ≤ 0.06 | > 16 |
| Daptomycin                  | 100.0%                 |       |       | 0.25              | 0.5               | ≤ 0.03 | 0.5  |
| Doripenem                   | No Breakpoints Defined |       |       | 0.06              | 0.06              | ≤ 0.03 | 0.25 |
| Doxycycline                 | 98.9%                  | 0.5%  | 0.5%  | ≤ 0.12            | 0.25              | ≤ 0.12 | 16   |
| Ertapenem                   |                        |       |       | 0.5               | 0.5               | 0.06   | 1    |
| Gentamicin                  | 97.9%                  | 0.4%  | 1.8%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 32 |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12 |
| Linezolid                   | 100.0%                 |       |       | 2                 | 2                 | ≤ 0.12 | 4    |
| Meropenem                   | No Breakpoints Defined |       |       | 0.12              | 0.25              | ≤ 0.03 | 0.5  |
| Moxifloxacin                | 90.8%                  | 0.5%  | 8.7%  | ≤ 0.06            | 0.25              | ≤ 0.06 | > 16 |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1    | 2    |
| Tigecycline *               | 100.0%                 |       |       | 0.12              | 0.25              | 0.06   | 0.5  |
| Tobramycin                  | 97.3%                  | 0.5%  | 2.1%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 64 |
| Trimethoprim Sulfa          | 98.9%                  |       | 1.1%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8  |
| Vancomycin                  | 100.0%                 |       |       | 1                 | 1                 | 0.25   | 1    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. coli* Susceptibility - National

### *Escherichia coli* (500)

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 99.6%                  | 0.4%  |       | ≤ 1               | 4                 | ≤ 1    | 32    |
| Amoxicillin Clavulanic Acid | 77.0%                  | 16.2% | 6.8%  | 4                 | 16                | 0.5    | > 32  |
| Aztreonam                   | 93.4%                  | 1.6%  | 5.0%  | ≤ 0.12            | 0.5               | ≤ 0.12 | > 64  |
| Cefazolin                   | 70.6%                  | 11.2% | 18.2% | 2                 | 32                | ≤ 0.5  | > 128 |
| Cefepime                    | 96.8%                  | 2.2%  | 1.0%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | > 64  |
| Cefoxitin                   | 92.6%                  | 4.0%  | 3.4%  | 4                 | 8                 | 1      | > 32  |
| Ceftazidime                 | 93.0%                  | 1.0%  | 6.0%  | ≤ 0.25            | 1                 | ≤ 0.25 | > 32  |
| Ceftriaxone                 | 91.2%                  | 0.4%  | 8.4%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | > 64  |
| Ciprofloxacin               | 74.0%                  | 0.2%  | 25.8% | ≤ 0.06            | > 16              | ≤ 0.06 | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | ≤ 0.06 | > 16  |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.25  |
| Doxycycline                 | 70.8%                  | 5.0%  | 24.2% | 2                 | 32                | 0.5    | > 32  |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.5   |
| Gentamicin                  | 90.8%                  | 0.4%  | 8.8%  | ≤ 0.5             | 2                 | ≤ 0.5  | > 32  |
| Imipenem                    | 100.0%                 |       |       | 0.12              | 0.25              | 0.06   | 1     |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12  |
| Moxifloxacin *              | 74.0%                  |       | 26.0% | ≤ 0.06            | > 16              | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | 97.0%                  | 0.6%  | 2.4%  | ≤ 1               | 4                 | ≤ 1    | > 512 |
| Tigecycline *               | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 2     |
| Tobramycin                  | 92.0%                  | 3.6%  | 4.4%  | ≤ 0.5             | 4                 | ≤ 0.5  | 64    |
| Trimethoprim Sulfa          | 73.0%                  |       | 27.0% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

# CANWARD 2012

## *P. aeruginosa* Susceptibility - National

### *Pseudomonas aeruginosa* (264)

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 94.7%                  | 3.0%  | 2.3%  | 4                 | 8                 | ≤ 1    | > 64  |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | > 32              | > 32              | 16     | > 32  |
| Aztreonam                   | 78.4%                  | 10.2% | 11.4% | 4                 | 32                | ≤ 0.12 | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | 128    | > 128 |
| Cefepime                    | 90.2%                  | 6.8%  | 3.0%  | 4                 | 8                 | ≤ 0.25 | 64    |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Ceftazidime                 | 86.0%                  | 4.9%  | 9.1%  | 4                 | 16                | ≤ 0.25 | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |       | 16                | > 64              | 1      | > 64  |
| Ciprofloxacin               | 83.3%                  | 6.4%  | 10.2% | 0.25              | 4                 | ≤ 0.06 | > 16  |
| Colistin                    | 98.5%                  | 0.4%  | 1.1%  | 1                 | 1                 | 0.25   | > 16  |
| Doripenem                   | 89.4%                  | 5.7%  | 4.9%  | 0.5               | 4                 | ≤ 0.03 | 32    |
| Doxycycline                 | No Breakpoints Defined |       |       | 32                | > 32              | 1      | > 32  |
| Ertapenem                   | No Breakpoints Defined |       |       | 8                 | > 32              | 0.12   | > 32  |
| Gentamicin                  | 90.5%                  | 4.2%  | 5.3%  | 1                 | 4                 | ≤ 0.5  | > 32  |
| Imipenem                    | 72.3%                  | 9.1%  | 18.6% | 2                 | 16                | 0.12   | > 32  |
| Meropenem                   | 81.4%                  | 9.5%  | 9.1%  | 0.5               | 4                 | ≤ 0.03 | > 32  |
| Moxifloxacin                | No Breakpoints Defined |       |       | 2                 | 16                | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | 87.5%                  | 7.6%  | 4.9%  | 4                 | 32                | ≤ 1    | 512   |
| Tigecycline                 | No Breakpoints Defined |       |       | 16                | > 16              | 1      | > 16  |
| Tobramycin                  | 95.1%                  | 0.4%  | 4.5%  | ≤ 0.5             | 2                 | ≤ 0.5  | > 64  |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | 8                 | > 8               | 0.5    | > 8   |

# CANWARD 2012

## *K. pneumoniae* Susceptibility - National

### *Klebsiella pneumoniae* (169)

| Drug                        | Susceptibility         |       |       |                   | Range             |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | ≤ 1               | ≤ 1    | 2     |
| Amoxicillin Clavulanic Acid | 97.0%                  | 1.2%  | 1.8%  | 2                 | 8                 | 1      | > 32  |
| Aztreonam                   | 96.4%                  | 0.6%  | 3.0%  | ≤ 0.12            | 0.25              | ≤ 0.12 | > 64  |
| Cefazolin                   | 91.7%                  | 2.4%  | 5.9%  | 1                 | 2                 | ≤ 0.5  | > 128 |
| Cefepime                    | 98.8%                  |       | 1.2%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 64    |
| Cefoxitin                   | 95.3%                  | 1.2%  | 3.6%  | 2                 | 8                 | 1      | > 32  |
| Ceftazidime                 | 97.0%                  |       | 3.0%  | ≤ 0.25            | 0.5               | ≤ 0.25 | > 32  |
| Ceftriaxone                 | 95.3%                  | 1.2%  | 3.6%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | > 64  |
| Ciprofloxacin               | 97.6%                  |       | 2.4%  | ≤ 0.06            | 0.25              | ≤ 0.06 | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | ≤ 0.06 | > 16  |
| Doripenem                   | 99.4%                  |       | 0.6%  | ≤ 0.03            | 0.06              | ≤ 0.03 | 4     |
| Doxycycline                 | 82.8%                  | 3.0%  | 14.2% | 2                 | 16                | 1      | > 32  |
| Ertapenem                   | 98.8%                  | 0.6%  | 0.6%  | ≤ 0.03            | 0.06              | ≤ 0.03 | 16    |
| Gentamicin                  | 98.2%                  |       | 1.8%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 32  |
| Imipenem                    | 98.8%                  | 0.6%  | 0.6%  | 0.25              | 0.5               | 0.12   | 4     |
| Meropenem                   | 99.4%                  |       | 0.6%  | ≤ 0.03            | 0.06              | ≤ 0.03 | 8     |
| Moxifloxacin *              | 98.2%                  | 0.6%  | 1.2%  | 0.12              | 0.5               | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | 97.6%                  | 0.6%  | 1.8%  | 2                 | 8                 | ≤ 1    | > 512 |
| Tigecycline *               | 95.9%                  | 3.0%  | 1.2%  | 0.5               | 1                 | 0.25   | 8     |
| Tobramycin                  | 99.4%                  | 0.6%  |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 8     |
| Trimethoprim Sulfa          | 91.7%                  |       | 8.3%  | ≤ 0.12            | 1                 | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

# CANWARD 2012

## *S. pneumoniae* Susceptibility - National

### ***Streptococcus pneumoniae* (136)**

| Drug                        | Susceptibility         |       |       | Range             |                   |         |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|---------|------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min     | Max  |
| Amoxicillin Clavulanic Acid | 96.3%                  | 1.5%  | 2.2%  | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | 8    |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | 1    |
| Cefuroxime                  | 93.4%                  |       | 6.6%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | 8    |
| Chloramphenicol             | 98.5%                  |       | 1.5%  | 2                 | 4                 | ≤ 0.12  | 16   |
| Ciprofloxacin               | 97.8%                  |       | 2.2%  | 1                 | 2                 | 0.12    | > 16 |
| Clarithromycin              | 76.5%                  | 1.5%  | 22.1% | ≤ 0.03            | 4                 | ≤ 0.03  | > 32 |
| Clindamycin                 | 90.4%                  |       | 9.6%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | > 64 |
| Daptomycin                  | No Breakpoints Defined |       |       | 0.12              | 0.12              | ≤ 0.03  | 0.25 |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | 1    |
| Doxycycline                 | 86.0%                  | 1.5%  | 12.5% | ≤ 0.25            | 1                 | ≤ 0.25  | 16   |
| Ertapenem                   | 95.6%                  | 4.4%  |       | ≤ 0.06            | 0.12              | ≤ 0.06  | 2    |
| Imipenem                    | 93.4%                  | 3.7%  | 2.9%  | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | 1    |
| Levofloxacin                | 98.5%                  |       | 1.5%  | 1                 | 1                 | ≤ 0.06  | 16   |
| Linezolid                   | 100.0%                 |       |       | 1                 | 1                 | ≤ 0.12  | 2    |
| Meropenem                   | 94.1%                  | 2.2%  | 3.7%  | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | 1    |
| Moxifloxacin                | 98.5%                  | 0.7%  | 0.7%  | 0.12              | 0.25              | ≤ 0.06  | 4    |
| Penicillin                  | 88.9%                  | 7.1%  | 4.0%  | ≤ 0.03            | 0.12              | ≤ 0.03  | 4    |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1     | 4    |
| Telithromycin               | 100.0%                 |       |       | 0.008             | 0.12              | ≤ 0.002 | 0.5  |
| Tigecycline *               | 100.0%                 |       |       | ≤ 0.015           | 0.03              | ≤ 0.015 | 0.03 |
| Trimethoprim Sulfa          | 89.0%                  | 5.1%  | 5.9%  | 0.25              | 1                 | ≤ 0.12  | 8    |
| Vancomycin                  | 100.0%                 |       |       | 0.25              | 0.25              | ≤ 0.12  | 0.5  |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *S. aureus*, MRSA Susceptibility - National

### ***Staphylococcus aureus*, MRSA (125)**

| Drug                        | Susceptibility         |       |        | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |       |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res  |                   |                   | Min    | Max   |
| Amikacin                    | 87.2%                  | 12.0% | 0.8%   | 8                 | 32                | ≤ 1    | 64    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |        | 8                 | 32                | 2      | 32    |
| Aztreonam                   | No Breakpoints Defined |       |        | > 64              | > 64              | > 64   | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |        | 32                | 128               | 1      | > 128 |
| Cefepime                    | No Breakpoints Defined |       |        | 64                | > 64              | 4      | > 64  |
| Cefoxitin                   |                        |       | 100.0% | 32                | > 32              | 16     | > 32  |
| Ceftazidime                 | No Breakpoints Defined |       |        | > 32              | > 32              | 16     | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |        | > 64              | > 64              | 16     | > 64  |
| Ciprofloxacin               | 27.2%                  |       | 72.8%  | 16                | > 16              | 0.25   | > 16  |
| Clarithromycin              | 21.6%                  |       | 78.4%  | > 32              | > 32              | 0.12   | > 32  |
| Clindamycin                 | 68.8%                  |       | 31.2%  | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | > 16   | > 16  |
| Daptomycin                  | 99.2%                  |       | 0.8%   | 0.25              | 0.5               | 0.12   | 2     |
| Doripenem                   | No Breakpoints Defined |       |        | 1                 | 16                | 0.12   | 32    |
| Doxycycline                 | 100.0%                 |       |        | ≤ 0.12            | 1                 | ≤ 0.12 | 4     |
| Ertapenem                   | No Breakpoints Defined |       |        | 16                | > 32              | 1      | > 32  |
| Gentamicin                  | 98.4%                  | 0.8%  | 0.8%   | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 32  |
| Imipenem                    | No Breakpoints Defined |       |        | 1                 | 32                | 0.06   | > 32  |
| Linezolid                   | 100.0%                 |       |        | 2                 | 2                 | 0.5    | 4     |
| Meropenem                   | No Breakpoints Defined |       |        | 4                 | 16                | 0.25   | > 32  |
| Moxifloxacin                | 27.2%                  | 3.2%  | 69.6%  | 2                 | > 16              | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |        | 32                | 128               | 4      | 256   |
| Tigecycline *               | 97.6%                  |       |        | 0.12              | 0.5               | 0.06   | 1     |
| Tobramycin                  | 64.0%                  | 0.8%  | 35.2%  | 1                 | > 64              | ≤ 0.5  | > 64  |
| Trimethoprim Sulfa          | 96.0%                  |       | 4.0%   | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8   |
| Vancomycin                  | 100.0%                 |       |        | 1                 | 1                 | 0.5    | 2     |

\*Interpretive breakpoints defined by FDA (tigecycline)



# CANWARD 2012

## *S. aureus*, CA-MRSA Susceptibility - National

### ***Staphylococcus aureus*, CA-MRSA (48)**

| Drug                        | Susceptibility         |       |        | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|------|
|                             | % Sus                  | % Int | % Res  |                   |                   | Min    | Max  |
| Amikacin                    | 97.9%                  | 2.1%  |        | 8                 | 16                | 2      | 32   |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |        | 8                 | 16                | 2      | 32   |
| Aztreonam                   | No Breakpoints Defined |       |        | > 64              | > 64              | > 64   | > 64 |
| Cefazolin                   | No Breakpoints Defined |       |        | 16                | 64                | 1      | 128  |
| Cefepime                    | No Breakpoints Defined |       |        | 32                | > 64              | 4      | > 64 |
| Cefoxitin                   |                        |       | 100.0% | 32                | > 32              | 16     | > 32 |
| Ceftazidime                 | No Breakpoints Defined |       |        | > 32              | > 32              | 32     | > 32 |
| Ceftriaxone                 | No Breakpoints Defined |       |        | 64                | > 64              | 16     | > 64 |
| Ciprofloxacin               | 39.6%                  |       | 60.4%  | 16                | 16                | 0.25   | > 16 |
| Clarithromycin              | 35.4%                  |       | 64.6%  | > 32              | > 32              | 0.12   | > 32 |
| Clindamycin                 | 85.4%                  |       | 14.6%  | ≤ 0.12            | > 8               | ≤ 0.12 | > 8  |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | > 16   | > 16 |
| Daptomycin                  | 97.9%                  |       | 2.1%   | 0.25              | 0.5               | 0.25   | 2    |
| Doripenem                   | No Breakpoints Defined |       |        | 1                 | 2                 | 0.12   | 8    |
| Doxycycline                 | 100.0%                 |       |        | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 0.25 |
| Ertapenem                   | No Breakpoints Defined |       |        | 2                 | 8                 | 1      | 8    |
| Gentamicin                  | 97.9%                  | 2.1%  |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 8    |
| Imipenem                    | No Breakpoints Defined |       |        | 0.5               | 2                 | 0.06   | 32   |
| Linezolid                   | 100.0%                 |       |        | 2                 | 2                 | 1      | 4    |
| Meropenem                   | No Breakpoints Defined |       |        | 2                 | 4                 | 0.25   | 32   |
| Moxifloxacin                | 39.6%                  | 6.3%  | 54.2%  | 2                 | 2                 | ≤ 0.06 | 8    |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |        | 16                | 64                | 4      | 128  |
| Tigecycline *               | 100.0%                 |       |        | 0.12              | 0.12              | 0.06   | 0.25 |
| Tobramycin                  | 97.9%                  | 2.1%  |        | ≤ 0.5             | 1                 | ≤ 0.5  | 8    |
| Trimethoprim Sulfa          | 100.0%                 |       |        | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 0.5  |
| Vancomycin                  | 100.0%                 |       |        | 0.5               | 1                 | 0.5    | 2    |

\*Interpretive breakpoints defined by FDA (tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. aureus*, HA-MRSA Susceptibility - National

### ***Staphylococcus aureus*, HA-MRSA (68)**

| Drug                        | Susceptibility         |       |        | Range             |                   |        |       |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 77.9%                  | 20.6% | 1.5%   | 16                | 32                | ≤ 1    | 64    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |        | 16                | 32                | 2      | 32    |
| Aztreonam                   | No Breakpoints Defined |       |        | > 64              | > 64              | > 64   | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |        | 64                | > 128             | 2      | > 128 |
| Cefepime                    | No Breakpoints Defined |       |        | > 64              | > 64              | 4      | > 64  |
| Cefoxitin                   |                        |       | 100.0% | > 32              | > 32              | 16     | > 32  |
| Ceftazidime                 | No Breakpoints Defined |       |        | > 32              | > 32              | 16     | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |        | > 64              | > 64              | 16     | > 64  |
| Ciprofloxacin               | 11.8%                  |       | 88.2%  | > 16              | > 16              | 0.25   | > 16  |
| Clarithromycin              | 8.8%                   |       | 91.2%  | > 32              | > 32              | 0.12   | > 32  |
| Clindamycin                 | 54.4%                  |       | 45.6%  | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | > 16   | > 16  |
| Daptomycin                  | 100.0%                 |       |        | 0.25              | 0.5               | 0.12   | 0.5   |
| Doripenem                   | No Breakpoints Defined |       |        | 4                 | 32                | 0.25   | 32    |
| Doxycycline                 | 100.0%                 |       |        | ≤ 0.12            | 2                 | ≤ 0.12 | 4     |
| Ertapenem                   | No Breakpoints Defined |       |        | 16                | > 32              | 2      | > 32  |
| Gentamicin                  | 100.0%                 |       |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 4     |
| Imipenem                    | No Breakpoints Defined |       |        | 4                 | > 32              | 0.12   | > 32  |
| Linezolid                   | 100.0%                 |       |        | 2                 | 4                 | 0.5    | 4     |
| Meropenem                   | No Breakpoints Defined |       |        | 8                 | 32                | 0.5    | > 32  |
| Moxifloxacin                | 11.8%                  | 1.5%  | 86.8%  | 8                 | > 16              | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |        | 64                | 128               | 4      | 256   |
| Tigecycline *               | 95.6%                  |       |        | 0.12              | 0.5               | 0.12   | 1     |
| Tobramycin                  | 36.8%                  |       | 63.2%  | > 64              | > 64              | ≤ 0.5  | > 64  |
| Trimethoprim Sulfa          | 92.6%                  |       | 7.4%   | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8   |
| Vancomycin                  | 100.0%                 |       |        | 1                 | 1                 | 0.5    | 1     |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. faecalis* Susceptibility - National

### ***Enterococcus faecalis* (92)**

| Drug                        | Susceptibility |         |       | Range             |                   |        |      |
|-----------------------------|----------------|---------|-------|-------------------|-------------------|--------|------|
|                             | % Sus          | % Int   | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max  |
| Amikacin                    | No Breakpoints | Defined |       | > 64              | > 64              | 8      | > 64 |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |       | 0.5               | 1                 | 0.12   | 1    |
| Aztreonam                   | No Breakpoints | Defined |       | > 64              | > 64              | > 64   | > 64 |
| Cefazolin                   | No Breakpoints | Defined |       | 32                | 32                | 4      | 64   |
| Cefepime                    | No Breakpoints | Defined |       | 32                | > 64              | 2      | > 64 |
| Cefoxitin                   | No Breakpoints | Defined |       | > 32              | > 32              | 16     | > 32 |
| Ceftazidime                 | No Breakpoints | Defined |       | > 32              | > 32              | 4      | > 32 |
| Ceftriaxone                 | No Breakpoints | Defined |       | > 64              | > 64              | 1      | > 64 |
| Ciprofloxacin               | 68.5%          | 4.3%    | 27.2% | 1                 | > 16              | 0.25   | > 16 |
| Clarithromycin              | No Breakpoints | Defined |       | 32                | > 32              | 0.06   | > 32 |
| Clindamycin                 | No Breakpoints | Defined |       | > 8               | > 8               | 1      | > 8  |
| Colistin                    | No Breakpoints | Defined |       | > 16              | > 16              | > 16   | > 16 |
| Daptomycin                  | 100.0%         |         |       | 1                 | 2                 | 0.12   | 4    |
| Doripenem                   | No Breakpoints | Defined |       | 2                 | 4                 | 0.5    | 8    |
| Doxycycline                 | 42.4%          | 43.5%   | 14.1% | 8                 | 16                | ≤ 0.12 | 32   |
| Ertapenem                   | No Breakpoints | Defined |       | 16                | 16                | 2      | 32   |
| Gentamicin                  | No Breakpoints | Defined |       | 16                | > 32              | 1      | > 32 |
| Imipenem                    | No Breakpoints | Defined |       | 1                 | 2                 | 0.25   | 4    |
| Linezolid                   | 96.7%          | 3.3%    |       | 2                 | 2                 | 1      | 4    |
| Meropenem                   | No Breakpoints | Defined |       | 4                 | 8                 | 1      | 16   |
| Moxifloxacin                | No Breakpoints | Defined |       | 0.25              | 16                | 0.12   | > 16 |
| Piperacillin Tazobactam     | No Breakpoints | Defined |       | 4                 | 4                 | ≤ 1    | 8    |
| Tigecycline *               | 100.0%         |         |       | 0.12              | 0.12              | ≤ 0.03 | 0.25 |
| Tobramycin                  | No Breakpoints | Defined |       | 16                | > 64              | 4      | > 64 |
| Trimethoprim Sulfa          | No Breakpoints | Defined |       | ≤ 0.12            | 0.5               | ≤ 0.12 | > 8  |
| Vancomycin                  | 100.0%         |         |       | 1                 | 2                 | 0.5    | 4    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. cloacae* Susceptibility – National

### *Enterobacter cloacae* (69)

| Drug                        | Susceptibility         |       |       |                   | Range             |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 8     |
| Amoxicillin Clavulanic Acid | 2.9%                   | 2.9%  | 94.2% | > 32              | > 32              | 4      | > 32  |
| Aztreonam                   | 75.4%                  |       | 24.6% | ≤ 0.12            | 64                | ≤ 0.12 | > 64  |
| Cefazolin                   | 1.4%                   | 1.4%  | 97.1% | > 128             | > 128             | 2      | > 128 |
| Cefepime                    | 97.1%                  | 1.4%  | 1.4%  | ≤ 0.25            | 2                 | ≤ 0.25 | 32    |
| Cefoxitin                   | 4.3%                   | 2.9%  | 92.8% | > 32              | > 32              | 8      | > 32  |
| Ceftazidime                 | 75.4%                  | 1.4%  | 23.2% | 0.5               | > 32              | ≤ 0.25 | > 32  |
| Ceftriaxone                 | 72.5%                  | 1.4%  | 26.1% | ≤ 0.25            | > 64              | ≤ 0.25 | > 64  |
| Ciprofloxacin               | 94.2%                  | 1.4%  | 4.3%  | ≤ 0.06            | 0.12              | ≤ 0.06 | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | > 16              | 0.12   | > 16  |
| Doripenem                   | 98.6%                  | 1.4%  |       | 0.06              | 0.12              | ≤ 0.03 | 2     |
| Doxycycline                 | 91.3%                  | 4.3%  | 4.3%  | 2                 | 4                 | 2      | 32    |
| Ertapenem                   | 85.5%                  | 8.7%  | 5.8%  | 0.06              | 1                 | ≤ 0.03 | 32    |
| Gentamicin                  | 98.6%                  |       | 1.4%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 32  |
| Imipenem                    | 97.1%                  |       | 2.9%  | 0.5               | 0.5               | 0.12   | 4     |
| Meropenem                   | 98.6%                  | 1.4%  |       | 0.06              | 0.12              | ≤ 0.03 | 2     |
| Moxifloxacin *              | 92.8%                  | 4.4%  | 2.9%  | ≤ 0.06            | 0.25              | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | 82.6%                  | 5.8%  | 11.6% | 2                 | 128               | ≤ 1    | 256   |
| Tigecycline *               | 98.6%                  |       | 1.4%  | 0.5               | 1                 | 0.25   | 8     |
| Tobramycin                  | 98.6%                  |       | 1.4%  | ≤ 0.5             | 1                 | ≤ 0.5  | 16    |
| Trimethoprim Sulfa          | 89.9%                  |       | 10.1% | ≤ 0.12            | 4                 | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

# CANWARD 2012

## *S. epidermidis* Susceptibility - National

### ***Staphylococcus epidermidis* (72)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max  |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 16                | ≤ 1    | 16   |
| Amoxicillin Clavulanic Acid | 80.6%                  |       | 19.4% | 1                 | 16                | ≤ 0.06 | 16   |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | 64     | > 64 |
| Cefazolin                   | 80.6%                  | 2.8%  | 16.7% | 2                 | 128               | ≤ 0.5  | 128  |
| Cefepime                    | 68.1%                  | 11.1% | 20.8% | 4                 | > 64              | ≤ 0.25 | > 64 |
| Cefoxitin                   | No Breakpoints Defined |       |       | 16                | > 32              | 1      | > 32 |
| Ceftazidime                 | 25.0%                  | 18.1% | 56.9% | 32                | > 32              | 2      | > 32 |
| Ceftriaxone                 | 43.1%                  | 36.1% | 20.8% | 16                | > 64              | 0.5    | > 64 |
| Ciprofloxacin               | 44.4%                  |       | 55.6% | 8                 | > 16              | ≤ 0.06 | > 16 |
| Clarithromycin              | 29.2%                  |       | 70.8% | > 32              | > 32              | ≤ 0.03 | > 32 |
| Clindamycin                 | 55.6%                  | 1.4%  | 43.1% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8  |
| Colistin                    | No Breakpoints Defined |       |       | > 16              | > 16              | 4      | > 16 |
| Daptomycin                  | 100.0%                 |       |       | 0.25              | 0.25              | ≤ 0.03 | 0.5  |
| Doripenem                   | No Breakpoints Defined |       |       | 1                 | 16                | ≤ 0.03 | 32   |
| Doxycycline                 | 97.2%                  | 2.8%  |       | 0.5               | 1                 | ≤ 0.12 | 8    |
| Ertapenem                   | 45.1%                  | 7.8%  | 47.1% | 4                 | > 32              | 0.25   | > 32 |
| Gentamicin                  | 55.6%                  | 6.9%  | 37.5% | ≤ 0.5             | > 32              | ≤ 0.5  | > 32 |
| Imipenem                    | 72.2%                  | 4.2%  | 23.6% | 0.25              | 32                | ≤ 0.03 | > 32 |
| Linezolid                   | 100.0%                 |       |       | 1                 | 1                 | ≤ 0.12 | 2    |
| Piperacillin Tazobactam     | 83.3%                  |       | 16.7% | ≤ 1               | 16                | ≤ 1    | 64   |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.12              | 0.25              | 0.06   | 1    |
| Tobramycin                  | 56.9%                  | 12.5% | 30.6% | 2                 | 64                | ≤ 0.5  | > 64 |
| Trimethoprim Sulfa          | 54.2%                  |       | 45.8% | ≤ 0.12            | 8                 | ≤ 0.12 | > 8  |
| Vancomycin                  | 100.0%                 |       |       | 1                 | 2                 | 0.5    | 2    |

# CANWARD 2012

## *S. marcescens* Susceptibility - National

### *Serratia marcescens* (40)

| Drug                        | Susceptibility         |       |        | Range             |                   |        |        |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |        | 2                 | 4                 | ≤ 1    | 8      |
| Amoxicillin Clavulanic Acid | 2.5%                   | 2.5%  | 95.0%  | > 32              | > 32              | 4      | > 32   |
| Aztreonam                   | 100.0%                 |       |        | ≤ 0.12            | 0.25              | ≤ 0.12 | 2      |
| Cefazolin                   |                        |       | 100.0% | > 128             | > 128             | 128    | > 128  |
| Cefepime                    | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   | 27.5%                  | 55.0% | 17.5%  | 16                | 32                | 8      | > 32   |
| Ceftazidime                 | 100.0%                 |       |        | ≤ 0.25            | 0.5               | ≤ 0.25 | 1      |
| Ceftriaxone                 | 97.5%                  |       | 2.5%   | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 8      |
| Ciprofloxacin               | 92.5%                  | 2.5%  | 5.0%   | ≤ 0.06            | 0.5               | ≤ 0.06 | 16     |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | 0.5    | > 16   |
| Doripenem                   | 100.0%                 |       |        | 0.12              | 0.25              | 0.06   | 0.25   |
| Doxycycline                 | 45.0%                  | 30.0% | 25.0%  | 8                 | 16                | 2      | > 32   |
| Ertapenem                   | 100.0%                 |       |        | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.25   |
| Gentamicin                  | 100.0%                 |       |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 2      |
| Imipenem                    | 100.0%                 |       |        | 0.5               | 1                 | 0.25   | 1      |
| Meropenem                   | 100.0%                 |       |        | 0.06              | 0.06              | ≤ 0.03 | 0.12   |
| Moxifloxacin *              | 92.5%                  | 2.5%  | 5.0%   | 0.25              | 2                 | ≤ 0.06 | 16     |
| Piperacillin Tazobactam     | 97.5%                  | 2.5%  |        | ≤ 1               | 2                 | ≤ 1    | 32     |
| Tigecycline *               | 97.5%                  |       | 2.5%   | 1                 | 2                 | 1      | 8      |
| Tobramycin                  | 95.0%                  | 2.5%  | 2.5%   | 1                 | 2                 | ≤ 0.5  | 16     |
| Trimethoprim Sulfa          | 100.0%                 |       |        | 0.25              | 0.5               | ≤ 0.12 | 2      |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

# CANWARD 2012

## *K. oxytoca* Susceptibility - National

### *Klebsiella oxytoca* (50)

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 4     |
| Amoxicillin Clavulanic Acid | 82.0%                  | 10.0% | 8.0%  | 2                 | 16                | 1      | > 32  |
| Aztreonam                   | 92.0%                  | 2.0%  | 6.0%  | ≤ 0.12            | 1                 | ≤ 0.12 | 64    |
| Cefazolin                   | 26.0%                  | 32.0% | 42.0% | 4                 | > 128             | 1      | > 128 |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 0.5   |
| Cefoxitin                   | 98.0%                  |       | 2.0%  | 2                 | 4                 | 0.5    | 32    |
| Ceftazidime                 | 100.0%                 |       |       | ≤ 0.25            | 0.5               | ≤ 0.25 | 1     |
| Ceftriaxone                 | 94.0%                  | 2.0%  | 4.0%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 8     |
| Ciprofloxacin               | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | 1     |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | ≤ 0.06 | > 16  |
| Doripenem                   | 100.0%                 |       |       | 0.06              | 0.06              | ≤ 0.03 | 0.12  |
| Doxycycline                 | 98.0%                  | 2.0%  |       | 1                 | 2                 | 1      | 8     |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12  |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5 |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 0.5   |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.06  |
| Moxifloxacin *              | 98.0%                  | 2.0%  |       | ≤ 0.06            | 0.12              | ≤ 0.06 | 4     |
| Piperacillin Tazobactam     | 84.0%                  | 2.0%  | 14.0% | 2                 | 128               | ≤ 1    | > 512 |
| Tigecycline *               | 100.0%                 |       |       | 0.5               | 0.5               | 0.25   | 1     |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 2     |
| Trimethoprim Sulfa          | 98.0%                  |       | 2.0%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

# CANWARD 2012

## *S. maltophilia* Susceptibility - National

### ***Stenotrophomonas maltophilia* (43)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | No Breakpoints Defined |       |       | 32                | > 64              | 4      | > 64  |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | 16     | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | 2      | > 128 |
| Cefepime                    | No Breakpoints Defined |       |       | 32                | > 64              | ≤ 0.25 | > 64  |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | 4      | > 32  |
| Ceftazidime                 | 16.3%                  | 7.0%  | 76.7% | > 32              | > 32              | 1      | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |       | > 64              | > 64              | 4      | > 64  |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 2                 | 8                 | 0.5    | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 4                 | > 16              | 0.25   | > 16  |
| Doripenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Doxycycline                 | No Breakpoints Defined |       |       | 2                 | 4                 | 0.5    | 16    |
| Ertapenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Gentamicin                  | No Breakpoints Defined |       |       | 8                 | > 32              | 1      | > 32  |
| Imipenem                    | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Meropenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | 16     | > 32  |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.5               | 4                 | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | 256               | > 512             | ≤ 1    | > 512 |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.5               | 2                 | 0.25   | 4     |
| Tobramycin                  | No Breakpoints Defined |       |       | 8                 | 64                | 1      | > 64  |
| Trimethoprim Sulfa          | 69.0%                  |       | 31.0% | 0.5               | > 8               | ≤ 0.12 | > 8   |



# CANWARD 2012

## *E. faecium* Susceptibility - National

### ***Enterococcus faecium* (35)**

| Drug                        | Susceptibility |         |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |       |
|-----------------------------|----------------|---------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus          | % Int   | % Res |                   |                   | Min    | Max   |
| Amikacin                    | No Breakpoints | Defined |       | 16                | > 64              | 8      | > 64  |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |       | > 32              | > 32              | 0.12   | > 32  |
| Aztreonam                   | No Breakpoints | Defined |       | > 64              | > 64              | 64     | > 64  |
| Cefazolin                   | No Breakpoints | Defined |       | > 128             | > 128             | 16     | > 128 |
| Cefepime                    | No Breakpoints | Defined |       | > 64              | > 64              | 4      | > 64  |
| Cefoxitin                   | No Breakpoints | Defined |       | > 32              | > 32              | 16     | > 32  |
| Ceftazidime                 | No Breakpoints | Defined |       | > 32              | > 32              | > 32   | > 32  |
| Ceftriaxone                 | No Breakpoints | Defined |       | > 64              | > 64              | 1      | > 64  |
| Ciprofloxacin               | 17.1%          |         | 82.9% | > 16              | > 16              | 0.5    | > 16  |
| Clarithromycin              | No Breakpoints | Defined |       | > 32              | > 32              | 0.12   | > 32  |
| Clindamycin                 | No Breakpoints | Defined |       | > 8               | > 8               | ≤ 0.12 | > 8   |
| Colistin                    | No Breakpoints | Defined |       | > 16              | > 16              | > 16   | > 16  |
| Daptomycin                  | 100.0%         |         |       | 1                 | 2                 | 1      | 2     |
| Doripenem                   | No Breakpoints | Defined |       | > 32              | > 32              | 1      | > 32  |
| Doxycycline                 | 82.9%          | 8.6%    | 8.6%  | 2                 | 8                 | ≤ 0.12 | 16    |
| Ertapenem                   | No Breakpoints | Defined |       | > 32              | > 32              | 4      | > 32  |
| Gentamicin                  | No Breakpoints | Defined |       | 8                 | 8                 | 2      | > 32  |
| Imipenem                    | No Breakpoints | Defined |       | > 32              | > 32              | 0.5    | > 32  |
| Linezolid                   | 91.4%          | 8.6%    |       | 2                 | 2                 | 1      | 4     |
| Meropenem                   | No Breakpoints | Defined |       | > 32              | > 32              | 2      | > 32  |
| Moxifloxacin                | No Breakpoints | Defined |       | > 16              | > 16              | 0.25   | > 16  |
| Piperacillin Tazobactam     | No Breakpoints | Defined |       | > 512             | > 512             | 4      | > 512 |
| Tigecycline                 | No Breakpoints | Defined |       | 0.06              | 0.12              | 0.06   | 0.12  |
| Tobramycin                  | No Breakpoints | Defined |       | 64                | > 64              | 32     | > 64  |
| Trimethoprim Sulfa          | No Breakpoints | Defined |       | 0.5               | > 8               | ≤ 0.12 | > 8   |
| Vancomycin                  | 71.4%          |         | 28.6% | 1                 | > 32              | 0.25   | > 32  |

# CANWARD 2012

## *S. agalactiae* Susceptibility - National

### ***Streptococcus agalactiae* (43)**

| Drug                        | Susceptibility         |       |       | Range             |                   |         |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|---------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min     | Max    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | ≤ 0.06            | 0.12              | ≤ 0.06  | 0.12   |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12 |
| Cefuroxime                  | No Breakpoints Defined |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | ≤ 0.25 |
| Chloramphenicol             | 100.0%                 |       |       | 4                 | 4                 | 2       | 4      |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 0.5               | 1                 | 0.25    | > 16   |
| Clarithromycin              | 74.4%                  | 4.7%  | 20.9% | ≤ 0.03            | 16                | ≤ 0.03  | > 32   |
| Clindamycin                 | 81.4%                  |       | 18.6% | ≤ 0.12            | > 64              | ≤ 0.12  | > 64   |
| Daptomycin                  | 100.0%                 |       |       | 0.25              | 0.25              | 0.06    | 0.25   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Doxycycline                 | No Breakpoints Defined |       |       | 8                 | 16                | ≤ 0.25  | 16     |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.06            | 0.12              | ≤ 0.06  | 0.12   |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Levofloxacin                | 95.3%                  |       | 4.7%  | 1                 | 1                 | 0.5     | 32     |
| Linezolid                   | 100.0%                 |       |       | 2                 | 2                 | 1       | 2      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06 |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.12              | 0.25              | ≤ 0.06  | 4      |
| Penicillin                  | 100.0%                 |       |       | 0.06              | 0.06              | ≤ 0.03  | 0.12   |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1     | ≤ 1    |
| Telithromycin               | No Breakpoints Defined |       |       | 0.015             | 0.12              | 0.008   | 1      |
| Tigecycline *               | 100.0%                 |       |       | 0.03              | 0.06              | ≤ 0.015 | 0.06   |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | 1      |
| Vancomycin                  | 100.0%                 |       |       | 0.5               | 0.5               | 0.25    | 0.5    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *P. mirabilis* Susceptibility - National

### ***Proteus mirabilis* (39)**

| Drug                        | Susceptibility         |       |       |                   | Range             |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | 2                 | 4                 | ≤ 1    | 8     |
| Amoxicillin Clavulanic Acid | 87.2%                  |       | 12.8% | 1                 | > 32              | 0.5    | > 32  |
| Aztreonam                   | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 0.25  |
| Cefazolin                   | 2.6%                   | 66.7% | 30.8% | 4                 | > 128             | 2      | > 128 |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | 0.5               | ≤ 0.25 | 1     |
| Cefoxitin                   | 87.2%                  | 7.7%  | 5.1%  | 4                 | 16                | 2      | 32    |
| Ceftazidime                 | 100.0%                 |       |       | ≤ 0.25            | 4                 | ≤ 0.25 | 4     |
| Ceftriaxone                 | 92.3%                  | 7.7%  |       | ≤ 0.25            | 1                 | ≤ 0.25 | 2     |
| Ciprofloxacin               | 92.3%                  | 2.6%  | 5.1%  | ≤ 0.06            | 1                 | ≤ 0.06 | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | > 16              | > 16              | ≤ 0.06 | > 16  |
| Doripenem                   | 100.0%                 |       |       | 0.12              | 0.25              | 0.06   | 0.5   |
| Doxycycline                 |                        | 2.6%  | 97.4% | 32                | > 32              | 8      | > 32  |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.06  |
| Gentamicin                  | 89.7%                  | 2.6%  | 7.7%  | ≤ 0.5             | 8                 | ≤ 0.5  | 16    |
| Imipenem                    | 30.8%                  | 48.7% | 20.5% | 2                 | 4                 | 0.25   | 4     |
| Meropenem                   | 100.0%                 |       |       | 0.06              | 0.12              | ≤ 0.03 | 0.25  |
| Moxifloxacin *              | 84.6%                  | 5.1%  | 10.3% | 0.5               | 8                 | 0.25   | > 16  |
| Piperacillin Tazobactam     | 100.0%                 |       |       | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1   |
| Tigecycline *               | 17.9%                  | 46.2% | 35.9% | 4                 | 8                 | 1      | 8     |
| Tobramycin                  | 94.9%                  | 2.6%  | 2.6%  | ≤ 0.5             | 2                 | ≤ 0.5  | 16    |
| Trimethoprim Sulfa          | 84.6%                  |       | 15.4% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

# CANWARD 2012

## *S. pyogenes* Susceptibility - National

### ***Streptococcus pyogenes* (36)**

| Drug                        | Susceptibility         |       |       | Range             |                   |         |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|---------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min     | Max    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | 0.12   |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12 |
| Cefuroxime                  | No Breakpoints Defined |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | 0.5    |
| Chloramphenicol             | 100.0%                 |       |       | 2                 | 4                 | 0.5     | 4      |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 0.5               | 2                 | 0.12    | 2      |
| Clarithromycin              | 94.4%                  |       | 5.6%  | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | > 32   |
| Clindamycin                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | 0.25   |
| Daptomycin                  | 100.0%                 |       |       | 0.06              | 0.12              | ≤ 0.03  | 0.12   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Doxycycline                 | No Breakpoints Defined |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | 16     |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06 |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Levofloxacin                | 100.0%                 |       |       | 0.5               | 2                 | 0.25    | 2      |
| Linezolid                   | 100.0%                 |       |       | 1                 | 2                 | 1       | 2      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | 0.12   |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.12              | 0.25              | ≤ 0.06  | 0.5    |
| Penicillin                  | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | 0.06   |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1     | ≤ 1    |
| Telithromycin               | No Breakpoints Defined |       |       | 0.008             | 0.015             | 0.004   | 0.25   |
| Tigecycline *               | 100.0%                 |       |       | ≤ 0.015           | 0.06              | ≤ 0.015 | 0.25   |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | ≤ 0.12            | 0.25              | ≤ 0.12  | 1      |
| Vancomycin                  | 100.0%                 |       |       | 0.5               | 0.5               | 0.25    | 0.5    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *C. freundii* Susceptibility - National

### *Citrobacter freundii* (11)

| Drug                        | Susceptibility         |       |       |                   | Range             |        |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 2      |
| Amoxicillin Clavulanic Acid |                        | 18.2% | 81.8% | > 32              | > 32              | 16     | > 32   |
| Aztreonam                   | 90.9%                  |       | 9.1%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 32     |
| Cefazolin                   |                        | 18.2% | 81.8% | 16                | > 128             | 4      | > 128  |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   | 9.1%                   |       | 90.9% | > 32              | > 32              | 8      | > 32   |
| Ceftazidime                 | 90.9%                  |       | 9.1%  | 0.5               | 1                 | ≤ 0.25 | 32     |
| Ceftriaxone                 | 90.9%                  |       | 9.1%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 16     |
| Ciprofloxacin               | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | 0.12   |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.25              | 0.12   | 0.5    |
| Doripenem                   | 100.0%                 |       |       | 0.06              | 0.06              | ≤ 0.03 | 0.12   |
| Doxycycline                 | 81.8%                  |       | 18.2% | 2                 | 32                | 1      | 32     |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.5    |
| Gentamicin                  | 81.8%                  |       | 18.2% | ≤ 0.5             | 32                | ≤ 0.5  | > 32   |
| Imipenem                    | 100.0%                 |       |       | 0.5               | 0.5               | 0.25   | 1      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.12   |
| Moxifloxacin *              | 100.0%                 |       |       | 0.12              | 0.5               | ≤ 0.06 | 0.5    |
| Piperacillin Tazobactam     | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 4      |
| Tigecycline *               | 100.0%                 |       |       | 0.5               | 0.5               | 0.25   | 1      |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | 4                 | ≤ 0.5  | 4      |
| Trimethoprim Sulfa          | 72.7%                  |       | 27.3% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8    |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *A. baumannii* Susceptibility - National

### ***Acinetobacter baumannii* (14)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 2     |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | 8                 | 16                | 8      | 16    |
| Aztreonam                   | No Breakpoints Defined |       |       | 32                | > 64              | 4      | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | 128    | > 128 |
| Cefepime                    | 92.9%                  |       | 7.1%  | 2                 | 8                 | 0.5    | 64    |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | 8      | > 32  |
| Ceftazidime                 | 92.9%                  |       | 7.1%  | 4                 | 8                 | 2      | > 32  |
| Ceftriaxone                 | 35.7%                  | 57.1% | 7.1%  | 16                | 32                | 4      | > 64  |
| Ciprofloxacin               | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 0.5   |
| Colistin                    | 100.0%                 |       |       | 0.5               | 1                 | 0.25   | 1     |
| Doripenem                   | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.12   | 1     |
| Doxycycline                 | 100.0%                 |       |       | 0.25              | 0.5               | ≤ 0.12 | 1     |
| Ertapenem                   | No Breakpoints Defined |       |       | 8                 | 16                | 1      | 32    |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5 |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 0.5   |
| Meropenem                   | 100.0%                 |       |       | 0.25              | 1                 | 0.25   | 4     |
| Moxifloxacin                | No Breakpoints Defined |       |       | ≤ 0.06            | 0.25              | ≤ 0.06 | 0.25  |
| Piperacillin Tazobactam     | 92.9%                  |       | 7.1%  | 4                 | 16                | ≤ 1    | 256   |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.12   | 1     |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5 |
| Trimethoprim Sulfa          | 100.0%                 |       |       | ≤ 0.12            | 0.5               | ≤ 0.12 | 2     |

# CANWARD 2012

## *S. aureus*, MSSA Susceptibility - West

### ***Staphylococcus aureus* , MSSA (190)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max  |
| Amikacin                    | 98.9%                  |       | 1.1%  | 2                 | 4                 | ≤ 1    | > 64 |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | 0.5               | 1                 | ≤ 0.06 | 1    |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | 64     | > 64 |
| Cefazolin                   | No Breakpoints Defined |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 1    |
| Cefepime                    | No Breakpoints Defined |       |       | 2                 | 4                 | 0.5    | 4    |
| Cefoxitin                   | 100.0%                 |       |       | 4                 | 4                 | 2      | 4    |
| Ceftazidime                 | No Breakpoints Defined |       |       | 16                | 32                | 4      | 32   |
| Ceftriaxone                 | No Breakpoints Defined |       |       | 4                 | 4                 | 1      | 8    |
| Ciprofloxacin               | 88.9%                  | 2.1%  | 8.9%  | 0.5               | 2                 | ≤ 0.06 | > 16 |
| Clarithromycin              | 77.9%                  |       | 22.1% | 0.25              | > 32              | 0.06   | > 32 |
| Clindamycin                 | 93.7%                  | 0.5%  | 5.8%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8  |
| Colistin                    | No Breakpoints Defined |       |       | > 16              | > 16              | > 16   | > 16 |
| Daptomycin                  | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 0.5  |
| Doripenem                   | No Breakpoints Defined |       |       | 0.06              | 0.06              | ≤ 0.03 | 0.12 |
| Doxycycline                 | 97.9%                  | 0.5%  | 1.6%  | ≤ 0.12            | 0.25              | ≤ 0.12 | 16   |
| Ertapenem                   | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.12   | 0.5  |
| Gentamicin                  | 96.8%                  |       | 3.2%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 32 |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.06 |
| Linezolid                   | 100.0%                 |       |       | 2                 | 2                 | 1      | 4    |
| Meropenem                   | No Breakpoints Defined |       |       | 0.12              | 0.25              | 0.06   | 0.25 |
| Moxifloxacin                | 91.6%                  | 1.1%  | 7.4%  | ≤ 0.06            | 0.25              | ≤ 0.06 | > 16 |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1    | 2    |
| Tigecycline *               | 100.0%                 |       |       | 0.12              | 0.25              | 0.06   | 0.5  |
| Tobramycin                  | 96.3%                  |       | 3.7%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 64 |
| Trimethoprim Sulfa          | 98.4%                  |       | 1.6%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8  |
| Vancomycin                  | 100.0%                 |       |       | 1                 | 1                 | 0.5    | 1    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. coli* Susceptibility - West

### *Escherichia coli* (163)

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 99.4%                  | 0.6%  |       | ≤ 1               | 4                 | ≤ 1    | 32    |
| Amoxicillin Clavulanic Acid | 76.7%                  | 14.7% | 8.6%  | 8                 | 16                | 0.5    | > 32  |
| Aztreonam                   | 95.1%                  | 1.8%  | 3.1%  | ≤ 0.12            | 0.5               | ≤ 0.12 | > 64  |
| Cefazolin                   | 71.2%                  | 11.7% | 17.2% | 2                 | 32                | ≤ 0.5  | > 128 |
| Cefepime                    | 98.2%                  | 1.2%  | 0.6%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | > 64  |
| Cefoxitin                   | 91.4%                  | 4.3%  | 4.3%  | 4                 | 8                 | 1      | > 32  |
| Ceftazidime                 | 94.5%                  | 0.6%  | 4.9%  | ≤ 0.25            | 1                 | ≤ 0.25 | > 32  |
| Ceftriaxone                 | 92.6%                  | 0.6%  | 6.7%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | > 64  |
| Ciprofloxacin               | 74.8%                  |       | 25.2% | ≤ 0.06            | > 16              | ≤ 0.06 | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.25              | ≤ 0.06 | > 16  |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12  |
| Doxycycline                 | 68.7%                  | 7.4%  | 23.9% | 2                 | 32                | 0.5    | > 32  |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.25  |
| Gentamicin                  | 91.4%                  |       | 8.6%  | ≤ 0.5             | 2                 | ≤ 0.5  | > 32  |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.25              | 0.06   | 1     |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12  |
| Moxifloxacin *              | 74.9%                  |       | 25.1% | ≤ 0.06            | 16                | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | 96.9%                  |       | 3.1%  | ≤ 1               | 4                 | ≤ 1    | 512   |
| Tigecycline *               | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 2     |
| Tobramycin                  | 93.3%                  | 3.7%  | 3.1%  | ≤ 0.5             | 4                 | ≤ 0.5  | 32    |
| Trimethoprim Sulfa          | 72.4%                  |       | 27.6% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE





# CANWARD 2012

## *P. aeruginosa* Susceptibility - West

### ***Pseudomonas aeruginosa* (69)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max   |
| Amikacin                    | 87.0%                  | 8.7%  | 4.3%  | 4                 | 32                | ≤ 1    | > 64  |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Aztreonam                   | 71.0%                  | 8.7%  | 20.3% | 8                 | 32                | 0.25   | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | > 128  | > 128 |
| Cefepime                    | 88.4%                  | 4.3%  | 7.2%  | 4                 | 16                | 1      | 64    |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Ceftazidime                 | 87.0%                  | 5.8%  | 7.2%  | 4                 | 16                | 1      | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |       | 16                | > 64              | 2      | > 64  |
| Ciprofloxacin               | 78.3%                  | 8.7%  | 13.0% | 0.25              | 4                 | ≤ 0.06 | > 16  |
| Colistin                    | 98.6%                  |       | 1.4%  | 1                 | 1                 | 0.25   | > 16  |
| Doripenem                   | 89.9%                  | 1.4%  | 8.7%  | 0.5               | 4                 | ≤ 0.03 | 32    |
| Doxycycline                 | No Breakpoints Defined |       |       | 32                | > 32              | 4      | > 32  |
| Ertapenem                   | No Breakpoints Defined |       |       | 16                | > 32              | 0.12   | > 32  |
| Gentamicin                  | 85.5%                  | 5.8%  | 8.7%  | 1                 | 8                 | ≤ 0.5  | > 32  |
| Imipenem                    | 71.0%                  | 8.7%  | 20.3% | 2                 | 16                | 0.25   | 32    |
| Meropenem                   | 79.7%                  | 8.7%  | 11.6% | 0.5               | 8                 | ≤ 0.03 | > 32  |
| Moxifloxacin                | No Breakpoints Defined |       |       | 2                 | 16                | 0.25   | > 16  |
| Piperacillin Tazobactam     | 85.5%                  | 8.7%  | 5.8%  | 4                 | 64                | ≤ 1    | 512   |
| Tigecycline                 | No Breakpoints Defined |       |       | 16                | > 16              | 2      | > 16  |
| Tobramycin                  | 94.2%                  | 1.4%  | 4.3%  | ≤ 0.5             | 4                 | ≤ 0.5  | > 64  |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | 8                 | > 8               | 0.5    | > 8   |

# CANWARD 2012

## *K. pneumoniae* Susceptibility - West

### ***Klebsiella pneumoniae* (47)**

| Drug                        | Susceptibility         |       |       |                   | Range             |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | ≤ 1               | ≤ 1    | 2     |
| Amoxicillin Clavulanic Acid | 97.9%                  | 2.1%  |       | 2                 | 8                 | 1      | 16    |
| Aztreonam                   | 97.9%                  |       | 2.1%  | ≤ 0.12            | 0.25              | ≤ 0.12 | > 64  |
| Cefazolin                   | 91.5%                  | 2.1%  | 6.4%  | 1                 | 2                 | 1      | > 128 |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 4     |
| Cefoxitin                   | 93.6%                  | 2.1%  | 4.3%  | 2                 | 8                 | 1      | 32    |
| Ceftazidime                 | 97.9%                  |       | 2.1%  | ≤ 0.25            | 0.5               | ≤ 0.25 | > 32  |
| Ceftriaxone                 | 93.6%                  | 2.1%  | 4.3%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 16    |
| Ciprofloxacin               | 100.0%                 |       |       | ≤ 0.06            | 0.12              | ≤ 0.06 | 0.5   |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.25   | 1     |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.12  |
| Doxycycline                 | 80.9%                  | 4.3%  | 14.9% | 2                 | 16                | 1      | > 32  |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12  |
| Gentamicin                  | 95.7%                  |       | 4.3%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 32  |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 0.5   |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.06  |
| Moxifloxacin *              | 100.0%                 |       |       | 0.12              | 0.5               | ≤ 0.06 | 1     |
| Piperacillin Tazobactam     | 97.9%                  |       | 2.1%  | 2                 | 8                 | ≤ 1    | 128   |
| Tigecycline *               | 95.7%                  | 2.1%  | 2.1%  | 0.5               | 2                 | 0.25   | 8     |
| Tobramycin                  | 97.9%                  | 2.1%  |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 8     |
| Trimethoprim Sulfa          | 89.4%                  |       | 10.6% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. pneumoniae* Susceptibility - West

### ***Streptococcus pneumoniae* (57)**

| Drug                        | Susceptibility         |       |       |                   | Range             |         |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|---------|------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min     | Max  |
| Amoxicillin Clavulanic Acid | 94.7%                  |       | 5.3%  | ≤ 0.06            | 0.12              | ≤ 0.06  | 8    |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | 0.25              | ≤ 0.12  | 1    |
| Cefuroxime                  | 91.2%                  |       | 8.8%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | 8    |
| Chloramphenicol             | 100.0%                 |       |       | 2                 | 4                 | ≤ 0.12  | 4    |
| Ciprofloxacin               | 100.0%                 |       |       | 1                 | 2                 | 0.5     | 2    |
| Clarithromycin              | 75.4%                  | 1.8%  | 22.8% | ≤ 0.03            | > 32              | ≤ 0.03  | > 32 |
| Clindamycin                 | 89.5%                  |       | 10.5% | ≤ 0.12            | > 64              | ≤ 0.12  | > 64 |
| Daptomycin                  | No Breakpoints Defined |       |       | 0.12              | 0.12              | ≤ 0.03  | 0.25 |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03  | 1    |
| Doxycycline                 | 84.2%                  | 1.8%  | 14.0% | ≤ 0.25            | 2                 | ≤ 0.25  | 16   |
| Ertapenem                   | 94.7%                  | 5.3%  |       | ≤ 0.06            | 0.25              | ≤ 0.06  | 2    |
| Imipenem                    | 91.2%                  | 3.5%  | 5.3%  | ≤ 0.03            | 0.06              | ≤ 0.03  | 1    |
| Levofloxacin                | 100.0%                 |       |       | 1                 | 1                 | 0.12    | 1    |
| Linezolid                   | 100.0%                 |       |       | 1                 | 2                 | ≤ 0.12  | 2    |
| Meropenem                   | 93.0%                  | 1.8%  | 5.3%  | ≤ 0.06            | 0.12              | ≤ 0.06  | 1    |
| Moxifloxacin                | 100.0%                 |       |       | 0.12              | 0.25              | ≤ 0.06  | 0.25 |
| Penicillin                  | 87.8%                  | 6.1%  | 6.1%  | ≤ 0.03            | 0.5               | ≤ 0.03  | 4    |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1     | 4    |
| Telithromycin               | 100.0%                 |       |       | 0.008             | 0.25              | ≤ 0.002 | 0.5  |
| Tigecycline *               | 100.0%                 |       |       | ≤ 0.015           | 0.03              | ≤ 0.015 | 0.03 |
| Trimethoprim Sulfa          | 86.0%                  | 5.3%  | 8.8%  | 0.25              | 2                 | ≤ 0.12  | 8    |
| Vancomycin                  | 100.0%                 |       |       | 0.25              | 0.25              | ≤ 0.12  | 0.5  |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *S. aureus*-MRSA Susceptibility - West

### ***Staphylococcus aureus*, MRSA (64)**

| Drug                        | Susceptibility         |        |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |       |
|-----------------------------|------------------------|--------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int  | % Res |                   |                   | Min    | Max   |
| Amikacin                    | 82.8%                  | 15.6%  | 1.6%  | 8                 | 32                | ≤ 1    | 64    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |        |       | 8                 | 16                | 2      | 32    |
| Aztreonam                   | No Breakpoints Defined |        |       | > 64              | > 64              | > 64   | > 64  |
| Cefazolin                   | No Breakpoints Defined |        |       | 32                | 128               | 2      | > 128 |
| Cefepime                    | No Breakpoints Defined |        |       | 64                | > 64              | 4      | > 64  |
| Cefoxitin                   |                        | 100.0% |       | 32                | > 32              | 16     | > 32  |
| Ceftazidime                 | No Breakpoints Defined |        |       | > 32              | > 32              | 32     | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |        |       | > 64              | > 64              | 16     | > 64  |
| Ciprofloxacin               | 29.7%                  |        | 70.3% | 16                | > 16              | 0.25   | > 16  |
| Clarithromycin              | 21.9%                  |        | 78.1% | > 32              | > 32              | 0.12   | > 32  |
| Clindamycin                 | 62.5%                  |        | 37.5% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |
| Colistin                    | No Breakpoints Defined |        |       | > 16              | > 16              | > 16   | > 16  |
| Daptomycin                  | 98.4%                  |        | 1.6%  | 0.25              | 0.5               | 0.12   | 2     |
| Doripenem                   | No Breakpoints Defined |        |       | 1                 | 8                 | 0.12   | 32    |
| Doxycycline                 | 100.0%                 |        |       | ≤ 0.12            | 1                 | ≤ 0.12 | 4     |
| Ertapenem                   | No Breakpoints Defined |        |       | 8                 | 32                | 2      | 32    |
| Gentamicin                  | 98.4%                  |        | 1.6%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 32  |
| Imipenem                    | No Breakpoints Defined |        |       | 1                 | 8                 | 0.06   | > 32  |
| Linezolid                   | 100.0%                 |        |       | 2                 | 2                 | 0.5    | 4     |
| Meropenem                   | No Breakpoints Defined |        |       | 4                 | 16                | 0.5    | > 32  |
| Moxifloxacin                | 29.7%                  | 1.6%   | 68.8% | 2                 | 8                 | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | No Breakpoints Defined |        |       | 32                | 64                | 4      | 256   |
| Tigecycline *               | 96.9%                  |        | 3.1%  | 0.12              | 0.5               | 0.06   | 1     |
| Tobramycin                  | 68.8%                  |        | 31.3% | ≤ 0.5             | > 64              | ≤ 0.5  | > 64  |
| Trimethoprim Sulfa          | 96.9%                  |        | 3.1%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8   |
| Vancomycin                  | 100.0%                 |        |       | 1                 | 1                 | 0.5    | 2     |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. faecalis* Susceptibility - West

### ***Enterococcus faecalis* (34)**

| Drug                        | Susceptibility |         |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|----------------|---------|-------|-------------------|-------------------|--------|------|
|                             | % Sus          | % Int   | % Res |                   |                   | Min    | Max  |
| Amikacin                    | No Breakpoints | Defined |       | > 64              | > 64              | 32     | > 64 |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |       | 0.5               | 1                 | 0.25   | 1    |
| Aztreonam                   | No Breakpoints | Defined |       | > 64              | > 64              | > 64   | > 64 |
| Cefazolin                   | No Breakpoints | Defined |       | 32                | 32                | 8      | 64   |
| Cefepime                    | No Breakpoints | Defined |       | 32                | > 64              | 2      | > 64 |
| Cefoxitin                   | No Breakpoints | Defined |       | > 32              | > 32              | > 32   | > 32 |
| Ceftazidime                 | No Breakpoints | Defined |       | > 32              | > 32              | 4      | > 32 |
| Ceftriaxone                 | No Breakpoints | Defined |       | > 64              | > 64              | 1      | > 64 |
| Ciprofloxacin               | 64.7%          | 2.9%    | 32.4% | 1                 | > 16              | 0.5    | > 16 |
| Clarithromycin              | No Breakpoints | Defined |       | 32                | > 32              | 0.06   | > 32 |
| Clindamycin                 | No Breakpoints | Defined |       | > 8               | > 8               | 2      | > 8  |
| Colistin                    | No Breakpoints | Defined |       | > 16              | > 16              | > 16   | > 16 |
| Daptomycin                  | 100.0%         |         |       | 1                 | 2                 | 0.5    | 4    |
| Doripenem                   | No Breakpoints | Defined |       | 4                 | 4                 | 1      | 8    |
| Doxycycline                 | 44.1%          | 41.2%   | 14.7% | 8                 | 16                | ≤ 0.12 | 16   |
| Ertapenem                   | No Breakpoints | Defined |       | 16                | 32                | 8      | 32   |
| Gentamicin                  | No Breakpoints | Defined |       | 8                 | 16                | 4      | > 32 |
| Imipenem                    | No Breakpoints | Defined |       | 1                 | 2                 | 0.5    | 2    |
| Linezolid                   | 97.1%          | 2.9%    |       | 2                 | 2                 | 1      | 4    |
| Meropenem                   | No Breakpoints | Defined |       | 4                 | 8                 | 1      | 16   |
| Moxifloxacin                | No Breakpoints | Defined |       | 0.25              | 16                | 0.12   | 16   |
| Piperacillin Tazobactam     | No Breakpoints | Defined |       | 4                 | 8                 | ≤ 1    | 8    |
| Tigecycline *               | 100.0%         |         |       | 0.12              | 0.12              | 0.06   | 0.25 |
| Tobramycin                  | No Breakpoints | Defined |       | 16                | 16                | 8      | > 64 |
| Trimethoprim Sulfa          | No Breakpoints | Defined |       | ≤ 0.12            | 0.25              | ≤ 0.12 | 1    |
| Vancomycin                  | 100.0%         |         |       | 1                 | 2                 | 0.5    | 4    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. cloacae* Susceptibility - West

### ***Enterobacter cloacae* (33)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 8     |
| Amoxicillin Clavulanic Acid | 3.0%                   |       | 97.0% | > 32              | > 32              | 4      | > 32  |
| Aztreonam                   | 66.7%                  |       | 33.3% | 0.25              | 64                | ≤ 0.12 | > 64  |
| Cefazolin                   |                        | 3.0%  | 97.0% | > 128             | > 128             | 4      | > 128 |
| Cefepime                    | 97.0%                  | 3.0%  |       | ≤ 0.25            | 2                 | ≤ 0.25 | 16    |
| Cefoxitin                   | 6.1%                   | 3.0%  | 90.9% | > 32              | > 32              | 8      | > 32  |
| Ceftazidime                 | 66.7%                  | 3.0%  | 30.3% | 0.5               | > 32              | ≤ 0.25 | > 32  |
| Ceftriaxone                 | 63.6%                  | 3.0%  | 33.3% | ≤ 0.25            | > 64              | ≤ 0.25 | > 64  |
| Ciprofloxacin               | 90.9%                  | 3.0%  | 6.1%  | ≤ 0.06            | 1                 | ≤ 0.06 | 4     |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | > 16              | 0.12   | > 16  |
| Doripenem                   | 97.0%                  | 3.0%  |       | 0.06              | 0.12              | ≤ 0.03 | 2     |
| Doxycycline                 | 87.9%                  | 9.1%  | 3.0%  | 4                 | 8                 | 2      | 32    |
| Ertapenem                   | 75.8%                  | 12.1% | 12.1% | 0.12              | 2                 | ≤ 0.03 | 32    |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 1     |
| Imipenem                    | 93.9%                  |       | 6.1%  | 0.5               | 0.5               | 0.25   | 4     |
| Meropenem                   | 97.0%                  | 3.0%  |       | 0.06              | 0.12              | ≤ 0.03 | 2     |
| Moxifloxacin *              | 87.9%                  | 9.1%  | 3.0%  | ≤ 0.06            | 4                 | ≤ 0.06 | 8     |
| Piperacillin Tazobactam     | 75.8%                  | 9.1%  | 15.2% | 2                 | 128               | ≤ 1    | 256   |
| Tigecycline *               | 97.0%                  |       | 3.0%  | 0.5               | 1                 | 0.25   | 8     |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 2     |
| Trimethoprim Sulfa          | 87.9%                  |       | 12.1% | ≤ 0.12            | 4                 | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. epidermidis* Susceptibility - West

### ***Staphylococcus epidermidis* (22)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max  |
| Amikacin                    | 100.0%                 |       |       | 2                 | 16                | ≤ 1    | 16   |
| Amoxicillin Clavulanic Acid | 72.7%                  |       | 27.3% | 2                 | 16                | ≤ 0.06 | 16   |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | 64     | > 64 |
| Cefazolin                   | 68.2%                  | 9.1%  | 22.7% | 4                 | 128               | ≤ 0.5  | 128  |
| Cefepime                    | 59.1%                  | 13.6% | 27.3% | 8                 | > 64              | ≤ 0.25 | > 64 |
| Cefoxitin                   | No Breakpoints Defined |       |       | 16                | > 32              | 2      | > 32 |
| Ceftazidime                 | 9.1%                   | 13.6% | 77.3% | 32                | > 32              | 4      | > 32 |
| Ceftriaxone                 | 27.3%                  | 45.5% | 27.3% | 16                | > 64              | 1      | > 64 |
| Ciprofloxacin               | 40.9%                  |       | 59.1% | 16                | > 16              | 0.12   | > 16 |
| Clarithromycin              | 18.2%                  |       | 81.8% | > 32              | > 32              | 0.06   | > 32 |
| Clindamycin                 | 54.5%                  |       | 45.5% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8  |
| Colistin                    | No Breakpoints Defined |       |       | > 16              | > 16              | 4      | > 16 |
| Daptomycin                  | 100.0%                 |       |       | 0.25              | 0.25              | 0.12   | 0.5  |
| Doripenem                   | No Breakpoints Defined |       |       | 4                 | 16                | ≤ 0.03 | 32   |
| Doxycycline                 | 90.9%                  | 9.1%  |       | 0.5               | 4                 | ≤ 0.12 | 8    |
| Ertapenem                   | 22.2%                  |       | 77.8% | 32                | > 32              | 0.25   | > 32 |
| Gentamicin                  | 45.5%                  | 4.5%  | 50.0% | 8                 | > 32              | ≤ 0.5  | > 32 |
| Imipenem                    | 63.6%                  | 4.5%  | 31.8% | 1                 | > 32              | ≤ 0.03 | > 32 |
| Linezolid                   | 100.0%                 |       |       | 1                 | 2                 | 0.5    | 2    |
| Meropenem                   | No Breakpoints Defined |       |       | 4                 | 32                | 0.06   | 32   |
| Moxifloxacin                | 40.9%                  | 4.5%  | 54.5% | 2                 | > 16              | ≤ 0.06 | > 16 |
| Piperacillin Tazobactam     | 72.7%                  |       | 27.3% | 2                 | 32                | ≤ 1    | 32   |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.25              | 0.25              | 0.12   | 0.5  |
| Tobramycin                  | 36.4%                  | 13.6% | 50.0% | 8                 | > 64              | ≤ 0.5  | > 64 |
| Trimethoprim Sulfa          | 40.9%                  |       | 59.1% | 4                 | 8                 | ≤ 0.12 | > 8  |
| Vancomycin                  | 100.0%                 |       |       | 1                 | 2                 | 1      | 2    |

# CANWARD 2012

## *S. marcescens* Susceptibility - West

### ***Serratia marcescens* (10)**

| Drug                        | Susceptibility         |       |        |                   | Range             |        |        |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |        | ≤ 1               | 2                 | ≤ 1    | 4      |
| Amoxicillin Clavulanic Acid |                        |       | 100.0% | > 32              | > 32              | 32     | > 32   |
| Aztreonam                   | 100.0%                 |       |        | ≤ 0.12            | 0.25              | ≤ 0.12 | 1      |
| Cefazolin                   |                        |       | 100.0% | > 128             | > 128             | > 128  | > 128  |
| Cefepime                    | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   | 30.0%                  | 50.0% | 20.0%  | 16                | > 32              | 8      | > 32   |
| Ceftazidime                 | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 0.5    |
| Ceftriaxone                 | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 1      |
| Ciprofloxacin               | 100.0%                 |       |        | ≤ 0.06            | 0.12              | ≤ 0.06 | 0.12   |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | 0.5    | > 16   |
| Doripenem                   | 100.0%                 |       |        | 0.06              | 0.12              | 0.06   | 0.12   |
| Doxycycline                 | 40.0%                  | 40.0% | 20.0%  | 8                 | 16                | 2      | 16     |
| Ertapenem                   | 100.0%                 |       |        | ≤ 0.03            | 0.12              | ≤ 0.03 | 0.12   |
| Gentamicin                  | 100.0%                 |       |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |       |        | 0.5               | 0.5               | 0.25   | 0.5    |
| Meropenem                   | 100.0%                 |       |        | 0.06              | 0.06              | ≤ 0.03 | 0.06   |
| Moxifloxacin *              | 100.0%                 |       |        | 0.25              | 0.5               | 0.12   | 0.5    |
| Piperacillin Tazobactam     | 100.0%                 |       |        | ≤ 1               | ≤ 1               | ≤ 1    | 8      |
| Tigecycline *               | 100.0%                 |       |        | 1                 | 2                 | 1      | 2      |
| Tobramycin                  | 100.0%                 |       |        | 1                 | 2                 | ≤ 0.5  | 2      |
| Trimethoprim Sulfa          | 100.0%                 |       |        | 0.25              | 0.5               | ≤ 0.12 | 0.5    |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE





# CANWARD 2012

## *K. oxytoca* Susceptibility - West

### *Klebsiella oxytoca* (25)

| Drug                        | Susceptibility         |       |       | Range             |                   |        |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 4      |
| Amoxicillin Clavulanic Acid | 80.0%                  | 12.0% | 8.0%  | 2                 | 16                | 1      | > 32   |
| Aztreonam                   | 96.0%                  | 4.0%  |       | ≤ 0.12            | 1                 | ≤ 0.12 | 8      |
| Cefazolin                   | 24.0%                  | 28.0% | 48.0% | 4                 | > 128             | 1      | > 128  |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   | 96.0%                  |       | 4.0%  | 2                 | 4                 | 1      | 32     |
| Ceftazidime                 | 100.0%                 |       |       | ≤ 0.25            | 0.5               | ≤ 0.25 | 1      |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 1      |
| Ciprofloxacin               | 100.0%                 |       |       | ≤ 0.06            | 0.25              | ≤ 0.06 | 1      |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 2                 | 0.25   | > 16   |
| Doripenem                   | 100.0%                 |       |       | 0.06              | 0.06              | ≤ 0.03 | 0.12   |
| Doxycycline                 | 96.0%                  | 4.0%  |       | 1                 | 2                 | 1      | 8      |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12   |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 0.5    |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.06   |
| Moxifloxacin *              | 96.0%                  | 4.0%  |       | 0.12              | 0.5               | ≤ 0.06 | 4      |
| Piperacillin Tazobactam     | 84.0%                  |       | 16.0% | 2                 | 128               | ≤ 1    | > 512  |
| Tigecycline *               | 100.0%                 |       |       | 0.5               | 1                 | 0.25   | 1      |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Trimethoprim Sulfa          | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 0.25   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. maltophilia* Susceptibility - West

### ***Stenotrophomonas maltophilia* (20)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | No Breakpoints Defined |       |       | 32                | > 64              | 4      | > 64  |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Aztreonam                   |                        |       |       | > 64              | > 64              | 32     | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | 2      | > 128 |
| Cefepime                    | No Breakpoints Defined |       |       | 32                | > 64              | ≤ 0.25 | > 64  |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | 4      | > 32  |
| Ceftazidime                 | 19.0%                  |       | 81.0% | > 32              | > 32              | 1      | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |       | > 64              | > 64              | 4      | > 64  |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 1                 | 4                 | 0.5    | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 4                 | 16                | 0.25   | > 16  |
| Doripenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Doxycycline                 | No Breakpoints Defined |       |       | 2                 | 4                 | 1      | 4     |
| Ertapenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Gentamicin                  | No Breakpoints Defined |       |       | 8                 | > 32              | 1      | > 32  |
| Imipenem                    | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Meropenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | 16     | > 32  |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.25              | 1                 | ≤ 0.06 | 8     |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | 128               | > 512             | ≤ 1    | > 512 |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.5               | 1                 | 0.25   | 4     |
| Tobramycin                  | No Breakpoints Defined |       |       | 8                 | 64                | 2      | > 64  |
| Trimethoprim Sulfa          | 75.0%                  |       | 25.0% | 0.25              | > 8               | ≤ 0.12 | > 8   |

# CANWARD 2012

## *E. faecium* Susceptibility - West

### ***Enterococcus faecium* (11)**

| Drug                        | Susceptibility |         |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |       |
|-----------------------------|----------------|---------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus          | % Int   | % Res |                   |                   | Min    | Max   |
| Amikacin                    | No Breakpoints | Defined |       | 16                | 32                | 8      | 32    |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |       | > 32              | > 32              | 0.25   | > 32  |
| Aztreonam                   | No Breakpoints | Defined |       | > 64              | > 64              | > 64   | > 64  |
| Cefazolin                   | No Breakpoints | Defined |       | > 128             | > 128             | 64     | > 128 |
| Cefepime                    | No Breakpoints | Defined |       | > 64              | > 64              | 4      | > 64  |
| Cefoxitin                   | No Breakpoints | Defined |       | > 32              | > 32              | 32     | > 32  |
| Ceftazidime                 | No Breakpoints | Defined |       | > 32              | > 32              | > 32   | > 32  |
| Ceftriaxone                 | No Breakpoints | Defined |       | > 64              | > 64              | 2      | > 64  |
| Ciprofloxacin               | 18.2%          |         | 81.8% | > 16              | > 16              | 0.5    | > 16  |
| Clarithromycin              | No Breakpoints | Defined |       | > 32              | > 32              | 1      | > 32  |
| Clindamycin                 | No Breakpoints | Defined |       | > 8               | > 8               | ≤ 0.12 | > 8   |
| Colistin                    | No Breakpoints | Defined |       | > 16              | > 16              | > 16   | > 16  |
| Daptomycin                  | 100.0%         |         |       | 1                 | 2                 | 1      | 2     |
| Doripenem                   | No Breakpoints | Defined |       | > 32              | > 32              | 8      | > 32  |
| Doxycycline                 | 90.9%          | 9.1%    |       | ≤ 0.12            | 4                 | ≤ 0.12 | 8     |
| Ertapenem                   | No Breakpoints | Defined |       | > 32              | > 32              | 16     | > 32  |
| Gentamicin                  | No Breakpoints | Defined |       | 4                 | > 32              | 2      | > 32  |
| Imipenem                    | No Breakpoints | Defined |       | > 32              | > 32              | 2      | > 32  |
| Linezolid                   | 90.9%          | 9.1%    |       | 2                 | 2                 | 1      | 4     |
| Meropenem                   | No Breakpoints | Defined |       | > 32              | > 32              | 8      | > 32  |
| Moxifloxacin                | No Breakpoints | Defined |       | 16                | > 16              | 0.25   | > 16  |
| Piperacillin Tazobactam     | No Breakpoints | Defined |       | > 512             | > 512             | 8      | > 512 |
| Tigecycline                 | No Breakpoints | Defined |       | 0.06              | 0.12              | 0.06   | 0.12  |
| Tobramycin                  | No Breakpoints | Defined |       | 64                | > 64              | 32     | > 64  |
| Trimethoprim Sulfa          | No Breakpoints | Defined |       | 0.25              | > 8               | ≤ 0.12 | > 8   |
| Vancomycin                  | 72.7%          |         | 27.3% | 0.5               | > 32              | 0.25   | > 32  |

# CANWARD 2012

## *S. agalactiae* Susceptibility - West

### ***Streptococcus agalactiae* (17)**

| Drug                        | Susceptibility         |       |       | Range             |                   |         |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|---------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min     | Max    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | ≤ 0.06            | 0.12              | ≤ 0.06  | 0.12   |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12 |
| Cefuroxime                  | No Breakpoints Defined |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | ≤ 0.25 |
| Chloramphenicol             | 100.0%                 |       |       | 4                 | 4                 | 2       | 4      |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 0.5               | 1                 | 0.25    | 2      |
| Clarithromycin              | 70.6%                  | 5.9%  | 23.5% | ≤ 0.03            | 16                | ≤ 0.03  | > 32   |
| Clindamycin                 | 76.5%                  |       | 23.5% | ≤ 0.12            | > 64              | ≤ 0.12  | > 64   |
| Daptomycin                  | 100.0%                 |       |       | 0.25              | 0.25              | 0.06    | 0.25   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Doxycycline                 | No Breakpoints Defined |       |       | 8                 | 16                | ≤ 0.25  | 16     |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.06            | 0.12              | ≤ 0.06  | 0.12   |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Levofloxacin                | 100.0%                 |       |       | 1                 | 1                 | 0.5     | 2      |
| Linezolid                   | 100.0%                 |       |       | 2                 | 2                 | 1       | 2      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06 |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.12              | 0.25              | ≤ 0.06  | 0.5    |
| Penicillin                  | 100.0%                 |       |       | 0.06              | 0.06              | ≤ 0.03  | 0.12   |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1     | ≤ 1    |
| Telithromycin               | No Breakpoints Defined |       |       | 0.015             | 0.12              | 0.008   | 0.12   |
| Tigecycline *               | 100.0%                 |       |       | 0.03              | 0.06              | ≤ 0.015 | 0.06   |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | ≤ 0.12            | 0.25              | ≤ 0.12  | 0.25   |
| Vancomycin                  | 100.0%                 |       |       | 0.5               | 0.5               | 0.25    | 0.5    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *P. mirabilis* Susceptibility - West

### *Proteus mirabilis* (11)

| Drug                        | Susceptibility         |       |        | Range             |                   |        |       |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |        | 2                 | 4                 | ≤ 1    | 4     |
| Amoxicillin Clavulanic Acid | 72.7%                  |       | 27.3%  | 1                 | > 32              | 0.5    | > 32  |
| Aztreonam                   | 100.0%                 |       |        | ≤ 0.12            | 0.25              | ≤ 0.12 | 0.25  |
| Cefazolin                   |                        | 63.6% | 36.4%  | 4                 | > 128             | 4      | > 128 |
| Cefepime                    | 100.0%                 |       |        | ≤ 0.25            | 0.5               | ≤ 0.25 | 1     |
| Cefoxitin                   | 81.8%                  | 9.1%  | 9.1%   | 4                 | 16                | 2      | 32    |
| Ceftazidime                 | 100.0%                 |       |        | ≤ 0.25            | 4                 | ≤ 0.25 | 4     |
| Ceftriaxone                 | 90.9%                  | 9.1%  |        | ≤ 0.25            | 1                 | ≤ 0.25 | 2     |
| Ciprofloxacin               | 90.9%                  |       | 9.1%   | ≤ 0.06            | 1                 | ≤ 0.06 | 8     |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | > 16   | > 16  |
| Doripenem                   | 100.0%                 |       |        | 0.25              | 0.25              | 0.06   | 0.5   |
| Doxycycline                 |                        |       | 100.0% | 32                | > 32              | 32     | > 32  |
| Ertapenem                   | 100.0%                 |       |        | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.06  |
| Gentamicin                  | 90.9%                  |       | 9.1%   | ≤ 0.5             | 1                 | ≤ 0.5  | 16    |
| Imipenem                    | 27.3%                  | 45.5% | 27.3%  | 2                 | 4                 | 0.5    | 4     |
| Meropenem                   | 100.0%                 |       |        | 0.06              | 0.12              | ≤ 0.03 | 0.25  |
| Moxifloxacin *              | 72.7%                  | 9.1%  | 18.2%  | 0.5               | 8                 | 0.25   | > 16  |
| Piperacillin Tazobactam     | 100.0%                 |       |        | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1   |
| Tigecycline *               | 18.2%                  | 54.5% | 27.3%  | 4                 | 8                 | 2      | 8     |
| Tobramycin                  | 100.0%                 |       |        | ≤ 0.5             | 1                 | ≤ 0.5  | 2     |
| Trimethoprim Sulfa          | 72.7%                  |       | 27.3%  | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. pyogenes* Susceptibility - West

### ***Streptococcus pyogenes* (16)**

| Drug                        | Susceptibility         |       |       | Range             |                   |         |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|---------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min     | Max    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | 0.12   |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12 |
| Cefuroxime                  |                        |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | 0.5    |
| Chloramphenicol             | 100.0%                 |       |       | 2                 | 4                 | 0.5     | 4      |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 0.5               | 0.5               | 0.12    | 2      |
| Clarithromycin              | 93.8%                  |       | 6.3%  | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | 8      |
| Clindamycin                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | 0.25   |
| Daptomycin                  | 100.0%                 |       |       | 0.06              | 0.12              | 0.06    | 0.12   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Doxycycline                 | No Breakpoints Defined |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | 8      |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06 |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Levofloxacin                | 100.0%                 |       |       | 0.5               | 1                 | 0.25    | 2      |
| Linezolid                   | 100.0%                 |       |       | 1                 | 2                 | 1       | 2      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06 |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.12              | 0.25              | ≤ 0.06  | 0.25   |
| Penicillin                  | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1     | ≤ 1    |
| Telithromycin               | No Breakpoints Defined |       |       | 0.008             | 0.015             | 0.004   | 0.25   |
| Tigecycline *               | 100.0%                 |       |       | 0.03              | 0.03              | ≤ 0.015 | 0.25   |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | ≤ 0.12            | 0.25              | ≤ 0.12  | 0.25   |
| Vancomycin                  | 100.0%                 |       |       | 0.5               | 0.5               | 0.25    | 0.5    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *C. freundii* Susceptibility - West

### ***Citrobacter freundii* (4)**

| Drug                        | Susceptibility |       |        |                   | Range             |        |        |
|-----------------------------|----------------|-------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus          | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%         |       |        | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Amoxicillin Clavulanic Acid |                |       | 100.0% | > 32              | > 32              | > 32   | > 32   |
| Aztreonam                   | 100.0%         |       |        | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Cefazolin                   |                |       | 100.0% | 16                | 128               | 8      | 128    |
| Cefepime                    | 100.0%         |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   |                |       | 100.0% | > 32              | > 32              | > 32   | > 32   |
| Ceftazidime                 | 100.0%         |       |        | 0.5               | 0.5               | ≤ 0.25 | 0.5    |
| Ceftriaxone                 | 100.0%         |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Ciprofloxacin               | 100.0%         |       |        | ≤ 0.06            | 0.12              | ≤ 0.06 | 0.12   |
| Colistin                    |                |       |        | 0.25              | 0.25              | 0.25   | 0.25   |
| Doripenem                   | 100.0%         |       |        | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.06   |
| Doxycycline                 | 100.0%         |       |        | 2                 | 2                 | 2      | 2      |
| Ertapenem                   | 100.0%         |       |        | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Gentamicin                  | 100.0%         |       |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%         |       |        | 0.5               | 0.5               | 0.25   | 0.5    |
| Meropenem                   | 100.0%         |       |        | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Moxifloxacin *              | 100.0%         |       |        | ≤ 0.06            | 0.5               | ≤ 0.06 | 0.5    |
| Piperacillin Tazobactam     | 100.0%         |       |        | ≤ 1               | 2                 | ≤ 1    | 2      |
| Tigecycline *               | 100.0%         |       |        | 0.25              | 0.5               | 0.25   | 0.5    |
| Tobramycin                  | 100.0%         |       |        | ≤ 0.5             | 1                 | ≤ 0.5  | 1      |
| Trimethoprim Sulfa          | 75.0%          |       | 25.0%  | ≤ 0.12            | > 8               | ≤ 0.12 | > 8    |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *A. baumannii* Susceptibility - West

### ***Acinetobacter baumannii* (8)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 2     |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | 8                 | 16                | 8      | 16    |
| Aztreonam                   | No Breakpoints Defined |       |       | 32                | > 64              | 16     | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | 128    | > 128 |
| Cefepime                    | 87.5%                  |       | 12.5% | 2                 | 64                | 1      | 64    |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Ceftazidime                 | 87.5%                  |       | 12.5% | 8                 | > 32              | 2      | > 32  |
| Ceftriaxone                 | 25.0%                  | 62.5% | 12.5% | 16                | > 64              | 8      | > 64  |
| Ciprofloxacin               | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 0.5   |
| Colistin                    | 100.0%                 |       |       | 0.5               | 1                 | 0.25   | 1     |
| Doripenem                   | No Breakpoints Defined |       |       | 0.25              | 1                 | 0.12   | 1     |
| Doxycycline                 | 100.0%                 |       |       | 0.25              | 1                 | ≤ 0.12 | 1     |
| Ertapenem                   | No Breakpoints Defined |       |       | 8                 | 32                | 2      | 32    |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5 |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 0.5   |
| Meropenem                   | 100.0%                 |       |       | 0.25              | 4                 | 0.25   | 4     |
| Moxifloxacin                | No Breakpoints Defined |       |       | ≤ 0.06            | 0.25              | ≤ 0.06 | 0.25  |
| Piperacillin Tazobactam     | 87.5%                  |       | 12.5% | 4                 | 256               | ≤ 1    | 256   |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.25   | 0.5   |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5 |
| Trimethoprim Sulfa          | 100.0%                 |       |       | ≤ 0.12            | 2                 | ≤ 0.12 | 2     |



# CANWARD 2012

## *S. aureus* Susceptibility - Ontario

### ***Staphylococcus aureus*, MSSA (211)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max  |
| Amikacin                    | 99.5%                  | 0.5%  |       | 4                 | 4                 | ≤ 1    | 32   |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | 0.5               | 1                 | ≤ 0.06 | 1    |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | 64     | > 64 |
| Cefazolin                   | No Breakpoints Defined |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 2    |
| Cefepime                    | No Breakpoints Defined |       |       | 2                 | 4                 | 1      | 4    |
| Cefoxitin                   | 99.1%                  |       | 0.9%  | 4                 | 4                 | 0.25   | 8    |
| Ceftazidime                 | No Breakpoints Defined |       |       | 16                | 16                | 4      | 32   |
| Ceftriaxone                 | No Breakpoints Defined |       |       | 4                 | 4                 | 1      | 8    |
| Ciprofloxacin               | 87.2%                  | 2.4%  | 10.4% | 0.5               | 4                 | ≤ 0.06 | > 16 |
| Clarithromycin              | 72.5%                  | 0.5%  | 27.0% | 0.25              | > 32              | ≤ 0.03 | > 32 |
| Clindamycin                 | 96.2%                  |       | 3.8%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8  |
| Colistin                    | No Breakpoints Defined |       |       | > 16              | > 16              | > 16   | > 16 |
| Daptomycin                  | 100.0%                 |       |       | 0.25              | 0.5               | ≤ 0.03 | 0.5  |
| Doripenem                   | No Breakpoints Defined |       |       | 0.06              | 0.06              | ≤ 0.03 | 0.25 |
| Doxycycline                 | 99.5%                  | 0.5%  |       | ≤ 0.12            | 0.25              | ≤ 0.12 | 8    |
| Ertapenem                   | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.12   | 1    |
| Gentamicin                  | 97.2%                  | 0.9%  | 1.9%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 32 |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12 |
| Linezolid                   | 100.0%                 |       |       | 2                 | 2                 | ≤ 0.12 | 4    |
| Meropenem                   | No Breakpoints Defined |       |       | 0.12              | 0.25              | 0.06   | 0.5  |
| Moxifloxacin                | 91.5%                  | 0.5%  | 8.1%  | ≤ 0.06            | 0.25              | ≤ 0.06 | > 16 |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1    | 2    |
| Tigecycline *               | 100.0%                 |       |       | 0.12              | 0.25              | 0.06   | 0.25 |
| Tobramycin                  | 96.2%                  | 1.4%  | 2.4%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 64 |
| Trimethoprim Sulfa          | 99.5%                  |       | 0.5%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 8    |
| Vancomycin                  | 100.0%                 |       |       | 1                 | 1                 | 0.25   | 1    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. coli* Susceptibility - Ontario

### *Escherichia coli* (172)

| Drug                        | Susceptibility         |       |       |                   | Range             |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 4                 | ≤ 1    | 8     |
| Amoxicillin Clavulanic Acid | 73.3%                  | 19.8% | 7.0%  | 4                 | 16                | 1      | > 32  |
| Aztreonam                   | 90.7%                  | 2.9%  | 6.4%  | ≤ 0.12            | 4                 | ≤ 0.12 | > 64  |
| Cefazolin                   | 69.2%                  | 8.7%  | 22.1% | 2                 | > 128             | ≤ 0.5  | > 128 |
| Cefepime                    | 95.9%                  | 2.3%  | 1.7%  | ≤ 0.25            | 1                 | ≤ 0.25 | > 64  |
| Cefoxitin                   | 94.8%                  | 2.9%  | 2.3%  | 4                 | 8                 | 1      | > 32  |
| Ceftazidime                 | 90.1%                  | 2.3%  | 7.6%  | ≤ 0.25            | 4                 | ≤ 0.25 | > 32  |
| Ceftriaxone                 | 87.2%                  | 0.6%  | 12.2% | ≤ 0.25            | 32                | ≤ 0.25 | > 64  |
| Ciprofloxacin               | 72.1%                  |       | 27.9% | ≤ 0.06            | > 16              | ≤ 0.06 | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | ≤ 0.06 | 8     |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.06  |
| Doxycycline                 | 68.6%                  | 5.2%  | 26.2% | 2                 | 32                | 0.5    | > 32  |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.5   |
| Gentamicin                  | 87.8%                  | 0.6%  | 11.6% | ≤ 0.5             | 32                | ≤ 0.5  | > 32  |
| Imipenem                    | 100.0%                 |       |       | 0.12              | 0.25              | 0.06   | 0.5   |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12  |
| Moxifloxacin *              | 72.1%                  |       | 27.9% | ≤ 0.06            | > 16              | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | 96.5%                  | 0.6%  | 2.9%  | 2                 | 4                 | ≤ 1    | 256   |
| Tigecycline *               | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 1     |
| Tobramycin                  | 89.0%                  | 3.5%  | 7.6%  | ≤ 0.5             | 8                 | ≤ 0.5  | 64    |
| Trimethoprim Sulfa          | 68.6%                  |       | 31.4% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *P. aeruginosa* Susceptibility - Ontario

### *Pseudomonas aeruginosa* (116)

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 96.6%                  | 1.7%  | 1.7%  | 2                 | 8                 | ≤ 1    | > 64  |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Aztreonam                   | 77.6%                  | 14.7% | 7.8%  | 4                 | 16                | ≤ 0.12 | 64    |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | > 128  | > 128 |
| Cefepime                    | 89.7%                  | 9.5%  | 0.9%  | 4                 | 16                | ≤ 0.25 | 32    |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Ceftazidime                 | 87.9%                  | 4.3%  | 7.8%  | 4                 | 16                | ≤ 0.25 | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |       | 16                | > 64              | 1      | > 64  |
| Ciprofloxacin               | 82.8%                  | 6.0%  | 11.2% | 0.25              | 4                 | ≤ 0.06 | > 16  |
| Colistin                    | 99.1%                  |       | 0.9%  | 1                 | 2                 | 0.25   | 8     |
| Doripenem                   | 86.2%                  | 10.3% | 3.4%  | 0.5               | 4                 | 0.06   | 16    |
| Doxycycline                 | No Breakpoints Defined |       |       | 32                | > 32              | 4      | > 32  |
| Ertapenem                   | No Breakpoints Defined |       |       | 16                | > 32              | 0.5    | > 32  |
| Gentamicin                  | 93.1%                  | 0.9%  | 6.0%  | 1                 | 4                 | ≤ 0.5  | > 32  |
| Imipenem                    | 70.7%                  | 7.8%  | 21.6% | 2                 | 16                | 0.12   | > 32  |
| Meropenem                   | 77.6%                  | 11.2% | 11.2% | 0.5               | 8                 | 0.06   | 32    |
| Moxifloxacin                | No Breakpoints Defined |       |       | 2                 | > 16              | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | 87.9%                  | 8.6%  | 3.4%  | 4                 | 32                | ≤ 1    | 256   |
| Tigecycline                 | No Breakpoints Defined |       |       | 16                | > 16              | 2      | > 16  |
| Tobramycin                  | 93.1%                  |       | 6.9%  | ≤ 0.5             | 1                 | ≤ 0.5  | > 64  |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | 8                 | > 8               | 0.5    | > 8   |

# CANWARD 2012

## *K. pneumoniae* Susceptibility - Ontario

### ***Klebsiella pneumoniae* (60)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 2     |
| Amoxicillin Clavulanic Acid | 93.3%                  | 1.7%  | 5.0%  | 2                 | 8                 | 1      | > 32  |
| Aztreonam                   | 93.3%                  | 1.7%  | 5.0%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 64  |
| Cefazolin                   | 90.0%                  | 1.7%  | 8.3%  | 1                 | 2                 | ≤ 0.5  | > 128 |
| Cefepime                    | 96.7%                  |       | 3.3%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 64    |
| Cefoxitin                   | 96.7%                  |       | 3.3%  | 4                 | 8                 | 1      | > 32  |
| Ceftazidime                 | 95.0%                  |       | 5.0%  | ≤ 0.25            | 0.5               | ≤ 0.25 | > 32  |
| Ceftriaxone                 | 93.3%                  | 1.7%  | 5.0%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | > 64  |
| Ciprofloxacin               | 95.0%                  |       | 5.0%  | ≤ 0.06            | 0.25              | ≤ 0.06 | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.25   | > 16  |
| Doripenem                   | 98.3%                  |       | 1.7%  | 0.06              | 0.06              | ≤ 0.03 | 4     |
| Doxycycline                 | 86.7%                  | 1.7%  | 11.7% | 2                 | 16                | 1      | > 32  |
| Ertapenem                   | 96.7%                  | 1.7%  | 1.7%  | ≤ 0.03            | 0.06              | ≤ 0.03 | 16    |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 1     |
| Imipenem                    | 98.3%                  |       | 1.7%  | 0.25              | 0.5               | 0.12   | 4     |
| Meropenem                   | 98.3%                  |       | 1.7%  | ≤ 0.03            | 0.06              | ≤ 0.03 | 8     |
| Moxifloxacin *              | 95.0%                  | 1.7%  | 3.3%  | 0.12              | 0.5               | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | 95.0%                  | 1.7%  | 3.3%  | 2                 | 4                 | ≤ 1    | > 512 |
| Tigecycline *               | 96.7%                  | 3.3%  |       | 0.5               | 1                 | 0.25   | 4     |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 4     |
| Trimethoprim Sulfa          | 90.0%                  |       | 10.0% | ≤ 0.12            | 1                 | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. pneumoniae* Susceptibility - Ontario

### ***Streptococcus pneumoniae* (44)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range   |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|---------|------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min     | Max  |
| Amoxicillin Clavulanic Acid | 95.5%                  | 4.5%  |       | ≤ 0.06            | 0.25              | ≤ 0.06  | 4    |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | 0.25              | ≤ 0.12  | 1    |
| Cefuroxime                  | 90.9%                  |       | 9.1%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | 8    |
| Chloramphenicol             | 95.5%                  |       | 4.5%  | 2                 | 4                 | ≤ 0.12  | 16   |
| Ciprofloxacin               | 97.7%                  |       | 2.3%  | 1                 | 1                 | 0.25    | > 16 |
| Clarithromycin              | 70.5%                  |       | 29.5% | ≤ 0.03            | 16                | ≤ 0.03  | > 32 |
| Clindamycin                 | 86.4%                  |       | 13.6% | ≤ 0.12            | 32                | ≤ 0.12  | > 64 |
| Daptomycin                  | No Breakpoints Defined |       |       | 0.12              | 0.12              | ≤ 0.03  | 0.25 |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.12              | ≤ 0.03  | 1    |
| Doxycycline                 | 79.5%                  | 2.3%  | 18.2% | ≤ 0.25            | 4                 | ≤ 0.25  | 8    |
| Ertapenem                   | 93.2%                  | 6.8%  |       | ≤ 0.06            | 0.25              | ≤ 0.06  | 2    |
| Imipenem                    | 90.9%                  | 6.8%  | 2.3%  | ≤ 0.03            | 0.06              | ≤ 0.03  | 1    |
| Levofloxacin                | 97.7%                  |       | 2.3%  | 1                 | 1                 | 0.25    | 16   |
| Linezolid                   | 100.0%                 |       |       | 1                 | 1                 | ≤ 0.12  | 2    |
| Meropenem                   | 90.9%                  | 4.5%  | 4.5%  | ≤ 0.06            | 0.12              | ≤ 0.06  | 1    |
| Moxifloxacin                | 97.7%                  |       | 2.3%  | 0.12              | 0.25              | ≤ 0.06  | 4    |
| Penicillin                  | 85.0%                  | 10.0% | 5.0%  | ≤ 0.03            | 0.12              | ≤ 0.03  | 2    |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1     | 4    |
| Telithromycin               | 100.0%                 |       |       | 0.008             | 0.06              | ≤ 0.002 | 0.25 |
| Tigecycline *               | 100.0%                 |       |       | ≤ 0.015           | 0.03              | ≤ 0.015 | 0.03 |
| Trimethoprim Sulfa          | 90.9%                  | 2.3%  | 6.8%  | 0.25              | 0.5               | ≤ 0.12  | 8    |
| Vancomycin                  | 100.0%                 |       |       | 0.25              | 0.5               | ≤ 0.12  | 0.5  |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *S. aureus*-MRSA Susceptibility - Ontario

### ***Staphylococcus aureus*, MRSA (39)**

| Drug                        | Susceptibility         |       |        | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |       |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res  |                   |                   | Min    | Max   |
| Amikacin                    | 92.3%                  | 7.7%  |        | 4                 | 16                | 2      | 32    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |        | 8                 | 32                | 2      | 32    |
| Aztreonam                   | No Breakpoints Defined |       |        | > 64              | > 64              | > 64   | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |        | 16                | > 128             | 1      | > 128 |
| Cefepime                    | No Breakpoints Defined |       |        | 64                | > 64              | 4      | > 64  |
| Cefoxitin                   |                        |       | 100.0% | 32                | > 32              | 16     | > 32  |
| Ceftazidime                 | No Breakpoints Defined |       |        | > 32              | > 32              | 32     | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |        | > 64              | > 64              | 16     | > 64  |
| Ciprofloxacin               | 35.9%                  |       | 64.1%  | 16                | > 16              | 0.25   | > 16  |
| Clarithromycin              | 25.6%                  |       | 74.4%  | > 32              | > 32              | 0.12   | > 32  |
| Clindamycin                 | 76.9%                  |       | 23.1%  | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | > 16   | > 16  |
| Daptomycin                  | 100.0%                 |       |        | 0.25              | 0.5               | 0.25   | 0.5   |
| Doripenem                   | No Breakpoints Defined |       |        | 1                 | 32                | 0.12   | 32    |
| Doxycycline                 | 100.0%                 |       |        | ≤ 0.12            | 1                 | ≤ 0.12 | 4     |
| Ertapenem                   | No Breakpoints Defined |       |        | 2                 | > 32              | 1      | > 32  |
| Gentamicin                  | 97.4%                  | 2.6%  |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 8     |
| Imipenem                    | No Breakpoints Defined |       |        | 1                 | > 32              | 0.06   | > 32  |
| Linezolid                   | 100.0%                 |       |        | 2                 | 4                 | 1      | 4     |
| Meropenem                   | No Breakpoints Defined |       |        | 2                 | 32                | 0.25   | > 32  |
| Moxifloxacin                | 35.9%                  | 2.6%  | 61.5%  | 2                 | > 16              | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |        | 16                | 128               | 4      | 128   |
| Tigecycline *               | 97.4%                  |       | 2.6%   | 0.12              | 0.25              | 0.12   | 1     |
| Tobramycin                  | 66.7%                  | 2.6%  | 30.8%  | 1                 | > 64              | ≤ 0.5  | > 64  |
| Trimethoprim Sulfa          | 97.4%                  |       | 2.6%   | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 4     |
| Vancomycin                  | 100.0%                 |       |        | 1                 | 1                 | 0.5    | 1     |

\*Interpretive breakpoints defined by FDA (tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *E. faecalis* Susceptibility - Ontario

### ***Enterococcus faecalis* (30)**

| Drug                        | Susceptibility |         |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|----------------|---------|-------|-------------------|-------------------|--------|------|
|                             | % Sus          | % Int   | % Res |                   |                   | Min    | Max  |
| Amikacin                    | No Breakpoints | Defined |       | > 64              | > 64              | 32     | > 64 |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |       | 0.5               | 1                 | 0.12   | 1    |
| Aztreonam                   | No Breakpoints | Defined |       | > 64              | > 64              | > 64   | > 64 |
| Cefazolin                   | No Breakpoints | Defined |       | 32                | 32                | 8      | 64   |
| Cefepime                    | No Breakpoints | Defined |       | 32                | > 64              | 2      | > 64 |
| Cefoxitin                   | No Breakpoints | Defined |       | > 32              | > 32              | 16     | > 32 |
| Ceftazidime                 | No Breakpoints | Defined |       | > 32              | > 32              | 32     | > 32 |
| Ceftriaxone                 | No Breakpoints | Defined |       | > 64              | > 64              | 2      | > 64 |
| Ciprofloxacin               | 76.7%          | 3.3%    | 20.0% | 1                 | > 16              | 0.5    | > 16 |
| Clarithromycin              | No Breakpoints | Defined |       | 2                 | > 32              | 0.06   | > 32 |
| Clindamycin                 | No Breakpoints | Defined |       | > 8               | > 8               | 1      | > 8  |
| Colistin                    | No Breakpoints | Defined |       | > 16              | > 16              | > 16   | > 16 |
| Daptomycin                  | 100.0%         |         |       | 1                 | 2                 | 0.12   | 4    |
| Doripenem                   | No Breakpoints | Defined |       | 2                 | 4                 | 0.5    | 8    |
| Doxycycline                 | 46.7%          | 40.0%   | 13.3% | 8                 | 16                | ≤ 0.12 | 16   |
| Ertapenem                   | No Breakpoints | Defined |       | 16                | 16                | 2      | 32   |
| Gentamicin                  | No Breakpoints | Defined |       | 16                | > 32              | 8      | > 32 |
| Imipenem                    | No Breakpoints | Defined |       | 1                 | 2                 | 0.25   | 2    |
| Linezolid                   | 93.3%          | 6.7%    |       | 2                 | 2                 | 1      | 4    |
| Meropenem                   | No Breakpoints | Defined |       | 4                 | 8                 | 1      | 16   |
| Moxifloxacin                | No Breakpoints | Defined |       | 0.25              | 16                | 0.12   | 16   |
| Piperacillin Tazobactam     | No Breakpoints | Defined |       | 2                 | 4                 | ≤ 1    | 4    |
| Tigecycline *               | 100.0%         |         |       | 0.12              | 0.12              | 0.06   | 0.25 |
| Tobramycin                  | No Breakpoints | Defined |       | 16                | > 64              | 8      | > 64 |
| Trimethoprim Sulfa          | No Breakpoints | Defined |       | ≤ 0.12            | 8                 | ≤ 0.12 | > 8  |
| Vancomycin                  | 100.0%         |         |       | 1                 | 2                 | 0.5    | 2    |

\*Interpretive breakpoints defined by FDA (tigecycline)



# CANWARD 2012

## *E. cloacae* Susceptibility - Ontario

### ***Enterobacter cloacae* (23)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 4     |
| Amoxicillin Clavulanic Acid | 4.3%                   | 4.3%  | 91.3% | > 32              | > 32              | 4      | > 32  |
| Aztreonam                   | 91.3%                  |       | 8.7%  | ≤ 0.12            | 2                 | ≤ 0.12 | 64    |
| Cefazolin                   | 4.3%                   |       | 95.7% | > 128             | > 128             | 2      | > 128 |
| Cefepime                    | 95.7%                  |       | 4.3%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 32    |
| Cefoxitin                   | 4.3%                   | 4.3%  | 91.3% | > 32              | > 32              | 8      | > 32  |
| Ceftazidime                 | 91.3%                  |       | 8.7%  | 0.5               | 4                 | ≤ 0.25 | > 32  |
| Ceftriaxone                 | 87.0%                  |       | 13.0% | ≤ 0.25            | 16                | ≤ 0.25 | > 64  |
| Ciprofloxacin               | 95.7%                  |       | 4.3%  | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | > 16              | 0.25   | > 16  |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.12  |
| Doxycycline                 | 91.3%                  |       | 8.7%  | 4                 | 4                 | 2      | 32    |
| Ertapenem                   | 95.7%                  | 4.3%  |       | 0.06              | 0.25              | ≤ 0.03 | 1     |
| Gentamicin                  | 95.7%                  |       | 4.3%  | ≤ 0.5             | 1                 | ≤ 0.5  | > 32  |
| Imipenem                    | 100.0%                 |       |       | 0.5               | 0.5               | 0.12   | 1     |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.25  |
| Moxifloxacin *              | 95.7%                  |       | 4.3%  | ≤ 0.06            | 0.25              | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | 95.7%                  |       | 4.3%  | 2                 | 8                 | ≤ 1    | 128   |
| Tigecycline *               | 100.0%                 |       |       | 0.5               | 1                 | 0.25   | 1     |
| Tobramycin                  | 95.7%                  |       | 4.3%  | ≤ 0.5             | 1                 | ≤ 0.5  | 16    |
| Trimethoprim Sulfa          | 91.3%                  |       | 8.7%  | ≤ 0.12            | 0.5               | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE





# CANWARD 2012

## *S. epidermidis* Susceptibility - Ontario

### ***Staphylococcus epidermidis* (22)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max  |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 4                 | ≤ 1    | 16   |
| Amoxicillin Clavulanic Acid | 86.4%                  |       | 13.6% | 1                 | 8                 | 0.12   | 16   |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | > 64   | > 64 |
| Cefazolin                   | 81.8%                  |       | 18.2% | 1                 | 64                | ≤ 0.5  | 128  |
| Cefepime                    | 72.7%                  | 13.6% | 13.6% | 4                 | 64                | ≤ 0.25 | > 64 |
| Cefoxitin                   | No Breakpoints Defined |       |       | 8                 | 32                | 1      | > 32 |
| Ceftazidime                 | 22.7%                  | 22.7% | 54.5% | 32                | > 32              | 4      | > 32 |
| Ceftriaxone                 | 50.0%                  | 36.4% | 13.6% | 8                 | > 64              | 0.5    | > 64 |
| Ciprofloxacin               | 54.5%                  |       | 45.5% | 0.25              | > 16              | ≤ 0.06 | > 16 |
| Clarithromycin              | 22.7%                  |       | 77.3% | > 32              | > 32              | ≤ 0.03 | > 32 |
| Clindamycin                 | 40.9%                  | 4.5%  | 54.5% | > 8               | > 8               | ≤ 0.12 | > 8  |
| Colistin                    | No Breakpoints Defined |       |       | > 16              | > 16              | > 16   | > 16 |
| Daptomycin                  | 100.0%                 |       |       | 0.25              | 0.25              | 0.12   | 0.25 |
| Doripenem                   | No Breakpoints Defined |       |       | 1                 | 16                | ≤ 0.03 | 16   |
| Doxycycline                 | 100.0%                 |       |       | 0.25              | 1                 | ≤ 0.12 | 1    |
| Ertapenem                   | 52.9%                  | 17.6% | 29.4% | 2                 | > 32              | 0.25   | > 32 |
| Gentamicin                  | 50.0%                  | 4.5%  | 45.5% | 4                 | 32                | ≤ 0.5  | > 32 |
| Imipenem                    | 77.3%                  | 4.5%  | 18.2% | 0.12              | 16                | ≤ 0.03 | 32   |
| Linezolid                   | 100.0%                 |       |       | 0.5               | 1                 | 0.25   | 1    |
| Meropenem                   | No Breakpoints Defined |       |       | 2                 | 16                | 0.06   | 32   |
| Moxifloxacin                | 54.5%                  |       | 45.5% | ≤ 0.06            | > 16              | ≤ 0.06 | > 16 |
| Piperacillin Tazobactam     | 90.9%                  |       | 9.1%  | ≤ 1               | 4                 | ≤ 1    | 64   |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.12              | 0.25              | 0.06   | 1    |
| Tobramycin                  | 50.0%                  | 18.2% | 31.8% | 2                 | 16                | ≤ 0.5  | > 64 |
| Trimethoprim Sulfa          | 63.6%                  |       | 36.4% | ≤ 0.12            | 4                 | ≤ 0.12 | 8    |
| Vancomycin                  | 100.0%                 |       |       | 1                 | 2                 | 1      | 2    |

# CANWARD 2012

## *S. marcescens* Susceptibility - Ontario

### *Serratia marcescens* (15)

| Drug                        | Susceptibility         |       |        |                   | Range             |        |        |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |        | 2                 | 4                 | ≤ 1    | 8      |
| Amoxicillin Clavulanic Acid |                        | 6.7%  | 93.3%  | > 32              | > 32              | 16     | > 32   |
| Aztreonam                   | 100.0%                 |       |        | ≤ 0.12            | 0.25              | ≤ 0.12 | 2      |
| Cefazolin                   |                        |       | 100.0% | > 128             | > 128             | 128    | > 128  |
| Cefepime                    | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   | 26.7%                  | 46.7% | 26.7%  | 16                | 32                | 8      | > 32   |
| Ceftazidime                 | 100.0%                 |       |        | ≤ 0.25            | 1                 | ≤ 0.25 | 1      |
| Ceftriaxone                 | 93.3%                  |       | 6.7%   | ≤ 0.25            | 0.5               | ≤ 0.25 | 8      |
| Ciprofloxacin               | 80.0%                  | 6.7%  | 13.3%  | ≤ 0.06            | 4                 | ≤ 0.06 | 16     |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | > 16   | > 16   |
| Doripenem                   | 100.0%                 |       |        | 0.12              | 0.25              | 0.06   | 0.25   |
| Doxycycline                 | 33.3%                  | 33.3% | 33.3%  | 8                 | 16                | 4      | > 32   |
| Ertapenem                   | 100.0%                 |       |        | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.25   |
| Gentamicin                  | 100.0%                 |       |        | ≤ 0.5             | 1                 | ≤ 0.5  | 1      |
| Imipenem                    | 100.0%                 |       |        | 0.5               | 1                 | 0.25   | 1      |
| Meropenem                   | 100.0%                 |       |        | 0.06              | 0.06              | ≤ 0.03 | 0.12   |
| Moxifloxacin *              | 80.0%                  | 6.7%  | 13.3%  | 0.25              | 16                | ≤ 0.06 | 16     |
| Piperacillin Tazobactam     | 93.3%                  | 6.7%  |        | ≤ 1               | 2                 | ≤ 1    | 32     |
| Tigecycline *               | 93.3%                  |       | 6.7%   | 1                 | 2                 | 1      | 8      |
| Tobramycin                  | 86.7%                  | 6.7%  | 6.7%   | 2                 | 8                 | ≤ 0.5  | 16     |
| Trimethoprim Sulfa          | 100.0%                 |       |        | 0.25              | 1                 | ≤ 0.12 | 1      |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *K. oxytoca* Susceptibility - Ontario

### ***Klebsiella oxytoca* (12)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 4      |
| Amoxicillin Clavulanic Acid | 83.3%                  | 8.3%  | 8.3%  | 2                 | 16                | 2      | 32     |
| Aztreonam                   | 91.7%                  |       | 8.3%  | ≤ 0.12            | 1                 | ≤ 0.12 | 32     |
| Cefazolin                   |                        | 58.3% | 41.7% | 4                 | 64                | 4      | > 128  |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 0.5    |
| Cefoxitin                   | 100.0%                 |       |       | 2                 | 4                 | 0.5    | 8      |
| Ceftazidime                 | 100.0%                 |       |       | ≤ 0.25            | 0.5               | ≤ 0.25 | 0.5    |
| Ceftriaxone                 | 91.7%                  |       | 8.3%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 8      |
| Ciprofloxacin               | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | ≤ 0.06 | 1      |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.06   |
| Doxycycline                 | 100.0%                 |       |       | 1                 | 2                 | 1      | 2      |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.5               | 0.25   | 0.5    |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.06   |
| Moxifloxacin *              | 100.0%                 |       |       | ≤ 0.06            | 0.12              | ≤ 0.06 | 0.12   |
| Piperacillin Tazobactam     | 83.3%                  | 8.3%  | 8.3%  | 2                 | 64                | ≤ 1    | 512    |
| Tigecycline *               | 100.0%                 |       |       | 0.5               | 0.5               | 0.25   | 1      |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Trimethoprim Sulfa          | 91.7%                  |       | 8.3%  | ≤ 0.12            | 1                 | ≤ 0.12 | > 8    |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. maltophilia* Susceptibility - Ontario

### ***Stenotrophomonas maltophilia* (9)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max   |
| Amikacin                    | No Breakpoints Defined |       |       | 32                | > 64              | 4      | > 64  |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | 16     | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | > 128  | > 128 |
| Cefepime                    | No Breakpoints Defined |       |       | 32                | 64                | 4      | 64    |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Ceftazidime                 | 22.2%                  |       | 77.8% | > 32              | > 32              | 2      | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |       | > 64              | > 64              | 64     | > 64  |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 2                 | 8                 | 0.5    | 8     |
| Colistin                    | No Breakpoints Defined |       |       | 1                 | > 16              | 0.5    | > 16  |
| Doripenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Doxycycline                 | No Breakpoints Defined |       |       | 2                 | 4                 | 0.5    | 4     |
| Ertapenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Gentamicin                  | No Breakpoints Defined |       |       | 8                 | 16                | 1      | 16    |
| Imipenem                    | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Meropenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.5               | 4                 | 0.12   | 4     |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | 256               | > 512             | 16     | > 512 |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.5               | 2                 | 0.25   | 2     |
| Tobramycin                  | No Breakpoints Defined |       |       | 4                 | 64                | 1      | 64    |
| Trimethoprim Sulfa          | 66.7%                  |       | 33.3% | 0.5               | > 8               | ≤ 0.12 | > 8   |

# CANWARD 2012

## *E. faecium* Susceptibility - Ontario

### ***Enterococcus faecium* (17)**

| Drug                        | Susceptibility |         |        | Range             |                   |        |       |
|-----------------------------|----------------|---------|--------|-------------------|-------------------|--------|-------|
|                             | % Sus          | % Int   | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | No Breakpoints | Defined |        | 64                | > 64              | 16     | > 64  |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |        | > 32              | > 32              | 4      | > 32  |
| Aztreonam                   | No Breakpoints | Defined |        | > 64              | > 64              | > 64   | > 64  |
| Cefazolin                   | No Breakpoints | Defined |        | > 128             | > 128             | > 128  | > 128 |
| Cefepime                    | No Breakpoints | Defined |        | > 64              | > 64              | > 64   | > 64  |
| Cefoxitin                   | No Breakpoints | Defined |        | > 32              | > 32              | > 32   | > 32  |
| Ceftazidime                 | No Breakpoints | Defined |        | > 32              | > 32              | > 32   | > 32  |
| Ceftriaxone                 | No Breakpoints | Defined |        | > 64              | > 64              | > 64   | > 64  |
| Ciprofloxacin               |                |         | 100.0% | > 16              | > 16              | 16     | > 16  |
| Clarithromycin              | No Breakpoints | Defined |        | > 32              | > 32              | 0.5    | > 32  |
| Clindamycin                 | No Breakpoints | Defined |        | > 8               | > 8               | ≤ 0.12 | > 8   |
| Colistin                    | No Breakpoints | Defined |        | > 16              | > 16              | > 16   | > 16  |
| Daptomycin                  | 100.0%         |         |        | 1                 | 2                 | 1      | 2     |
| Doripenem                   | No Breakpoints | Defined |        | > 32              | > 32              | > 32   | > 32  |
| Doxycycline                 | 76.5%          | 5.9%    | 17.6%  | 4                 | 16                | ≤ 0.12 | 16    |
| Ertapenem                   | No Breakpoints | Defined |        | > 32              | > 32              | > 32   | > 32  |
| Gentamicin                  | No Breakpoints | Defined |        | 8                 | 8                 | 4      | 8     |
| Imipenem                    | No Breakpoints | Defined |        | > 32              | > 32              | > 32   | > 32  |
| Linezolid                   | 94.1%          | 5.9%    |        | 2                 | 2                 | 1      | 4     |
| Meropenem                   | No Breakpoints | Defined |        | > 32              | > 32              | > 32   | > 32  |
| Moxifloxacin                | No Breakpoints | Defined |        | > 16              | > 16              | 16     | > 16  |
| Piperacillin Tazobactam     | No Breakpoints | Defined |        | > 512             | > 512             | 64     | > 512 |
| Tigecycline                 | No Breakpoints | Defined |        | 0.12              | 0.12              | 0.06   | 0.12  |
| Tobramycin                  | No Breakpoints | Defined |        | 64                | > 64              | 64     | > 64  |
| Trimethoprim Sulfa          | No Breakpoints | Defined |        | 1                 | > 8               | ≤ 0.12 | > 8   |
| Vancomycin                  | 58.8%          |         | 41.2%  | 1                 | > 32              | 0.5    | > 32  |

# CANWARD 2012

## *S. agalactiae* Susceptibility - Ontario

### ***Streptococcus agalactiae* (5)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Cefuroxime                  | No Breakpoints Defined |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Chloramphenicol             | 100.0%                 |       |       | 2                 | 4                 | 2      | 4      |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 1                 | 1                 | 0.25   | 1      |
| Clarithromycin              | 60.0%                  |       | 40.0% | 0.06              | 2                 | ≤ 0.03 | 2      |
| Clindamycin                 | 60.0%                  |       | 40.0% | ≤ 0.12            | > 64              | ≤ 0.12 | > 64   |
| Daptomycin                  | 100.0%                 |       |       | 0.12              | 0.25              | 0.06   | 0.25   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Doxycycline                 | No Breakpoints Defined |       |       | 8                 | 8                 | 8      | 8      |
| Ertapenem                   | 100.0%                 |       |       | 0.12              | 0.12              | ≤ 0.06 | 0.12   |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Levofloxacin                | 100.0%                 |       |       | 1                 | 1                 | 0.5    | 1      |
| Linezolid                   | 100.0%                 |       |       | 1                 | 1                 | 1      | 1      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.12              | 0.25              | ≤ 0.06 | 0.25   |
| Penicillin                  | 100.0%                 |       |       | 0.06              | 0.06              | ≤ 0.03 | 0.06   |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Telithromycin               | No Breakpoints Defined |       |       | 0.015             | 0.015             | 0.008  | 0.015  |
| Tigecycline *               | 100.0%                 |       |       | 0.03              | 0.03              | 0.03   | 0.03   |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Vancomycin                  | 100.0%                 |       |       | 0.5               | 0.5               | 0.25   | 0.5    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *P. mirabilis* Susceptibility - Ontario

### ***Proteus mirabilis* (14)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |       | 2                 | 4                 | ≤ 1    | 4      |
| Amoxicillin Clavulanic Acid | 92.9%                  |       | 7.1%  | 1                 | 2                 | 0.5    | > 32   |
| Aztreonam                   | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Cefazolin                   | 7.1%                   | 57.1% | 35.7% | 4                 | 8                 | 2      | > 128  |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   | 92.9%                  |       | 7.1%  | 4                 | 8                 | 2      | 32     |
| Ceftazidime                 | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 4      |
| Ceftriaxone                 | 92.9%                  | 7.1%  |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 2      |
| Ciprofloxacin               | 85.7%                  | 7.1%  | 7.1%  | ≤ 0.06            | 2                 | ≤ 0.06 | > 16   |
| Colistin                    | No Breakpoints Defined |       |       | > 16              | > 16              | > 16   | > 16   |
| Doripenem                   | 100.0%                 |       |       | 0.12              | 0.25              | 0.06   | 0.25   |
| Doxycycline                 |                        |       | 92.9% | 32                | > 32              | 8      | > 32   |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Gentamicin                  | 92.9%                  |       | 7.1%  | ≤ 0.5             | 1                 | ≤ 0.5  | 16     |
| Imipenem                    | 28.6%                  | 50.0% | 21.4% | 2                 | 4                 | 0.25   | 4      |
| Meropenem                   | 100.0%                 |       |       | 0.06              | 0.12              | ≤ 0.03 | 0.12   |
| Moxifloxacin *              | 78.6%                  | 7.1%  | 14.3% | 0.5               | > 16              | 0.25   | > 16   |
| Piperacillin Tazobactam     | 100.0%                 |       |       | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Tigecycline *               | 7.1%                   | 42.9% | 50.0% | 4                 | 8                 | 1      | 8      |
| Tobramycin                  | 92.9%                  | 7.1%  |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 8      |
| Trimethoprim Sulfa          | 92.9%                  |       | 7.1%  | ≤ 0.12            | 2                 | ≤ 0.12 | > 8    |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. pyogenes* Susceptibility - Ontario

### *Streptococcus pyogenes* (12)

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range   |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|---------|--------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min     | Max    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06 |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12 |
| Cefuroxime                  | No Breakpoints Defined |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | ≤ 0.25 |
| Chloramphenicol             | 100.0%                 |       |       | 2                 | 4                 | 2       | 4      |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 0.5               | 2                 | 0.25    | 2      |
| Clarithromycin              | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | 0.12   |
| Clindamycin                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12 |
| Daptomycin                  | 100.0%                 |       |       | 0.06              | 0.12              | ≤ 0.03  | 0.12   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Doxycycline                 | No Breakpoints Defined |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | ≤ 0.25 |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06 |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Levofloxacin                | 100.0%                 |       |       | 1                 | 2                 | 0.25    | 2      |
| Linezolid                   | 100.0%                 |       |       | 1                 | 2                 | 1       | 2      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06 |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.25              | 0.5               | ≤ 0.06  | 0.5    |
| Penicillin                  | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1     | ≤ 1    |
| Telithromycin               | No Breakpoints Defined |       |       | 0.008             | 0.008             | 0.004   | 0.015  |
| Tigecycline *               | 100.0%                 |       |       | ≤ 0.015           | 0.03              | ≤ 0.015 | 0.06   |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | ≤ 0.12            | 0.5               | ≤ 0.12  | 1      |
| Vancomycin                  | 100.0%                 |       |       | 0.5               | 0.5               | 0.25    | 0.5    |

\*Interpretive breakpoints defined by FDA (tigecycline)



# CANWARD 2012

## *C. freundii* Susceptibility - Ontario

### *Citrobacter freundii* (4)

| Drug                        | Susceptibility         |       |       |                   | Range             |        |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 2      |
| Amoxicillin Clavulanic Acid |                        | 25.0% | 75.0% | 32                | > 32              | 16     | > 32   |
| Aztreonam                   |                        |       | 25.0% | ≤ 0.12            | 32                | ≤ 0.12 | 32     |
| Cefazolin                   |                        | 25.0% | 75.0% | 16                | > 128             | 4      | > 128  |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   | 25.0%                  |       | 75.0% | > 32              | > 32              | 8      | > 32   |
| Ceftazidime                 | 75.0%                  |       | 25.0% | 0.5               | 32                | 0.5    | 32     |
| Ceftriaxone                 | 75.0%                  |       | 25.0% | ≤ 0.25            | 16                | ≤ 0.25 | 16     |
| Ciprofloxacin               | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.12   | 0.5    |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.12              | ≤ 0.03 | 0.12   |
| Doxycycline                 | 50.0%                  |       | 50.0% | 4                 | 32                | 1      | 32     |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.5               | ≤ 0.03 | 0.5    |
| Gentamicin                  | 50.0%                  |       | 50.0% | ≤ 0.5             | > 32              | ≤ 0.5  | > 32   |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 1                 | 0.25   | 1      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.12              | ≤ 0.03 | 0.12   |
| Moxifloxacin *              | 100.0%                 |       |       | 0.12              | 0.5               | 0.12   | 0.5    |
| Piperacillin Tazobactam     | 100.0%                 |       |       | 2                 | 4                 | ≤ 1    | 4      |
| Tigecycline *               | 100.0%                 |       |       | 0.5               | 1                 | 0.25   | 1      |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | 4                 | ≤ 0.5  | 4      |
| Trimethoprim Sulfa          | 50.0%                  |       | 50.0% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8    |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *A. baumannii* Susceptibility - Ontario

### ***Acinetobacter baumannii* (7)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 85.7%                  |       | 14.3% | 2                 | > 64              | ≤ 1    | > 64  |
| Amoxicillin Clavulanic Acid | No breakpoints defined |       |       | 8                 | > 32              | 8      | > 32  |
| Cefazolin                   | No breakpoints defined |       |       | > 128             | > 128             | 128    | > 128 |
| Cefepime                    | 85.7%                  |       | 14.3% | 8                 | 32                | 2      | 32    |
| Cefoxitin                   | No breakpoints defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Ceftazidime                 | 71.4%                  | 14.3% | 14.3% | 4                 | > 32              | 2      | > 32  |
| Ceftriaxone                 | 42.9%                  | 42.9% | 14.3% | 16                | > 64              | 8      | > 64  |
| Ciprofloxacin               | 85.7%                  |       | 14.3% | 0.25              | > 16              | 0.12   | > 16  |
| Colistin                    | 100.0%                 |       |       | 0.5               | 1                 | 0.25   | 1     |
| Doripenem                   | No breakpoints defined |       |       | 0.25              | 32                | 0.12   | 32    |
| Doxycycline                 | 100.0%                 |       |       | ≤ 0.12            | 1                 | ≤ 0.12 | 1     |
| Ertapenem                   | No breakpoints defined |       |       | 8                 | > 32              | 2      | > 32  |
| Gentamicin                  | 71.4%                  | 14.3% | 14.3% | 1                 | > 32              | ≤ 0.5  | > 32  |
| Imipenem                    | 85.7%                  |       | 14.3% | 0.12              | > 32              | 0.12   | > 32  |
| Meropenem                   | 85.7%                  |       | 14.3% | 0.25              | > 32              | 0.12   | > 32  |
| Moxifloxacin                | No breakpoints defined |       |       | 0.12              | 16                | ≤ 0.06 | 16    |
| Piperacillin Tazobactam     | 71.4%                  | 14.3% | 14.3% | 16                | 512               | ≤ 1    | 512   |
| Tigecycline                 | No breakpoints defined |       |       | 0.25              | 2                 | 0.12   | 2     |
| Tobramycin                  | 85.7%                  |       | 14.3% | 1                 | > 64              | ≤ 0.5  | > 64  |
| Trimethoprim Sulfa          | 85.7%                  |       | 14.3% | 0.25              | > 8               | ≤ 0.12 | > 8   |

# CANWARD 2012

## *A. baumannii* Susceptibility - Ontario

### ***Acinetobacter baumannii* (2)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | 8                 | 16                | 8      | 16     |
| Aztreonam                   |                        |       |       | 8                 | 16                | 8      | 16     |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | > 128  | > 128  |
| Cefepime                    | 100.0%                 |       |       | 2                 | 4                 | 2      | 4      |
| Cefoxitin                   | No Breakpoints Defined |       |       | 32                | > 32              | 32     | > 32   |
| Ceftazidime                 | 100.0%                 |       |       | 4                 | 4                 | 4      | 4      |
| Ceftriaxone                 | 100.0%                 |       |       | 8                 | 8                 | 8      | 8      |
| Ciprofloxacin               | 100.0%                 |       |       | 0.12              | 0.25              | 0.12   | 0.25   |
| Colistin                    | 100.0%                 |       |       | 0.5               | 1                 | 0.5    | 1      |
| Doripenem                   | No Breakpoints Defined |       |       | 0.25              | 0.25              | 0.25   | 0.25   |
| Doxycycline                 | 100.0%                 |       |       | ≤ 0.12            | 0.25              | ≤ 0.12 | 0.25   |
| Ertapenem                   | No Breakpoints Defined |       |       | 4                 | 8                 | 4      | 8      |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.5               | 0.25   | 0.5    |
| Meropenem                   | 100.0%                 |       |       | 0.5               | 0.5               | 0.5    | 0.5    |
| Moxifloxacin                | No Breakpoints Defined |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Piperacillin Tazobactam     | 100.0%                 |       |       | ≤ 1               | 8                 | ≤ 1    | 8      |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.12              | 0.25              | 0.12   | 0.25   |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Trimethoprim Sulfa          | 100.0%                 |       |       | ≤ 0.12            | 0.25              | ≤ 0.12 | 0.25   |

# CANWARD 2012

## *S. aureus*, MSSA Susceptibility - Quebec

### ***Staphylococcus aureus* , MSSA (54)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max  |
| Amikacin                    | 100.0%                 |       |       | 2                 | 4                 | ≤ 1    | 8    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | 0.5               | 1                 | 0.12   | 1    |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | 0.5    | > 64 |
| Cefazolin                   | No Breakpoints Defined |       |       | ≤ 0.5             | 1                 | ≤ 0.5  | 1    |
| Cefepime                    | No Breakpoints Defined |       |       | 4                 | 4                 | ≤ 0.25 | 4    |
| Cefoxitin                   | 100.0%                 |       |       | 4                 | 4                 | 0.5    | 4    |
| Ceftazidime                 | No Breakpoints Defined |       |       | 16                | 32                | 8      | 32   |
| Ceftriaxone                 | No Breakpoints Defined |       |       | 4                 | 4                 | 0.5    | 8    |
| Ciprofloxacin               | 75.9%                  | 1.9%  | 22.2% | 0.5               | > 16              | ≤ 0.06 | > 16 |
| Clarithromycin              | 72.2%                  |       | 27.8% | 0.25              | > 32              | 0.12   | > 32 |
| Clindamycin                 | 92.6%                  |       | 7.4%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8  |
| Colistin                    | No Breakpoints Defined |       |       | > 16              | > 16              | ≤ 0.06 | > 16 |
| Daptomycin                  | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 0.5  |
| Doripenem                   | No Breakpoints Defined |       |       | 0.06              | 0.06              | ≤ 0.03 | 0.12 |
| Doxycycline                 | 100.0%                 |       |       | ≤ 0.12            | 0.25              | ≤ 0.12 | 4    |
| Ertapenem                   | No Breakpoints Defined |       |       | 0.5               | 0.5               | 0.06   | 0.5  |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 1    |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.06 |
| Linezolid                   | 100.0%                 |       |       | 2                 | 4                 | 1      | 4    |
| Meropenem                   | No Breakpoints Defined |       |       | 0.12              | 0.25              | ≤ 0.03 | 0.25 |
| Moxifloxacin                | 77.8%                  |       | 22.2% | ≤ 0.06            | 8                 | ≤ 0.06 | > 16 |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1    | 2    |
| Tigecycline *               | 100.0%                 |       |       | 0.12              | 0.25              | 0.06   | 0.25 |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 1    |
| Trimethoprim Sulfa          | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 0.5  |
| Vancomycin                  | 100.0%                 |       |       | 0.5               | 1                 | 0.25   | 1    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. coli* Susceptibility - Quebec

### ***Escherichia coli* (75)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 4                 | ≤ 1    | 8     |
| Amoxicillin Clavulanic Acid | 82.7%                  | 14.7% | 2.7%  | 4                 | 16                | 1      | > 32  |
| Aztreonam                   | 93.3%                  |       | 6.7%  | ≤ 0.12            | 0.25              | ≤ 0.12 | > 64  |
| Cefazolin                   | 77.3%                  | 8.0%  | 14.7% | 1                 | 16                | ≤ 0.5  | > 128 |
| Cefepime                    | 96.0%                  | 2.7%  | 1.3%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 32    |
| Cefoxitin                   | 93.3%                  | 4.0%  | 2.7%  | 4                 | 8                 | 2      | > 32  |
| Ceftazidime                 | 93.3%                  |       | 6.7%  | ≤ 0.25            | 1                 | ≤ 0.25 | > 32  |
| Ceftriaxone                 | 93.3%                  |       | 6.7%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | > 64  |
| Ciprofloxacin               | 72.0%                  |       | 28.0% | ≤ 0.06            | > 16              | ≤ 0.06 | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.12   | 2     |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.25  |
| Doxycycline                 | 72.0%                  | 1.3%  | 26.7% | 2                 | 32                | 0.5    | > 32  |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.25  |
| Gentamicin                  | 96.0%                  |       | 4.0%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | > 32  |
| Imipenem                    | 100.0%                 |       |       | 0.12              | 0.25              | 0.06   | 1     |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12  |
| Moxifloxacin *              | 7.0%                   |       | 28.0% | ≤ 0.06            | > 16              | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | 98.7%                  |       | 1.3%  | 2                 | 4                 | ≤ 1    | 128   |
| Tigecycline *               | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 1     |
| Tobramycin                  | 94.7%                  | 2.7%  | 2.7%  | ≤ 0.5             | 1                 | ≤ 0.5  | 32    |
| Trimethoprim Sulfa          | 85.3%                  |       | 14.7% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *P. aeruginosa* Susceptibility - Quebec

### ***Pseudomonas aeruginosa* (29)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | 2                 | 8                 | ≤ 1    | 16    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | > 32              | > 32              | 16     | > 32  |
| Aztreonam                   | 82.8%                  | 6.9%  | 10.3% | 4                 | 32                | 0.25   | 64    |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | > 128  | > 128 |
| Cefepime                    | 89.7%                  | 10.3% |       | 2                 | 16                | 0.5    | 16    |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Ceftazidime                 | 79.3%                  | 6.9%  | 13.8% | 2                 | 32                | 1      | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |       | 16                | > 64              | 4      | > 64  |
| Ciprofloxacin               | 89.7%                  | 6.9%  | 3.4%  | 0.12              | 2                 | ≤ 0.06 | 8     |
| Colistin                    | 96.6%                  |       | 3.4%  | 1                 | 2                 | 0.25   | > 16  |
| Doripenem                   | 96.6%                  |       | 3.4%  | 0.25              | 1                 | 0.06   | 16    |
| Doxycycline                 | No Breakpoints Defined |       |       | 16                | > 32              | 1      | > 32  |
| Ertapenem                   | No Breakpoints Defined |       |       | 8                 | 32                | 1      | > 32  |
| Gentamicin                  | 93.1%                  | 6.9%  |       | 1                 | 4                 | ≤ 0.5  | 8     |
| Imipenem                    | 75.9%                  | 6.9%  | 17.2% | 1                 | 8                 | 0.5    | 32    |
| Meropenem                   | 93.1%                  | 3.4%  | 3.4%  | 0.5               | 2                 | 0.06   | 16    |
| Moxifloxacin                | No Breakpoints Defined |       |       | 2                 | 8                 | 0.5    | > 16  |
| Piperacillin Tazobactam     | 89.7%                  | 3.4%  | 6.9%  | 4                 | 32                | ≤ 1    | 256   |
| Tigecycline                 | No Breakpoints Defined |       |       | 8                 | > 16              | 1      | > 16  |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | 1                 | ≤ 0.5  | 2     |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | 8                 | > 8               | 0.5    | > 8   |

# CANWARD 2012

## *K. pneumoniae* Susceptibility - Quebec

### ***Klebsiella pneumoniae* (32)**

| Drug                        | Susceptibility         |       |       |                   | Range             |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | ≤ 1               | ≤ 1    | 2     |
| Amoxicillin Clavulanic Acid | 100.0%                 |       |       | 2                 | 4                 | 1      | 8     |
| Aztreonam                   | 96.9%                  |       | 3.1%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 32    |
| Cefazolin                   | 96.9%                  |       | 3.1%  | 1                 | 2                 | ≤ 0.5  | > 128 |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 8     |
| Cefoxitin                   | 100.0%                 |       |       | 2                 | 4                 | 2      | 8     |
| Ceftazidime                 | 96.9%                  |       | 3.1%  | ≤ 0.25            | 0.5               | ≤ 0.25 | 32    |
| Ceftriaxone                 | 96.9%                  |       | 3.1%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 32    |
| Ciprofloxacin               | 96.9%                  |       | 3.1%  | ≤ 0.06            | 0.25              | ≤ 0.06 | 4     |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | ≤ 0.06 | 0.5   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.06  |
| Doxycycline                 | 84.4%                  | 3.1%  | 12.5% | 2                 | 16                | 1      | > 32  |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.06  |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5 |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.5               | 0.12   | 0.5   |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.06  |
| Moxifloxacin *              | 100.0%                 |       |       | 0.12              | 1                 | ≤ 0.06 | 2     |
| Piperacillin Tazobactam     | 100.0%                 |       |       | 2                 | 4                 | ≤ 1    | 8     |
| Tigecycline *               | 100.0%                 |       |       | 0.5               | 1                 | 0.25   | 2     |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5 |
| Trimethoprim Sulfa          | 93.8%                  |       | 6.3%  | ≤ 0.12            | 1                 | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. pneumoniae* Susceptibility - Quebec

### ***Streptococcus pneumoniae* (15)**

| Drug                        | Susceptibility         |       |       | Range             |                   |         |         |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|---------|---------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min     | Max     |
| Amoxicillin Clavulanic Acid | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06  |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12  |
| Cefuroxime                  | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | ≤ 0.25  |
| Chloramphenicol             | 100.0%                 |       |       | 2                 | 2                 | 0.25    | 4       |
| Ciprofloxacin               | 93.3%                  |       | 6.7%  | 1                 | 2                 | 0.12    | 8       |
| Clarithromycin              | 93.3%                  |       | 6.7%  | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | 8       |
| Clindamycin                 | 93.3%                  |       | 6.7%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | 16      |
| Daptomycin                  | No Breakpoints Defined |       |       | 0.12              | 0.12              | 0.06    | 0.12    |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03  |
| Doxycycline                 | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | ≤ 0.25  |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06  |
| Imipenem                    | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03  |
| Levofloxacin                | 93.3%                  |       | 6.7%  | 1                 | 1                 | 0.12    | 8       |
| Linezolid                   | 100.0%                 |       |       | 0.5               | 1                 | ≤ 0.12  | 1       |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06  |
| Moxifloxacin                | 93.3%                  | 6.7%  |       | 0.12              | 0.25              | ≤ 0.06  | 2       |
| Penicillin                  | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | 0.06    |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1     | ≤ 1     |
| Telithromycin               | 100.0%                 |       |       | 0.008             | 0.008             | ≤ 0.002 | 0.008   |
| Tigecycline *               | 100.0%                 |       |       | ≤ 0.015           | ≤ 0.015           | ≤ 0.015 | ≤ 0.015 |
| Trimethoprim Sulfa          | 93.3%                  | 6.7%  |       | 0.25              | 0.25              | ≤ 0.12  | 1       |
| Vancomycin                  | 100.0%                 |       |       | 0.25              | 0.25              | ≤ 0.12  | 0.5     |

\*Interpretive breakpoints defined by FDA (tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE





# CANWARD 2012

## *S. aureus*-MRSA Susceptibility - Quebec

### ***Staphylococcus aureus*, MRSA (7)**

| Drug                        | Susceptibility         |       |        | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |        |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res  |                   |                   | Min    | Max    |
| Amikacin                    | 85.7%                  | 14.3% |        | 16                | 32                | 2      | 32     |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |        | 16                | 16                | 2      | 16     |
| Aztreonam                   | No Breakpoints Defined |       |        | > 64              | > 64              | > 64   | > 64   |
| Cefazolin                   | No Breakpoints Defined |       |        | 16                | 128               | 2      | 128    |
| Cefepime                    | No Breakpoints Defined |       |        | 16                | > 64              | 4      | > 64   |
| Cefoxitin                   |                        |       | 100.0% | > 32              | > 32              | 16     | > 32   |
| Ceftazidime                 | No Breakpoints Defined |       |        | > 32              | > 32              | 16     | > 32   |
| Ceftriaxone                 | No Breakpoints Defined |       |        | 64                | > 64              | 16     | > 64   |
| Ciprofloxacin               |                        |       | 100.0% | > 16              | > 16              | > 16   | > 16   |
| Clarithromycin              |                        |       | 100.0% | > 32              | > 32              | > 32   | > 32   |
| Clindamycin                 | 57.1%                  |       | 42.9%  | ≤ 0.12            | > 8               | ≤ 0.12 | > 8    |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | > 16   | > 16   |
| Daptomycin                  | 100.0%                 |       |        | 0.25              | 0.25              | 0.25   | 0.25   |
| Doripenem                   | No Breakpoints Defined |       |        | 2                 | 8                 | 0.25   | 8      |
| Doxycycline                 | 100.0%                 |       |        | ≤ 0.12            | 0.5               | ≤ 0.12 | 0.5    |
| Ertapenem                   | No Breakpoints Defined |       |        | 16                | > 32              | 2      | > 32   |
| Gentamicin                  | 100.0%                 |       |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | No Breakpoints Defined |       |        | 1                 | 8                 | 0.12   | 8      |
| Linezolid                   | 100.0%                 |       |        | 2                 | 2                 | 1      | 2      |
| Meropenem                   | No Breakpoints Defined |       |        | 4                 | 16                | 0.5    | 16     |
| Moxifloxacin                |                        |       | 100.0% | 8                 | > 16              | 8      | > 16   |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |        | 32                | 64                | 4      | 64     |
| Tigecycline *               | 100.0%                 |       |        | 0.12              | 0.25              | 0.12   | 0.25   |
| Tobramycin                  | 42.9%                  |       | 57.1%  | > 64              | > 64              | ≤ 0.5  | > 64   |
| Trimethoprim Sulfa          | 100.0%                 |       |        | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Vancomycin                  | 100.0%                 |       |        | 1                 | 1                 | 0.5    | 1      |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. faecalis* Susceptibility - Quebec

### ***Enterococcus faecalis* (13)**

| Drug                        | Susceptibility |         |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|----------------|---------|-------|-------------------|-------------------|--------|------|
|                             | % Sus          | % Int   | % Res |                   |                   | Min    | Max  |
| Amikacin                    | No Breakpoints | Defined |       | > 64              | > 64              | 8      | > 64 |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |       | 0.5               | 1                 | 0.25   | 1    |
| Aztreonam                   | No Breakpoints | Defined |       | > 64              | > 64              | > 64   | > 64 |
| Cefazolin                   | No Breakpoints | Defined |       | 32                | 32                | 16     | 64   |
| Cefepime                    | No Breakpoints | Defined |       | 32                | > 64              | 16     | > 64 |
| Cefoxitin                   | No Breakpoints | Defined |       | > 32              | > 32              | > 32   | > 32 |
| Ceftazidime                 | No Breakpoints | Defined |       | > 32              | > 32              | > 32   | > 32 |
| Ceftriaxone                 | No Breakpoints | Defined |       | > 64              | > 64              | 32     | > 64 |
| Ciprofloxacin               | 76.9%          | 7.7%    | 15.4% | 1                 | > 16              | 0.25   | > 16 |
| Clarithromycin              | No Breakpoints | Defined |       | > 32              | > 32              | 0.06   | > 32 |
| Clindamycin                 | No Breakpoints | Defined |       | > 8               | > 8               | 8      | > 8  |
| Colistin                    | No Breakpoints | Defined |       | > 16              | > 16              | > 16   | > 16 |
| Daptomycin                  | 100.0%         |         |       | 1                 | 2                 | 0.25   | 2    |
| Doripenem                   | No Breakpoints | Defined |       | 2                 | 4                 | 2      | 8    |
| Doxycycline                 | 23.1%          | 46.2%   | 30.8% | 8                 | 16                | ≤ 0.12 | 32   |
| Ertapenem                   | No Breakpoints | Defined |       | 8                 | 16                | 4      | 32   |
| Gentamicin                  | No Breakpoints | Defined |       | 16                | > 32              | 1      | > 32 |
| Imipenem                    | No Breakpoints | Defined |       | 1                 | 2                 | 1      | 4    |
| Linezolid                   | 100.0%         |         |       | 2                 | 2                 | 1      | 2    |
| Meropenem                   | No Breakpoints | Defined |       | 4                 | 8                 | 4      | 16   |
| Moxifloxacin                | No Breakpoints | Defined |       | 0.25              | 8                 | 0.12   | 16   |
| Piperacillin Tazobactam     | No Breakpoints | Defined |       | 4                 | 4                 | 2      | 4    |
| Tigecycline *               | 100.0%         |         |       | 0.12              | 0.12              | ≤ 0.03 | 0.12 |
| Tobramycin                  | No Breakpoints | Defined |       | 16                | > 64              | 4      | > 64 |
| Trimethoprim Sulfa          | No Breakpoints | Defined |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 0.5  |
| Vancomycin                  | 100.0%         |         |       | 1                 | 2                 | 1      | 2    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. cloacae* Susceptibility - Quebec

### ***Enterobacter cloacae* (5)**

| Drug                        | Susceptibility         |       |        |                   | Range             |        |        |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |        | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Amoxicillin Clavulanic Acid |                        | 20.0% | 80.0%  | 32                | > 32              | 16     | > 32   |
| Aztreonam                   | 80.0%                  |       | 20.0%  | ≤ 0.12            | 64                | ≤ 0.12 | 64     |
| Cefazolin                   |                        |       | 100.0% | 128               | > 128             | 8      | > 128  |
| Cefepime                    | 100.0%                 |       |        | ≤ 0.25            | 2                 | ≤ 0.25 | 2      |
| Cefoxitin                   |                        |       | 100.0% | > 32              | > 32              | > 32   | > 32   |
| Ceftazidime                 | 80.0%                  |       | 20.0%  | ≤ 0.25            | > 32              | ≤ 0.25 | > 32   |
| Ceftriaxone                 | 80.0%                  |       | 20.0%  | ≤ 0.25            | > 64              | ≤ 0.25 | > 64   |
| Ciprofloxacin               | 100.0%                 |       |        | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Colistin                    | No Breakpoints Defined |       |        | 0.5               | > 16              | 0.25   | > 16   |
| Doripenem                   | 100.0%                 |       |        | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.06   |
| Doxycycline                 | 100.0%                 |       |        | 2                 | 4                 | 2      | 4      |
| Ertapenem                   | 80.0%                  | 20.0% |        | ≤ 0.03            | 1                 | ≤ 0.03 | 1      |
| Gentamicin                  | 100.0%                 |       |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |       |        | 0.25              | 0.5               | 0.25   | 0.5    |
| Meropenem                   | 100.0%                 |       |        | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.06   |
| Moxifloxacin *              | 100.0%                 |       |        | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Piperacillin Tazobactam     | 80.0%                  |       | 20.0%  | 2                 | 128               | ≤ 1    | 128    |
| Tigecycline *               | 100.0%                 |       |        | 0.5               | 1                 | 0.5    | 1      |
| Tobramycin                  | 100.0%                 |       |        | ≤ 0.5             | 1                 | ≤ 0.5  | 1      |
| Trimethoprim Sulfa          | 100.0%                 |       |        | ≤ 0.12            | 1                 | ≤ 0.12 | 1      |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline) CANADIAN ANTIMICROBIAL RESISTANCE ALLIANCE



# CANWARD 2012

## *S. epidermidis* Susceptibility - Quebec

### ***Staphylococcus epidermidis* (18)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max  |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 8                 | ≤ 1    | 16   |
| Amoxicillin Clavulanic Acid | 72.2%                  |       | 27.8% | 0.5               | 16                | ≤ 0.06 | 16   |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | > 64   | > 64 |
| Cefazolin                   | 83.3%                  |       | 16.7% | ≤ 0.5             | 128               | ≤ 0.5  | 128  |
| Cefepime                    | 66.7%                  |       | 33.3% | 2                 | > 64              | ≤ 0.25 | > 64 |
| Cefoxitin                   | No Breakpoints Defined |       |       | 8                 | > 32              | 1      | > 32 |
| Ceftazidime                 | 44.4%                  | 16.7% | 38.9% | 16                | > 32              | 2      | > 32 |
| Ceftriaxone                 | 55.6%                  | 16.7% | 27.8% | 4                 | > 64              | 0.5    | > 64 |
| Ciprofloxacin               | 38.9%                  |       | 61.1% | 16                | > 16              | ≤ 0.06 | > 16 |
| Clarithromycin              | 44.4%                  |       | 55.6% | > 32              | > 32              | 0.06   | > 32 |
| Clindamycin                 | 61.1%                  |       | 38.9% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8  |
| Colistin                    | No Breakpoints Defined |       |       | > 16              | > 16              | 8      | > 16 |
| Daptomycin                  | 100.0%                 |       |       | 0.12              | 0.25              | ≤ 0.03 | 0.5  |
| Doripenem                   | No Breakpoints Defined |       |       | 0.25              | 32                | ≤ 0.03 | 32   |
| Doxycycline                 | 100.0%                 |       |       | 0.25              | 1                 | ≤ 0.12 | 2    |
| Ertapenem                   | 53.3%                  | 6.7%  | 40.0% | 1                 | > 32              | 0.25   | > 32 |
| Gentamicin                  | 61.1%                  | 11.1% | 27.8% | ≤ 0.5             | > 32              | ≤ 0.5  | > 32 |
| Imipenem                    | 66.7%                  | 5.6%  | 27.8% | ≤ 0.03            | 32                | ≤ 0.03 | > 32 |
| Linezolid                   | 100.0%                 |       |       | 1                 | 1                 | ≤ 0.12 | 1    |
| Meropenem                   | No Breakpoints Defined |       |       | 0.5               | 32                | 0.06   | 32   |
| Moxifloxacin                | 38.9%                  |       | 61.1% | 2                 | > 16              | ≤ 0.06 | > 16 |
| Piperacillin Tazobactam     | 77.8%                  |       | 22.2% | ≤ 1               | 16                | ≤ 1    | 32   |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.12              | 0.25              | 0.12   | 1    |
| Tobramycin                  | 72.2%                  | 5.6%  | 22.2% | ≤ 0.5             | 64                | ≤ 0.5  | 64   |
| Trimethoprim Sulfa          | 50.0%                  |       | 50.0% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8  |
| Vancomycin                  | 100.0%                 |       |       | 1                 | 2                 | 0.5    | 2    |

# CANWARD 2012

## *S. marcescens* Susceptibility - Quebec

### *Serratia marcescens* (1)

| Drug                        | Susceptibility         |        |        |                   | Range             |        |        |
|-----------------------------|------------------------|--------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int  | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |        |        | 2                 | 2                 | 2      | 2      |
| Amoxicillin Clavulanic Acid |                        |        | 100.0% | > 32              | > 32              | > 32   | > 32   |
| Aztreonam                   | 100.0%                 |        |        | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Cefazolin                   |                        |        | 100.0% | > 128             | > 128             | > 128  | > 128  |
| Cefepime                    | 100.0%                 |        |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   |                        | 100.0% |        | 16                | 16                | 16     | 16     |
| Ceftazidime                 | 100.0%                 |        |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Ceftriaxone                 | 100.0%                 |        |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Ciprofloxacin               | 100.0%                 |        |        | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Colistin                    | No Breakpoints Defined |        |        | > 16              | > 16              | > 16   | > 16   |
| Doripenem                   | 100.0%                 |        |        | 0.12              | 0.12              | 0.12   | 0.12   |
| Doxycycline                 |                        | 100.0% |        | 8                 | 8                 | 8      | 8      |
| Ertapenem                   | 100.0%                 |        |        | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Gentamicin                  | 100.0%                 |        |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |        |        | 1                 | 1                 | 1      | 1      |
| Meropenem                   | 100.0%                 |        |        | 0.06              | 0.06              | 0.06   | 0.06   |
| Moxifloxacin *              | 100.0%                 |        |        | 0.25              | 0.25              | 0.25   | 0.25   |
| Piperacillin Tazobactam     | 100.0%                 |        |        | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Tigecycline *               | 100.0%                 |        |        | 1                 | 1                 | 1      | 1      |
| Tobramycin                  | 100.0%                 |        |        | 2                 | 2                 | 2      | 2      |
| Trimethoprim Sulfa          | 100.0%                 |        |        | 0.25              | 0.25              | 0.25   | 0.25   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *K. oxytoca* Susceptibility - Quebec

### *Klebsiella oxytoca* (5)

| Drug                        | Susceptibility         |       |       | Range             |                   |        |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 2      |
| Amoxicillin Clavulanic Acid | 100.0%                 |       |       | 2                 | 4                 | 1      | 4      |
| Aztreonam                   | 100.0%                 |       |       | ≤ 0.12            | 0.25              | ≤ 0.12 | 0.25   |
| Cefazolin                   | 80.0%                  |       | 20.0% | 1                 | 8                 | 1      | 8      |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   | 100.0%                 |       |       | 2                 | 4                 | 1      | 4      |
| Ceftazidime                 | 100.0%                 |       |       | ≤ 0.25            | 0.5               | ≤ 0.25 | 0.5    |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Ciprofloxacin               | 100.0%                 |       |       | ≤ 0.06            | 0.12              | ≤ 0.06 | 0.12   |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.25   | 0.5    |
| Doripenem                   | 100.0%                 |       |       | 0.06              | 0.06              | ≤ 0.03 | 0.06   |
| Doxycycline                 | 100.0%                 |       |       | 1                 | 1                 | 1      | 1      |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.25              | 0.25   | 0.25   |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Moxifloxacin *              | 100.0%                 |       |       | ≤ 0.06            | 0.12              | ≤ 0.06 | 0.12   |
| Piperacillin Tazobactam     | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 2      |
| Tigecycline *               | 100.0%                 |       |       | 0.25              | 0.5               | 0.25   | 0.5    |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | 2                 | ≤ 0.5  | 2      |
| Trimethoprim Sulfa          | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. maltophilia* Susceptibility - Quebec

### ***Stenotrophomonas maltophilia* (4)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    |                        |       |       | 32                | > 64              | 32     | > 64  |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | > 64   | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | > 128  | > 128 |
| Cefepime                    | No Breakpoints Defined |       |       | 32                | 64                | 32     | 64    |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Ceftazidime                 | 25.0%                  |       | 75.0% | 32                | > 32              | 8      | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |       | > 64              | > 64              | > 64   | > 64  |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 1                 | 8                 | 1      | 8     |
| Colistin                    | No Breakpoints Defined |       |       | 1                 | 8                 | 0.5    | 8     |
| Doripenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Doxycycline                 | No Breakpoints Defined |       |       | 1                 | 4                 | 0.5    | 4     |
| Ertapenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Gentamicin                  | No Breakpoints Defined |       |       | 16                | 32                | 16     | 32    |
| Imipenem                    | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Meropenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.25              | 2                 | 0.12   | 2     |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | 128               | 512               | 64     | 512   |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.5               | 2                 | 0.25   | 2     |
| Tobramycin                  | No Breakpoints Defined |       |       | 16                | > 64              | 8      | > 64  |
| Trimethoprim Sulfa          | 75.0%                  |       | 25.0% | 0.5               | > 8               | ≤ 0.12 | > 8   |

# CANWARD 2012

## *E. faecium* Susceptibility - Quebec

### ***Enterococcus faecium* (2)**

| Drug                        | Susceptibility |         |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |        |
|-----------------------------|----------------|---------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus          | % Int   | % Res |                   |                   | Min    | Max    |
| Amikacin                    | No Breakpoints | Defined |       | 32                | 32                | 32     | 32     |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |       | 0.25              | 1                 | 0.25   | 1      |
| Aztreonam                   | No Breakpoints | Defined |       | > 64              | > 64              | > 64   | > 64   |
| Cefazolin                   | No Breakpoints | Defined |       | 32                | 128               | 32     | 128    |
| Cefepime                    | No Breakpoints | Defined |       | 16                | > 64              | 16     | > 64   |
| Cefoxitin                   | No Breakpoints | Defined |       | 16                | 32                | 16     | 32     |
| Ceftazidime                 | No Breakpoints | Defined |       | > 32              | > 32              | > 32   | > 32   |
| Ceftriaxone                 | No Breakpoints | Defined |       | 1                 | > 64              | 1      | > 64   |
| Ciprofloxacin               | 100.0%         |         |       | 0.5               | 1                 | 0.5    | 1      |
| Clarithromycin              | No Breakpoints | Defined |       | 0.12              | 2                 | 0.12   | 2      |
| Clindamycin                 | No Breakpoints | Defined |       | 1                 | > 8               | 1      | > 8    |
| Colistin                    | No Breakpoints | Defined |       | > 16              | > 16              | > 16   | > 16   |
| Daptomycin                  | 100.0%         |         |       | 2                 | 2                 | 2      | 2      |
| Doripenem                   | No Breakpoints | Defined |       | 2                 | 8                 | 2      | 8      |
| Doxycycline                 | 100.0%         |         |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Ertapenem                   | No Breakpoints | Defined |       | 4                 | > 32              | 4      | > 32   |
| Gentamicin                  | No Breakpoints | Defined |       | 8                 | 8                 | 8      | 8      |
| Imipenem                    | No Breakpoints | Defined |       | 1                 | 4                 | 1      | 4      |
| Linezolid                   | 100.0%         |         |       | 2                 | 2                 | 2      | 2      |
| Meropenem                   | No Breakpoints | Defined |       | 2                 | 16                | 2      | 16     |
| Moxifloxacin                | No Breakpoints | Defined |       | 0.5               | 0.5               | 0.5    | 0.5    |
| Piperacillin Tazobactam     | No Breakpoints | Defined |       | 4                 | 16                | 4      | 16     |
| Tigecycline                 | No Breakpoints | Defined |       | 0.06              | 0.12              | 0.06   | 0.12   |
| Tobramycin                  | No Breakpoints | Defined |       | > 64              | > 64              | > 64   | > 64   |
| Trimethoprim Sulfa          | No Breakpoints | Defined |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Vancomycin                  | 100.0%         |         |       | 0.5               | 1                 | 0.5    | 1      |



# CANWARD 2012

## *S. agalactiae* Susceptibility - Quebec

### ***Streptococcus agalactiae* (11)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | 0.12   |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Cefuroxime                  | No Breakpoints Defined |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Chloramphenicol             | 100.0%                 |       |       | 4                 | 4                 | 2      | 4      |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 1                 | 1                 | 0.5    | 1      |
| Clarithromycin              | 81.8%                  | 9.1%  | 9.1%  | ≤ 0.03            | 0.5               | ≤ 0.03 | 32     |
| Clindamycin                 | 90.9%                  |       | 9.1%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 64   |
| Daptomycin                  | 100.0%                 |       |       | 0.25              | 0.25              | 0.12   | 0.25   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Doxycycline                 | No Breakpoints Defined |       |       | 8                 | 16                | ≤ 0.25 | 16     |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.06            | 0.12              | ≤ 0.06 | 0.12   |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Levofloxacin                | 100.0%                 |       |       | 1                 | 1                 | 0.5    | 1      |
| Linezolid                   | 100.0%                 |       |       | 2                 | 2                 | 1      | 2      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.12              | 0.25              | 0.12   | 0.25   |
| Penicillin                  | 100.0%                 |       |       | 0.06              | 0.06              | 0.06   | 0.06   |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Telithromycin               | No Breakpoints Defined |       |       | 0.015             | 0.12              | 0.015  | 0.12   |
| Tigecycline *               | 100.0%                 |       |       | 0.03              | 0.06              | 0.03   | 0.06   |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 0.25   |
| Vancomycin                  | 100.0%                 |       |       | 0.5               | 0.5               | 0.25   | 0.5    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *P. mirabilis* Susceptibility - Maritimes

### ***Proteus mirabilis* (5)**

| Drug                        | Susceptibility         |       |        | Range             |                   |        |        |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |        | 2                 | 4                 | ≤ 1    | 4      |
| Amoxicillin Clavulanic Acid | 100.0%                 |       |        | 1                 | 8                 | 1      | 8      |
| Aztreonam                   | 100.0%                 |       |        | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Cefazolin                   |                        | 80.0% | 20.0%  | 4                 | 16                | 4      | 16     |
| Cefepime                    | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   | 100.0%                 |       |        | 4                 | 4                 | 4      | 4      |
| Ceftazidime                 | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Ceftriaxone                 | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Ciprofloxacin               | 100.0%                 |       |        | ≤ 0.06            | 0.25              | ≤ 0.06 | 0.25   |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | ≤ 0.06 | > 16   |
| Doripenem                   | 100.0%                 |       |        | 0.25              | 0.25              | 0.12   | 0.25   |
| Doxycycline                 |                        |       | 100.0% | 32                | > 32              | 16     | > 32   |
| Ertapenem                   | 100.0%                 |       |        | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Gentamicin                  | 100.0%                 |       |        | ≤ 0.5             | 1                 | ≤ 0.5  | 1      |
| Imipenem                    | 40.0%                  | 60.0% |        | 2                 | 2                 | 0.25   | 2      |
| Meropenem                   | 100.0%                 |       |        | 0.06              | 0.06              | 0.06   | 0.06   |
| Moxifloxacin *              | 100.0%                 |       |        | 0.5               | 2                 | 0.25   | 2      |
| Piperacillin Tazobactam     | 100.0%                 |       |        | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Tigecycline *               | 40.0%                  | 60.0% |        | 4                 | 4                 | 1      | 4      |
| Tobramycin                  | 100.0%                 |       |        | ≤ 0.5             | 1                 | ≤ 0.5  | 1      |
| Trimethoprim Sulfa          | 100.0%                 |       |        | ≤ 0.12            | 1                 | ≤ 0.12 | 1      |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. pyogenes* Susceptibility - Quebec

### ***Streptococcus pyogenes* (4)**

| Drug                        | Susceptibility |         |       | Range             |                   |         |         |
|-----------------------------|----------------|---------|-------|-------------------|-------------------|---------|---------|
|                             | % Sus          | % Int   | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min     | Max     |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06  |
| Ceftriaxone                 | 100.0%         |         |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12  |
| Cefuroxime                  | No Breakpoints | Defined |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | ≤ 0.25  |
| Chloramphenicol             | 100.0%         |         |       | 2                 | 4                 | 1       | 4       |
| Ciprofloxacin               | No Breakpoints | Defined |       | 0.5               | 0.5               | 0.12    | 0.5     |
| Clarithromycin              | 100.0%         |         |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03  |
| Clindamycin                 | 100.0%         |         |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12  |
| Daptomycin                  | 100.0%         |         |       | 0.06              | 0.12              | 0.06    | 0.12    |
| Doripenem                   | 100.0%         |         |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03  |
| Doxycycline                 | No Breakpoints | Defined |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | ≤ 0.25  |
| Ertapenem                   | 100.0%         |         |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06  |
| Imipenem                    | No Breakpoints | Defined |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03  |
| Levofloxacin                | 100.0%         |         |       | 0.5               | 0.5               | 0.25    | 0.5     |
| Linezolid                   | 100.0%         |         |       | 1                 | 2                 | 1       | 2       |
| Meropenem                   | 100.0%         |         |       | ≤ 0.06            | 0.12              | ≤ 0.06  | 0.12    |
| Moxifloxacin                | No Breakpoints | Defined |       | 0.12              | 0.12              | ≤ 0.06  | 0.12    |
| Penicillin                  | 100.0%         |         |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03  |
| Piperacillin Tazobactam     | No Breakpoints | Defined |       | ≤ 1               | ≤ 1               | ≤ 1     | ≤ 1     |
| Telithromycin               | No Breakpoints | Defined |       | 0.008             | 0.008             | 0.004   | 0.008   |
| Tigecycline *               | 100.0%         |         |       | ≤ 0.015           | ≤ 0.015           | ≤ 0.015 | ≤ 0.015 |
| Trimethoprim Sulfa          | No Breakpoints | Defined |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12  |
| Vancomycin                  | 100.0%         |         |       | 0.25              | 0.5               | 0.25    | 0.5     |

\*Interpretive breakpoints defined by FDA (tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *C. freundii* Susceptibility - Quebec

### ***Citrobacter freundii* (1)**

| Drug                        | Susceptibility         |        |        | Range             |                   |        |        |
|-----------------------------|------------------------|--------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int  | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |        |        | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Amoxicillin Clavulanic Acid |                        | 100.0% |        | 16                | 16                | 16     | 16     |
| Aztreonam                   | 100.0%                 |        |        | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Cefazolin                   |                        | 100.0% |        | 4                 | 4                 | 4      | 4      |
| Cefepime                    | 100.0%                 |        |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   |                        |        | 100.0% | 32                | 32                | 32     | 32     |
| Ceftazidime                 | 100.0%                 |        |        | 0.5               | 0.5               | 0.5    | 0.5    |
| Ceftriaxone                 | 100.0%                 |        |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Ciprofloxacin               | 100.0%                 |        |        | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Colistin                    | No Breakpoints Defined |        |        | 0.25              | 0.25              | 0.25   | 0.25   |
| Doripenem                   | 100.0%                 |        |        | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Doxycycline                 | 100.0%                 |        |        | 2                 | 2                 | 2      | 2      |
| Ertapenem                   | 100.0%                 |        |        | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Gentamicin                  | 100.0%                 |        |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |        |        | 0.5               | 0.5               | 0.5    | 0.5    |
| Meropenem                   | 100.0%                 |        |        | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Moxifloxacin *              | 100.0%                 |        |        | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Piperacillin Tazobactam     | 100.0%                 |        |        | 2                 | 2                 | 2      | 2      |
| Tigecycline *               | 100.0%                 |        |        | 0.5               | 0.5               | 0.5    | 0.5    |
| Tobramycin                  | 100.0%                 |        |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Trimethoprim Sulfa          | 100.0%                 |        |        | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

# CANWARD 2012

## *A. baumannii* Susceptibility - Quebec

### ***Acinetobacter baumannii* (1)**

| Drug                        | Susceptibility         |        |       | Range             |                   |        |        |
|-----------------------------|------------------------|--------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int  | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |        |       | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |        |       | 16                | 16                | 16     | 16     |
| Aztreonam                   | No Breakpoints Defined |        |       | 32                | 32                | 32     | 32     |
| Cefazolin                   |                        |        |       | > 128             | > 128             | > 128  | > 128  |
| Cefepime                    | 100.0%                 |        |       | 2                 | 2                 | 2      | 2      |
| Cefoxitin                   | No Breakpoints Defined |        |       | > 32              | > 32              | > 32   | > 32   |
| Ceftazidime                 | 100.0%                 |        |       | 8                 | 8                 | 8      | 8      |
| Ceftriaxone                 |                        | 100.0% |       | 16                | 16                | 16     | 16     |
| Ciprofloxacin               | 100.0%                 |        |       | 0.12              | 0.12              | 0.12   | 0.12   |
| Colistin                    | 100.0%                 |        |       | 1                 | 1                 | 1      | 1      |
| Doripenem                   | No Breakpoints Defined |        |       | 0.12              | 0.12              | 0.12   | 0.12   |
| Doxycycline                 | 100.0%                 |        |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Ertapenem                   | No Breakpoints Defined |        |       | 4                 | 4                 | 4      | 4      |
| Gentamicin                  | 100.0%                 |        |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |        |       | 0.12              | 0.12              | 0.12   | 0.12   |
| Meropenem                   | 100.0%                 |        |       | 0.25              | 0.25              | 0.25   | 0.25   |
| Moxifloxacin                | No Breakpoints Defined |        |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Piperacillin Tazobactam     | 100.0%                 |        |       | 4                 | 4                 | 4      | 4      |
| Tigecycline                 | No Breakpoints Defined |        |       | 0.12              | 0.12              | 0.12   | 0.12   |
| Tobramycin                  | 100.0%                 |        |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Trimethoprim Sulfa          | 100.0%                 |        |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |

# CANWARD 2012

## *S. aureus*, MSSA Susceptibility - Maritimes

### ***Staphylococcus aureus* , MSSA (108)**

| Drug                        | Susceptibility |         |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|----------------|---------|-------|-------------------|-------------------|--------|------|
|                             | % Sus          | % Int   | % Res |                   |                   | Min    | Max  |
| Amikacin                    | 100.0%         |         |       | 4                 | 4                 | ≤ 1    | 8    |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |       | 0.5               | 1                 | 0.12   | 1    |
| Aztreonam                   | No Breakpoints | Defined |       | > 64              | > 64              | 64     | > 64 |
| Cefazolin                   | No Breakpoints | Defined |       | ≤ 0.5             | 1                 | ≤ 0.5  | 1    |
| Cefepime                    | No Breakpoints | Defined |       | 2                 | 4                 | 1      | 4    |
| Cefoxitin                   | 100.0%         |         |       | 4                 | 4                 | 1      | 4    |
| Ceftazidime                 | No Breakpoints | Defined |       | 16                | 32                | 8      | 32   |
| Ceftriaxone                 | No Breakpoints | Defined |       | 4                 | 4                 | 2      | 8    |
| Ciprofloxacin               | 91.7%          | 0.9%    | 7.4%  | 0.5               | 1                 | 0.12   | > 16 |
| Clarithromycin              | 79.6%          |         | 20.4% | 0.25              | > 32              | 0.12   | > 32 |
| Clindamycin                 | 95.4%          |         | 4.6%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8  |
| Colistin                    | No Breakpoints | Defined |       | > 16              | > 16              | > 16   | > 16 |
| Daptomycin                  | 100.0%         |         |       | 0.25              | 0.5               | 0.12   | 0.5  |
| Doripenem                   | No Breakpoints | Defined |       | 0.06              | 0.06              | ≤ 0.03 | 0.25 |
| Doxycycline                 | 99.1%          | 0.9%    |       | ≤ 0.12            | 0.25              | ≤ 0.12 | 8    |
| Ertapenem                   | No Breakpoints | Defined |       | 0.5               | 0.5               | 0.25   | 0.5  |
| Gentamicin                  | 100.0%         |         |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 1    |
| Imipenem                    | No Breakpoints | Defined |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.06 |
| Linezolid                   | 100.0%         |         |       | 2                 | 4                 | 1      | 4    |
| Meropenem                   | No Breakpoints | Defined |       | 0.12              | 0.25              | ≤ 0.03 | 0.5  |
| Moxifloxacin                | 94.4%          |         | 5.6%  | ≤ 0.06            | 0.12              | ≤ 0.06 | > 16 |
| Piperacillin Tazobactam     | No Breakpoints | Defined |       | ≤ 1               | ≤ 1               | ≤ 1    | 2    |
| Tigecycline *               | 100.0%         |         |       | 0.12              | 0.25              | 0.12   | 0.5  |
| Tobramycin                  | 100.0%         |         |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 1    |
| Trimethoprim Sulfa          | 98.1%          |         | 1.9%  | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 8  |
| Vancomycin                  | 100.0%         |         |       | 1                 | 1                 | 0.5    | 1    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. coli* Susceptibility - Maritimes

### *Escherichia coli* (90)

| Drug                        | Susceptibility         |       |       |                   | Range             |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 98.9%                  | 1.1%  |       | 2                 | 4                 | ≤ 1    | 32    |
| Amoxicillin Clavulanic Acid | 80.0%                  | 13.3% | 6.7%  | 4                 | 16                | 1      | > 32  |
| Aztreonam                   | 95.6%                  |       | 4.4%  | ≤ 0.12            | 0.25              | ≤ 0.12 | 64    |
| Cefazolin                   | 66.7%                  | 17.8% | 15.6% | 2                 | 8                 | 1      | > 128 |
| Cefepime                    | 96.7%                  | 3.3%  |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 16    |
| Cefoxitin                   | 90.0%                  | 5.6%  | 4.4%  | 4                 | 8                 | 1      | > 32  |
| Ceftazidime                 | 95.6%                  |       | 4.4%  | ≤ 0.25            | 1                 | ≤ 0.25 | > 32  |
| Ceftriaxone                 | 94.4%                  |       | 5.6%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | > 64  |
| Ciprofloxacin               | 77.8%                  | 1.1%  | 21.1% | ≤ 0.06            | > 16              | ≤ 0.06 | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.25              | ≤ 0.06 | > 16  |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12  |
| Doxycycline                 | 77.8%                  | 3.3%  | 18.9% | 2                 | 32                | 0.5    | > 32  |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.5   |
| Gentamicin                  | 91.1%                  | 1.1%  | 7.8%  | ≤ 0.5             | 2                 | ≤ 0.5  | > 32  |
| Imipenem                    | 100.0%                 |       |       | 0.12              | 0.25              | 0.06   | 1     |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | 0.12  |
| Moxifloxacin *              | 77.8%                  |       | 22.2% | ≤ 0.06            | 16                | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | 96.7%                  | 2.2%  | 1.1%  | ≤ 1               | 4                 | ≤ 1    | > 512 |
| Tigecycline *               | 100.0%                 |       |       | 0.25              | 0.25              | 0.12   | 1     |
| Tobramycin                  | 93.3%                  | 4.4%  | 2.2%  | ≤ 0.5             | 1                 | ≤ 0.5  | 32    |
| Trimethoprim Sulfa          | 72.2%                  |       | 27.8% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *P. aeruginosa* Susceptibility - Maritimes

### ***Pseudomonas aeruginosa* (50)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max   |
| Amikacin                    | 98.0%                  |       | 2.0%  | 4                 | 16                | ≤ 1    | > 64  |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | > 32              | > 32              | 16     | > 32  |
| Aztreonam                   | 88.0%                  | 4.0%  | 8.0%  | 4                 | 16                | ≤ 0.12 | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | 128    | > 128 |
| Cefepime                    | 94.0%                  | 2.0%  | 4.0%  | 2                 | 8                 | ≤ 0.25 | 32    |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Ceftazidime                 | 84.0%                  | 4.0%  | 12.0% | 4                 | 32                | ≤ 0.25 | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |       | 16                | > 64              | 1      | > 64  |
| Ciprofloxacin               | 88.0%                  | 4.0%  | 8.0%  | 0.12              | 2                 | ≤ 0.06 | 16    |
| Colistin                    | 98.0%                  | 2.0%  |       | 1                 | 1                 | 0.25   | 4     |
| Doripenem                   | 92.0%                  | 4.0%  | 4.0%  | 0.25              | 2                 | ≤ 0.03 | 8     |
| Doxycycline                 | No Breakpoints Defined |       |       | 16                | 32                | 1      | > 32  |
| Ertapenem                   | No Breakpoints Defined |       |       | 8                 | > 32              | 0.12   | > 32  |
| Gentamicin                  | 90.0%                  | 8.0%  | 2.0%  | 2                 | 4                 | ≤ 0.5  | > 32  |
| Imipenem                    | 76.0%                  | 14.0% | 10.0% | 2                 | 4                 | 0.5    | 32    |
| Meropenem                   | 86.0%                  | 10.0% | 4.0%  | 0.5               | 4                 | ≤ 0.03 | 8     |
| Moxifloxacin                | No Breakpoints Defined |       |       | 2                 | 8                 | 0.12   | > 16  |
| Piperacillin Tazobactam     | 88.0%                  | 6.0%  | 6.0%  | 4                 | 32                | ≤ 1    | 512   |
| Tigecycline                 | No Breakpoints Defined |       |       | 16                | 16                | 1      | > 16  |
| Tobramycin                  | 98.0%                  |       | 2.0%  | ≤ 0.5             | 2                 | ≤ 0.5  | 32    |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | 8                 | > 8               | 0.5    | > 8   |



# CANWARD 2012

## *K. pneumoniae* Susceptibility - Maritimes

### ***Klebsiella pneumoniae* (30)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max  |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | ≤ 1               | ≤ 1    | 2    |
| Amoxicillin Clavulanic Acid | 100.0%                 |       |       | 2                 | 8                 | 2      | 8    |
| Aztreonam                   | 100.0%                 |       |       | ≤ 0.12            | 0.25              | ≤ 0.12 | 0.5  |
| Cefazolin                   | 90.0%                  | 6.7%  | 3.3%  | 1                 | 2                 | 1      | 8    |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 0.5  |
| Cefoxitin                   | 90.0%                  | 3.3%  | 6.7%  | 4                 | 8                 | 2      | > 32 |
| Ceftazidime                 | 100.0%                 |       |       | ≤ 0.25            | 1                 | ≤ 0.25 | 4    |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | 0.5  |
| Ciprofloxacin               | 100.0%                 |       |       | ≤ 0.06            | 0.25              | ≤ 0.06 | 0.5  |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.12   | > 16 |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.12 |
| Doxycycline                 | 76.7%                  | 3.3%  | 20.0% | 2                 | 32                | 1      | 32   |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.12 |
| Gentamicin                  | 96.7%                  |       | 3.3%  | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 16   |
| Imipenem                    | 96.7%                  | 3.3%  |       | 0.25              | 0.25              | 0.12   | 2    |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.06 |
| Moxifloxacin *              | 100.0%                 |       |       | 0.12              | 1                 | ≤ 0.06 | 1    |
| Piperacillin Tazobactam     | 100.0%                 |       |       | 2                 | 8                 | ≤ 1    | 16   |
| Tigecycline *               | 90.0%                  | 6.7%  | 3.3%  | 0.5               | 2                 | 0.25   | 8    |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | 4    |
| Trimethoprim Sulfa          | 96.7%                  |       | 3.3%  | ≤ 0.12            | 0.5               | ≤ 0.12 | > 8  |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. pneumoniae* Susceptibility - Maritimes

### ***Streptococcus pneumoniae* (20)**

| Drug                        | Susceptibility         |       |       | Range             |                   |         |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|---------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min     | Max    |
| Amoxicillin Clavulanic Acid | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | 0.25   |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | 0.25   |
| Cefuroxime                  | 100.0%                 |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | ≤ 0.25 |
| Chloramphenicol             | 100.0%                 |       |       | 2                 | 4                 | 0.5     | 4      |
| Ciprofloxacin               | 95.0%                  |       | 5.0%  | 1                 | 2                 | 0.12    | 4      |
| Clarithromycin              | 80.0%                  | 5.0%  | 15.0% | ≤ 0.03            | 2                 | ≤ 0.03  | 4      |
| Clindamycin                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12 |
| Daptomycin                  | No Breakpoints Defined |       |       | 0.12              | 0.12              | ≤ 0.03  | 0.25   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | 0.12   |
| Doxycycline                 | 95.0%                  |       | 5.0%  | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | 2      |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | 0.12   |
| Imipenem                    | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | 0.06   |
| Levofloxacin                | 100.0%                 |       |       | 1                 | 1                 | ≤ 0.06  | 2      |
| Linezolid                   | 100.0%                 |       |       | 1                 | 1                 | ≤ 0.12  | 2      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | 0.12   |
| Moxifloxacin                | 100.0%                 |       |       | 0.12              | 0.25              | ≤ 0.06  | 0.25   |
| Penicillin                  | 89.5%                  | 10.5% |       | ≤ 0.03            | 0.25              | ≤ 0.03  | 0.25   |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1     | ≤ 1    |
| Telithromycin               | 100.0%                 |       |       | 0.008             | 0.06              | ≤ 0.002 | 0.25   |
| Tigecycline                 | 100.0%                 |       |       | ≤ 0.015           | 0.03              | ≤ 0.015 | 0.03   |
| Trimethoprim Sulfa          | 90.0%                  | 10.0% |       | ≤ 0.12            | 0.5               | ≤ 0.12  | 2      |
| Vancomycin                  | 100.0%                 |       |       | 0.25              | 0.25              | ≤ 0.12  | 0.5    |

\*Interpretive breakpoints defined by FDA (tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. aureus*, MRSA Susceptibility - Maritimes

### *Staphylococcus aureus*, MRSA (15)

| Drug                        | Susceptibility         |       |        | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |       |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res  |                   |                   | Min    | Max   |
| Amikacin                    | 93.3%                  | 6.7%  |        | 16                | 16                | 2      | 32    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |        | 16                | 32                | 8      | 32    |
| Aztreonam                   | No Breakpoints Defined |       |        | > 64              | > 64              | > 64   | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |        | 64                | > 128             | 2      | > 128 |
| Cefepime                    | No Breakpoints Defined |       |        | > 64              | > 64              | 16     | > 64  |
| Cefoxitin                   |                        |       | 100.0% | > 32              | > 32              | 32     | > 32  |
| Ceftazidime                 | No Breakpoints Defined |       |        | > 32              | > 32              | > 32   | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |        | > 64              | > 64              | 32     | > 64  |
| Ciprofloxacin               | 6.7%                   |       | 93.3%  | > 16              | > 16              | 0.25   | > 16  |
| Clarithromycin              | 20.0%                  |       | 80.0%  | > 32              | > 32              | 0.12   | > 32  |
| Clindamycin                 | 80.0%                  |       | 20.0%  | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | > 16   | > 16  |
| Daptomycin                  | 100.0%                 |       |        | 0.25              | 0.5               | 0.25   | 0.5   |
| Doripenem                   | No Breakpoints Defined |       |        | 2                 | 16                | 0.12   | 32    |
| Doxycycline                 | 100.0%                 |       |        | ≤ 0.12            | 0.25              | ≤ 0.12 | 0.25  |
| Ertapenem                   | No Breakpoints Defined |       |        | 16                | > 32              | 1      | > 32  |
| Gentamicin                  | 100.0%                 |       |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5 |
| Imipenem                    | No Breakpoints Defined |       |        | 1                 | 32                | 0.12   | > 32  |
| Linezolid                   | 100.0%                 |       |        | 2                 | 2                 | 1      | 2     |
| Meropenem                   | No Breakpoints Defined |       |        | 4                 | 16                | 0.5    | > 32  |
| Moxifloxacin                | 6.7%                   | 13.3% | 80.0%  | 8                 | > 16              | ≤ 0.06 | > 16  |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |        | 32                | 128               | 4      | 128   |
| Tigecycline *               | 100.0%                 |       |        | 0.12              | 0.12              | 0.12   | 0.25  |
| Tobramycin                  | 46.7%                  |       | 53.3%  | > 64              | > 64              | ≤ 0.5  | > 64  |
| Trimethoprim Sulfa          | 86.7%                  |       | 13.3%  | ≤ 0.12            | > 8               | ≤ 0.12 | > 8   |
| Vancomycin                  | 100.0%                 |       |        | 1                 | 1                 | 0.5    | 1     |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. faecalis* Susceptibility - Maritimes

### ***Enterococcus faecalis* (15)**

| Drug                        | Susceptibility |         |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|----------------|---------|-------|-------------------|-------------------|--------|------|
|                             | % Sus          | % Int   | % Res |                   |                   | Min    | Max  |
| Amikacin                    | No Breakpoints | Defined |       | > 64              | > 64              | 64     | > 64 |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |       | 0.5               | 1                 | 0.25   | 1    |
| Aztreonam                   | No Breakpoints | Defined |       | > 64              | > 64              | > 64   | > 64 |
| Cefazolin                   | No Breakpoints | Defined |       | 32                | 32                | 4      | 64   |
| Cefepime                    | No Breakpoints | Defined |       | 64                | > 64              | 8      | > 64 |
| Cefoxitin                   | No Breakpoints | Defined |       | > 32              | > 32              | > 32   | > 32 |
| Ceftazidime                 | No Breakpoints | Defined |       | > 32              | > 32              | > 32   | > 32 |
| Ceftriaxone                 | No Breakpoints | Defined |       | > 64              | > 64              | 4      | > 64 |
| Ciprofloxacin               | 53.3%          | 6.7%    | 40.0% | 1                 | > 16              | 0.5    | > 16 |
| Clarithromycin              | No Breakpoints | Defined |       | > 32              | > 32              | 0.12   | > 32 |
| Clindamycin                 | No Breakpoints | Defined |       | > 8               | > 8               | 1      | > 8  |
| Colistin                    | No Breakpoints | Defined |       | > 16              | > 16              | > 16   | > 16 |
| Daptomycin                  | 100.0%         |         |       | 1                 | 1                 | 0.25   | 2    |
| Doripenem                   | No Breakpoints | Defined |       | 4                 | 4                 | 2      | 4    |
| Doxycycline                 | 46.7%          | 53.3%   |       | 8                 | 8                 | ≤ 0.12 | 8    |
| Ertapenem                   | No Breakpoints | Defined |       | 16                | 16                | 4      | 32   |
| Gentamicin                  | No Breakpoints | Defined |       | 16                | > 32              | 4      | > 32 |
| Imipenem                    | No Breakpoints | Defined |       | 1                 | 2                 | 1      | 2    |
| Linezolid                   | 100.0%         |         |       | 2                 | 2                 | 1      | 2    |
| Meropenem                   | No Breakpoints | Defined |       | 4                 | 8                 | 2      | 8    |
| Moxifloxacin                | No Breakpoints | Defined |       | 0.25              | 16                | 0.12   | > 16 |
| Piperacillin Tazobactam     | No Breakpoints | Defined |       | 4                 | 4                 | ≤ 1    | 8    |
| Tigecycline *               | 100.0%         |         |       | 0.12              | 0.12              | 0.06   | 0.12 |
| Tobramycin                  | No Breakpoints | Defined |       | 16                | > 64              | 8      | > 64 |
| Trimethoprim Sulfa          | No Breakpoints | Defined |       | ≤ 0.12            | 0.5               | ≤ 0.12 | 2    |
| Vancomycin                  | 100.0%         |         |       | 1                 | 2                 | 1      | 2    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *E. cloacae* Susceptibility - Maritimes

### ***Enterobacter cloacae* (8)**

| Drug                        | Susceptibility         |       |        |                   | Range             |        |        |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |        | ≤ 1               | 2                 | ≤ 1    | 2      |
| Amoxicillin Clavulanic Acid |                        |       | 100.0% | > 32              | > 32              | 32     | > 32   |
| Aztreonam                   | 62.5%                  |       | 37.5%  | ≤ 0.12            | 32                | ≤ 0.12 | 32     |
| Cefazolin                   |                        |       | 100.0% | > 128             | > 128             | 64     | > 128  |
| Cefepime                    | 100.0%                 |       |        | ≤ 0.25            | 2                 | ≤ 0.25 | 2      |
| Cefoxitin                   |                        |       | 100.0% | > 32              | > 32              | 32     | > 32   |
| Ceftazidime                 | 62.5%                  |       | 37.5%  | 0.5               | > 32              | ≤ 0.25 | > 32   |
| Ceftriaxone                 | 62.5%                  |       | 37.5%  | ≤ 0.25            | > 64              | ≤ 0.25 | > 64   |
| Ciprofloxacin               | 100.0%                 |       |        | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Colistin                    | No Breakpoints Defined |       |        | 0.25              | > 16              | 0.12   | > 16   |
| Doripenem                   | 100.0%                 |       |        | 0.06              | 0.12              | 0.06   | 0.12   |
| Doxycycline                 | 100.0%                 |       |        | 2                 | 4                 | 2      | 4      |
| Ertapenem                   | 100.0%                 |       |        | 0.12              | 0.5               | ≤ 0.03 | 0.5    |
| Gentamicin                  | 100.0%                 |       |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |       |        | 0.5               | 1                 | 0.25   | 1      |
| Meropenem                   | 100.0%                 |       |        | 0.06              | 0.25              | ≤ 0.03 | 0.25   |
| Moxifloxacin *              | 100.0%                 |       |        | ≤ 0.06            | 0.12              | ≤ 0.06 | 0.12   |
| Piperacillin Tazobactam     | 75.0%                  | 12.5% | 12.5%  | 2                 | 128               | ≤ 1    | 128    |
| Tigecycline *               | 100.0%                 |       |        | 0.5               | 0.5               | 0.25   | 0.5    |
| Tobramycin                  | 100.0%                 |       |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Trimethoprim Sulfa          | 87.5%                  |       | 12.5%  | ≤ 0.12            | > 8               | ≤ 0.12 | > 8    |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *S. epidermidis* Susceptibility - Maritimes

### ***Staphylococcus epidermidis* (10)**

| Drug                        | Susceptibility         |       |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |      |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|------|
|                             | % Sus                  | % Int | % Res |                   |                   | Min    | Max  |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1  |
| Amoxicillin Clavulanic Acid | 100.0%                 |       |       | 1                 | 2                 | ≤ 0.06 | 4    |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | 64     | > 64 |
| Cefazolin                   | 100.0%                 |       |       | 2                 | 2                 | ≤ 0.5  | 4    |
| Cefepime                    | 80.0%                  | 20.0% |       | 4                 | 16                | 0.5    | 16   |
| Cefoxitin                   | No Breakpoints Defined |       |       | 8                 | 16                | 1      | 16   |
| Ceftazidime                 | 30.0%                  | 20.0% | 50.0% | 16                | > 32              | 4      | > 32 |
| Ceftriaxone                 | 40.0%                  | 50.0% | 10.0% | 16                | 32                | 1      | 64   |
| Ciprofloxacin               | 40.0%                  |       | 60.0% | 4                 | > 16              | 0.12   | > 16 |
| Clarithromycin              | 40.0%                  |       | 60.0% | > 32              | > 32              | ≤ 0.03 | > 32 |
| Clindamycin                 | 80.0%                  |       | 20.0% | ≤ 0.12            | > 8               | ≤ 0.12 | > 8  |
| Colistin                    | No Breakpoints Defined |       |       | > 16              | > 16              | 16     | > 16 |
| Daptomycin                  | 100.0%                 |       |       | 0.25              | 0.25              | ≤ 0.03 | 0.5  |
| Doripenem                   | No Breakpoints Defined |       |       | 1                 | 4                 | ≤ 0.03 | 8    |
| Doxycycline                 | 100.0%                 |       |       | 0.25              | 1                 | ≤ 0.12 | 1    |
| Ertapenem                   | 40.0%                  |       | 60.0% | 8                 | 16                | 0.5    | > 32 |
| Gentamicin                  | 80.0%                  | 10.0% | 10.0% | ≤ 0.5             | 8                 | ≤ 0.5  | 32   |
| Imipenem                    | 90.0%                  |       | 10.0% | 0.25              | 1                 | ≤ 0.03 | 16   |
| Linezolid                   | 100.0%                 |       |       | 1                 | 1                 | 0.25   | 1    |
| Meropenem                   | No Breakpoints Defined |       |       | 2                 | 4                 | 0.06   | 8    |
| Moxifloxacin                | 50.0%                  | 10.0% | 40.0% | 0.5               | > 16              | ≤ 0.06 | > 16 |
| Piperacillin Tazobactam     | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 2    |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.12              | 0.25              | 0.06   | 0.25 |
| Tobramycin                  | 90.0%                  | 10.0% |       | ≤ 0.5             | 2                 | ≤ 0.5  | 8    |
| Trimethoprim Sulfa          | 70.0%                  |       | 30.0% | ≤ 0.12            | 8                 | ≤ 0.12 | 8    |
| Vancomycin                  | 100.0%                 |       |       | 1                 | 2                 | 1      | 2    |

# CANWARD 2012

## *S. marcescens* Susceptibility - Maritimes

### *Serratia marcescens* (14)

| Drug                        | Susceptibility         |       |        |                   | Range             |        |        |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |        | 2                 | 4                 | ≤ 1    | 8      |
| Amoxicillin Clavulanic Acid |                        |       | 92.9%  | > 32              | > 32              | 4      | > 32   |
| Aztreonam                   |                        |       |        | ≤ 0.12            | 0.25              | ≤ 0.12 | 0.25   |
| Cefazolin                   |                        |       | 100.0% | > 128             | > 128             | > 128  | > 128  |
| Cefepime                    | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   |                        | 64.3% | 7.1%   | 16                | 16                | 8      | 32     |
| Ceftazidime                 | 100.0%                 |       |        | ≤ 0.25            | 0.5               | ≤ 0.25 | 1      |
| Ceftriaxone                 | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Ciprofloxacin               | 100.0%                 |       |        | ≤ 0.06            | 0.25              | ≤ 0.06 | 0.5    |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | 0.5    | > 16   |
| Doripenem                   | 100.0%                 |       |        | 0.12              | 0.25              | 0.06   | 0.25   |
| Doxycycline                 | 64.3%                  | 14.3% | 21.4%  | 4                 | 16                | 2      | 16     |
| Ertapenem                   | 100.0%                 |       |        | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.12   |
| Gentamicin                  | 100.0%                 |       |        | ≤ 0.5             | 1                 | ≤ 0.5  | 2      |
| Imipenem                    | 100.0%                 |       |        | 0.5               | 1                 | 0.5    | 1      |
| Meropenem                   | 100.0%                 |       |        | 0.06              | 0.06              | ≤ 0.03 | 0.06   |
| Moxifloxacin *              | 100.0%                 |       |        | 0.25              | 1                 | ≤ 0.06 | 2      |
| Piperacillin Tazobactam     | 100.0%                 |       |        | ≤ 1               | 4                 | ≤ 1    | 4      |
| Tigecycline *               | 100.0%                 |       |        | 1                 | 2                 | 1      | 2      |
| Tobramycin                  | 100.0%                 |       |        | 1                 | 4                 | ≤ 0.5  | 4      |
| Trimethoprim Sulfa          | 100.0%                 |       |        | 0.25              | 0.5               | 0.25   | 2      |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

# CANWARD 2012

## *K. oxytoca* Susceptibility - Maritimes

### ***Klebsiella oxytoca* (8)**

| Drug                        | Susceptibility         |       |       |                   | Range             |        |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 2      |
| Amoxicillin Clavulanic Acid | 75.0%                  | 12.5% | 12.5% | 4                 | 32                | 2      | 32     |
| Aztreonam                   | 75.0%                  |       | 25.0% | ≤ 0.12            | 64                | ≤ 0.12 | 64     |
| Cefazolin                   | 37.5%                  | 25.0% | 37.5% | 4                 | > 128             | 2      | > 128  |
| Cefepime                    | 100.0%                 |       |       | ≤ 0.25            | 0.5               | ≤ 0.25 | 0.5    |
| Cefoxitin                   | 100.0%                 |       |       | 2                 | 8                 | 1      | 8      |
| Ceftazidime                 | 100.0%                 |       |       | ≤ 0.25            | 1                 | ≤ 0.25 | 1      |
| Ceftriaxone                 | 75.0%                  | 12.5% | 12.5% | ≤ 0.25            | 4                 | ≤ 0.25 | 4      |
| Ciprofloxacin               | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Colistin                    | No Breakpoints Defined |       |       | 0.25              | 0.25              | 0.25   | 0.25   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.06   |
| Doxycycline                 | 100.0%                 |       |       | 2                 | 4                 | 1      | 4      |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.06   |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.5               | 0.25   | 0.5    |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Moxifloxacin *              | 100.0%                 |       |       | ≤ 0.06            | 0.12              | ≤ 0.06 | 0.12   |
| Piperacillin Tazobactam     | 75.0%                  |       | 25.0% | 2                 | 512               | ≤ 1    | 512    |
| Tigecycline *               | 100.0%                 |       |       | 0.25              | 1                 | 0.25   | 1      |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Trimethoprim Sulfa          | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)



# CANWARD 2012

## *S. maltophilia* Susceptibility - Maritimes

### ***Stenotrophomonas maltophilia* (9)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    |                        |       |       | 32                | > 64              | 8      | > 64  |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | > 32              | > 32              | 32     | > 32  |
| Aztreonam                   | No Breakpoints Defined |       |       | > 64              | > 64              | > 64   | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | > 128  | > 128 |
| Cefepime                    | No Breakpoints Defined |       |       | 32                | > 64              | 16     | > 64  |
| Cefoxitin                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Ceftazidime                 |                        | 33.3% | 66.7% | > 32              | > 32              | 16     | > 32  |
| Ceftriaxone                 | No Breakpoints Defined |       |       | > 64              | > 64              | > 64   | > 64  |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 8                 | > 16              | 1      | > 16  |
| Colistin                    | No Breakpoints Defined |       |       | 8                 | > 16              | 1      | > 16  |
| Doripenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Doxycycline                 | No Breakpoints Defined |       |       | 2                 | 16                | 2      | 16    |
| Ertapenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Gentamicin                  | No Breakpoints Defined |       |       | 8                 | > 32              | 2      | > 32  |
| Imipenem                    | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Meropenem                   | No Breakpoints Defined |       |       | > 32              | > 32              | > 32   | > 32  |
| Moxifloxacin                | No Breakpoints Defined |       |       | 1                 | > 16              | 0.12   | > 16  |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | 256               | > 512             | 64     | > 512 |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.5               | 4                 | 0.25   | 4     |
| Tobramycin                  | No Breakpoints Defined |       |       | 8                 | > 64              | 2      | > 64  |
| Trimethoprim Sulfa          | 55.6%                  |       | 44.4% | 1                 | > 8               | ≤ 0.12 | > 8   |

# CANWARD 2012

## *E. faecium* Susceptibility - Maritimes

### ***Enterococcus faecium* (5)**

| Drug                        | Susceptibility |         |       | MIC <sub>50</sub> | MIC <sub>90</sub> | Range  |       |
|-----------------------------|----------------|---------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus          | % Int   | % Res |                   |                   | Min    | Max   |
| Amikacin                    | No Breakpoints | Defined |       | 16                | 16                | 16     | 16    |
| Amoxicillin Clavulanic Acid | No Breakpoints | Defined |       | > 32              | > 32              | 0.12   | > 32  |
| Aztreonam                   | No Breakpoints | Defined |       | > 64              | > 64              | 64     | > 64  |
| Cefazolin                   | No Breakpoints | Defined |       | > 128             | > 128             | 16     | > 128 |
| Cefepime                    | No Breakpoints | Defined |       | > 64              | > 64              | 4      | > 64  |
| Cefoxitin                   | No Breakpoints | Defined |       | > 32              | > 32              | 16     | > 32  |
| Ceftazidime                 | No Breakpoints | Defined |       | > 32              | > 32              | > 32   | > 32  |
| Ceftriaxone                 | No Breakpoints | Defined |       | > 64              | > 64              | 4      | > 64  |
| Ciprofloxacin               | 40.0%          |         | 60.0% | > 16              | > 16              | 0.5    | > 16  |
| Clarithromycin              | No Breakpoints | Defined |       | > 32              | > 32              | 2      | > 32  |
| Clindamycin                 | No Breakpoints | Defined |       | > 8               | > 8               | 8      | > 8   |
| Colistin                    | No Breakpoints | Defined |       | > 16              | > 16              | > 16   | > 16  |
| Daptomycin                  | 100.0%         |         |       | 2                 | 2                 | 1      | 2     |
| Doripenem                   | No Breakpoints | Defined |       | > 32              | > 32              | 1      | > 32  |
| Doxycycline                 | 80.0%          | 20.0%   |       | ≤ 0.12            | 8                 | ≤ 0.12 | 8     |
| Ertapenem                   | No Breakpoints | Defined |       | > 32              | > 32              | 4      | > 32  |
| Gentamicin                  | No Breakpoints | Defined |       | 8                 | 8                 | 8      | 8     |
| Imipenem                    | No Breakpoints | Defined |       | > 32              | > 32              | 0.5    | > 32  |
| Linezolid                   | 80.0%          | 20.0%   |       | 2                 | 4                 | 1      | 4     |
| Meropenem                   | No Breakpoints | Defined |       | > 32              | > 32              | 2      | > 32  |
| Moxifloxacin                | No Breakpoints | Defined |       | 16                | > 16              | 0.25   | > 16  |
| Piperacillin Tazobactam     | No Breakpoints | Defined |       | > 512             | > 512             | 4      | > 512 |
| Tigecycline                 | No Breakpoints | Defined |       | 0.06              | 0.06              | 0.06   | 0.06  |
| Tobramycin                  | No Breakpoints | Defined |       | > 64              | > 64              | > 64   | > 64  |
| Trimethoprim Sulfa          | No Breakpoints | Defined |       | 0.5               | > 8               | ≤ 0.12 | > 8   |
| Vancomycin                  | 100.0%         |         |       | 0.5               | 1                 | 0.5    | 1     |

# CANWARD 2012

## *S. agalactiae* Susceptibility - Maritimes

### ***Streptococcus agalactiae* (10)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | ≤ 0.06            | 0.12              | ≤ 0.06 | 0.12   |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Cefuroxime                  | No Breakpoints Defined |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Chloramphenicol             | 100.0%                 |       |       | 4                 | 4                 | 2      | 4      |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 0.5               | > 16              | 0.5    | > 16   |
| Clarithromycin              | 80.0%                  |       | 20.0% | ≤ 0.03            | > 32              | ≤ 0.03 | > 32   |
| Clindamycin                 | 90.0%                  |       | 10.0% | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | > 64   |
| Daptomycin                  | 100.0%                 |       |       | 0.12              | 0.25              | 0.12   | 0.25   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Doxycycline                 | No Breakpoints Defined |       |       | 8                 | 16                | ≤ 0.25 | 16     |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.06            | 0.12              | ≤ 0.06 | 0.12   |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Levofloxacin                | 80.0%                  |       | 20.0% | 1                 | 32                | 0.5    | 32     |
| Linezolid                   | 100.0%                 |       |       | 2                 | 2                 | 1      | 2      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.12              | 4                 | 0.12   | 4      |
| Penicillin                  | 100.0%                 |       |       | 0.06              | 0.06              | ≤ 0.03 | 0.06   |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Telithromycin               | No Breakpoints Defined |       |       | 0.015             | 0.015             | 0.015  | 1      |
| Tigecycline *               | 100.0%                 |       |       | 0.06              | 0.06              | 0.03   | 0.06   |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | 1      |
| Vancomycin                  | 100.0%                 |       |       | 0.5               | 0.5               | 0.5    | 0.5    |

\*Interpretive breakpoints defined by FDA (tigecycline)

CANADIAN ANTIMICROBIAL  
RESISTANCE ALLIANCE



# CANWARD 2012

## *P. mirabilis* Susceptibility - Maritimes

### *Proteus mirabilis* (9)

| Drug                        | Susceptibility         |       |        | Range             |                   |        |        |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |        | 2                 | 8                 | ≤ 1    | 8      |
| Amoxicillin Clavulanic Acid | 88.9%                  |       |        | 1                 | > 32              | 0.5    | > 32   |
| Aztreonam                   | 100.0%                 |       |        | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Cefazolin                   |                        | 77.8% | 22.2%  | 4                 | > 128             | 4      | > 128  |
| Cefepime                    | 100.0%                 |       |        | ≤ 0.25            | 0.5               | ≤ 0.25 | 0.5    |
| Cefoxitin                   | 77.8%                  | 22.2% |        | 4                 | 16                | 4      | 16     |
| Ceftazidime                 | 100.0%                 |       |        | ≤ 0.25            | 4                 | ≤ 0.25 | 4      |
| Ceftriaxone                 | 88.9%                  | 11.1% |        | ≤ 0.25            | 2                 | ≤ 0.25 | 2      |
| Ciprofloxacin               | 100.0%                 |       |        | ≤ 0.06            | 0.25              | ≤ 0.06 | 0.25   |
| Colistin                    | No Breakpoints Defined |       |        | > 16              | > 16              | 16     | > 16   |
| Doripenem                   | 100.0%                 |       |        | 0.12              | 0.25              | 0.06   | 0.25   |
| Doxycycline                 |                        |       | 100.0% | > 32              | > 32              | 16     | > 32   |
| Ertapenem                   | 100.0%                 |       |        | ≤ 0.03            | ≤ 0.03            | ≤ 0.03 | ≤ 0.03 |
| Gentamicin                  | 77.8%                  | 11.1% | 11.1%  | 1                 | 16                | ≤ 0.5  | 16     |
| Imipenem                    | 33.3%                  | 44.4% | 22.2%  | 2                 | 4                 | 0.25   | 4      |
| Meropenem                   | 100.0%                 |       |        | 0.06              | 0.12              | ≤ 0.03 | 0.12   |
| Moxifloxacin *              | 100.0%                 |       |        | 0.5               | 1                 | 0.25   | 1      |
| Piperacillin Tazobactam     | 100.0%                 |       |        | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Tigecycline *               | 22.2%                  | 33.3% | 44.4%  | 4                 | 8                 | 2      | 8      |
| Tobramycin                  | 88.9%                  |       | 11.1%  | 1                 | 16                | ≤ 0.5  | 16     |
| Trimethoprim Sulfa          | 77.8%                  |       | 22.2%  | 0.25              | > 8               | ≤ 0.12 | > 8    |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

# CANWARD 2012

## *S. pyogenes* Susceptibility - Maritimes

### ***Streptococcus pyogenes* (4)**

| Drug                        | Susceptibility         |       |       | Range             |                   |         |        |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|---------|--------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min     | Max    |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06 |
| Ceftriaxone                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12 |
| Cefuroxime                  | No Breakpoints Defined |       |       | ≤ 0.25            | ≤ 0.25            | ≤ 0.25  | ≤ 0.25 |
| Chloramphenicol             | 100.0%                 |       |       | 2                 | 4                 | 2       | 4      |
| Ciprofloxacin               | No Breakpoints Defined |       |       | 0.5               | 1                 | 0.5     | 1      |
| Clarithromycin              | 75.0%                  |       | 25.0% | ≤ 0.03            | > 32              | ≤ 0.03  | > 32   |
| Clindamycin                 | 100.0%                 |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12 |
| Daptomycin                  | 100.0%                 |       |       | 0.06              | 0.12              | 0.06    | 0.12   |
| Doripenem                   | 100.0%                 |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Doxycycline                 | No Breakpoints Defined |       |       | ≤ 0.25            | 16                | ≤ 0.25  | 16     |
| Ertapenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06 |
| Imipenem                    | No Breakpoints Defined |       |       | ≤ 0.03            | ≤ 0.03            | ≤ 0.03  | ≤ 0.03 |
| Levofloxacin                | 100.0%                 |       |       | 0.5               | 1                 | 0.5     | 1      |
| Linezolid                   | 100.0%                 |       |       | 1                 | 2                 | 1       | 2      |
| Meropenem                   | 100.0%                 |       |       | ≤ 0.06            | ≤ 0.06            | ≤ 0.06  | ≤ 0.06 |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.12              | 0.25              | 0.12    | 0.25   |
| Penicillin                  | 100.0%                 |       |       | ≤ 0.03            | 0.06              | ≤ 0.03  | 0.06   |
| Piperacillin Tazobactam     | No Breakpoints Defined |       |       | ≤ 1               | ≤ 1               | ≤ 1     | ≤ 1    |
| Telithromycin               | No Breakpoints Defined |       |       | 0.008             | 0.015             | 0.004   | 0.015  |
| Tigecycline *               | 100.0%                 |       |       | 0.03              | 0.06              | ≤ 0.015 | 0.06   |
| Trimethoprim Sulfa          | No Breakpoints Defined |       |       | ≤ 0.12            | ≤ 0.12            | ≤ 0.12  | ≤ 0.12 |
| Vancomycin                  | 100.0%                 |       |       | 0.5               | 0.5               | 0.25    | 0.5    |

\*Interpretive breakpoints defined by FDA (tigecycline)

# CANWARD 2012

## *C. freundii* Susceptibility - Maritimes

### *Citrobacter freundii* (2)

| Drug                        | Susceptibility         |       |        |                   | Range             |        |        |
|-----------------------------|------------------------|-------|--------|-------------------|-------------------|--------|--------|
|                             | % Sus                  | % Int | % Res  | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max    |
| Amikacin                    | 100.0%                 |       |        | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Amoxicillin Clavulanic Acid |                        |       | 100.0% | 32                | > 32              | 32     | > 32   |
| Aztreonam                   | 100.0%                 |       |        | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |
| Cefazolin                   |                        |       | 100.0% | 32                | > 128             | 32     | > 128  |
| Cefepime                    | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Cefoxitin                   |                        |       | 100.0% | > 32              | > 32              | > 32   | > 32   |
| Ceftazidime                 | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Ceftriaxone                 | 100.0%                 |       |        | ≤ 0.25            | ≤ 0.25            | ≤ 0.25 | ≤ 0.25 |
| Ciprofloxacin               | 100.0%                 |       |        | ≤ 0.06            | ≤ 0.06            | ≤ 0.06 | ≤ 0.06 |
| Colistin                    | No Breakpoints Defined |       |        | 0.25              | 0.25              | 0.25   | 0.25   |
| Doripenem                   | 100.0%                 |       |        | 0.06              | 0.06              | 0.06   | 0.06   |
| Doxycycline                 | 100.0%                 |       |        | 2                 | 2                 | 2      | 2      |
| Ertapenem                   | 100.0%                 |       |        | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.06   |
| Gentamicin                  | 100.0%                 |       |        | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5  |
| Imipenem                    | 100.0%                 |       |        | 0.25              | 0.5               | 0.25   | 0.5    |
| Meropenem                   | 100.0%                 |       |        | ≤ 0.03            | 0.06              | ≤ 0.03 | 0.06   |
| Moxifloxacin *              | 100.0%                 |       |        | ≤ 0.06            | 0.25              | ≤ 0.06 | 0.25   |
| Piperacillin Tazobactam     | 100.0%                 |       |        | ≤ 1               | ≤ 1               | ≤ 1    | ≤ 1    |
| Tigecycline *               | 100.0%                 |       |        | 0.25              | 0.5               | 0.25   | 0.5    |
| Tobramycin                  | 100.0%                 |       |        | ≤ 0.5             | 1                 | ≤ 0.5  | 1      |
| Trimethoprim Sulfa          | 100.0%                 |       |        | ≤ 0.12            | ≤ 0.12            | ≤ 0.12 | ≤ 0.12 |

\*Interpretive breakpoints defined by FDA (moxifloxacin, tigecycline)

# CANWARD 2012

## *A. baumannii* Susceptibility - Maritimes

### ***Acinetobacter baumannii* (3)**

| Drug                        | Susceptibility         |       |       | Range             |                   |        |       |
|-----------------------------|------------------------|-------|-------|-------------------|-------------------|--------|-------|
|                             | % Sus                  | % Int | % Res | MIC <sub>50</sub> | MIC <sub>90</sub> | Min    | Max   |
| Amikacin                    | 100.0%                 |       |       | ≤ 1               | 2                 | ≤ 1    | 2     |
| Amoxicillin Clavulanic Acid | No Breakpoints Defined |       |       | 8                 | 16                | 8      | 16    |
| Aztreonam                   | No Breakpoints Defined |       |       | 16                | > 64              | 4      | > 64  |
| Cefazolin                   | No Breakpoints Defined |       |       | > 128             | > 128             | 128    | > 128 |
| Cefepime                    | 100.0%                 |       |       | 2                 | 8                 | 0.5    | 8     |
| Cefoxitin                   | No Breakpoints Defined |       |       | 16                | > 32              | 8      | > 32  |
| Ceftazidime                 | 100.0%                 |       |       | 2                 | 8                 | 2      | 8     |
| Ceftriaxone                 | 33.3%                  | 66.7% |       | 16                | 16                | 4      | 16    |
| Ciprofloxacin               | 100.0%                 |       |       | 0.25              | 0.5               | 0.25   | 0.5   |
| Colistin                    | 100.0%                 |       |       | 0.5               | 1                 | 0.5    | 1     |
| Doripenem                   | No Breakpoints Defined |       |       | 0.25              | 0.5               | 0.12   | 0.5   |
| Doxycycline                 | 100.0%                 |       |       | 0.25              | 0.5               | 0.25   | 0.5   |
| Ertapenem                   | No Breakpoints Defined |       |       | 2                 | 16                | 1      | 16    |
| Gentamicin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5 |
| Imipenem                    | 100.0%                 |       |       | 0.25              | 0.25              | 0.12   | 0.25  |
| Meropenem                   | 100.0%                 |       |       | 0.25              | 1                 | 0.25   | 1     |
| Moxifloxacin                | No Breakpoints Defined |       |       | 0.12              | 0.25              | 0.12   | 0.25  |
| Piperacillin Tazobactam     | 100.0%                 |       |       | ≤ 1               | 16                | ≤ 1    | 16    |
| Tigecycline                 | No Breakpoints Defined |       |       | 0.25              | 1                 | 0.12   | 1     |
| Tobramycin                  | 100.0%                 |       |       | ≤ 0.5             | ≤ 0.5             | ≤ 0.5  | ≤ 0.5 |
| Trimethoprim Sulfa          | 100.0%                 |       |       | 0.25              | 0.5               | ≤ 0.12 | 0.5   |

# CANWARD 2012 Prevalence of MRSA by Region

|                             | West        | Ontario     | Quebec      | Maritimes   | National    |
|-----------------------------|-------------|-------------|-------------|-------------|-------------|
| # MRSA                      | 64          | 39          | 7           | 15          | 125         |
| Total #<br><i>S. aureus</i> | 254         | 251         | 61          | 123         | 689         |
| % Prevalence                | <b>25.2</b> | <b>15.5</b> | <b>11.5</b> | <b>12.2</b> | <b>18.1</b> |



# CANWARD 2012

## Prevalence of CA/HA-MRSA by Region

| MRSA                 | West        | Ontario     | Quebec       | Maritimes   | National    |
|----------------------|-------------|-------------|--------------|-------------|-------------|
| CA-MRSA (n)          | 30          | 16          | 0            | 2           | 48          |
| HA-MRSA (n)          | 29          | 21          | 7            | 11          | 68          |
| Unique (n)           | 5           | 2           | 0            | 2           | 9           |
| % CA-MRSA/<br>region | <b>46.9</b> | <b>41.0</b> | <b>0.0</b>   | <b>13.3</b> | <b>38.4</b> |
| % HA-MRSA/<br>region | <b>45.3</b> | <b>53.8</b> | <b>100.0</b> | <b>73.3</b> | <b>54.4</b> |

# CANWARD 2012 Prevalence of VRE by Region

|  | West       | Ontario     | Quebec     | Maritimes  | National   |
|--|------------|-------------|------------|------------|------------|
| # VRE/region                                   | 3          | 7           | 0          | 0          | 10         |
| Total #<br><i>Enterococcus sp.</i><br>/ region | 46         | 47          | 15         | 20         | 128        |
| % Prevalence                                   | <b>6.5</b> | <b>14.9</b> | <b>0.0</b> | <b>0.0</b> | <b>708</b> |

9 *vanA*, 1 *vanB*

# CANWARD 2012

## Prevalence of ESBL producing *E. coli* by Region

|                        | West       | Ontario     | Quebec     | Maritimes  | National   |
|------------------------|------------|-------------|------------|------------|------------|
| # ESBL <i>E. coli</i>  | 8          | 20          | 5          | 5          | 38         |
| Total # <i>E. coli</i> | 163        | 172         | 75         | 90         | 500        |
| % Prevalence           | <b>4.9</b> | <b>11.6</b> | <b>6.7</b> | <b>5.6</b> | <b>7.6</b> |

# CANWARD 2012

## Prevalence of ESBL producing *K. pneumoniae* by Region

|                                 | West       | Ontario    | Quebec     | Maritimes  | National   |
|---------------------------------|------------|------------|------------|------------|------------|
| # ESBL<br><i>K. Pneumoniae</i>  | 3          | 2          | 1          | 0          | 6          |
| Total #<br><i>K. pneumoniae</i> | 47         | 60         | 32         | 30         | 169        |
| % Prevalence                    | <b>6.4</b> | <b>3.3</b> | <b>3.1</b> | <b>0.0</b> | <b>3.6</b> |